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Abstract 
Protein-protein interactions (PPIs) play a vital role in biological processes but are 
difficult to target therapeutically. However, targeting PPIs is an important challenge 
because their dysregulation is linked to many various disease states including cancers and 
neurological disorders. While high throughput screening (HTS) has long been the 
standard method for drug discovery, fragment-based screening (FBS) has emerged as a 
promising alternative strategy due to its greater coverage of chemical space with smaller 
library sizes. Successful cases like Vemurafenib and Venetoclax, continue to bolster FBS 
efforts. Though many techniques, including X-ray crystallography, surface plasmon 
resonance, and thermal shift assays, have all been used as screening tools, the central 
hypothesis of this dissertation is that 
19
F NMR is a powerful and time efficient FBS tool 
that is complementary to existing tools and is useful for characterizing proteins and small 
molecule ligands. Protein-Observed Fluorine NMR Spectroscopy (PrOF NMR) due to its 
high speed, lack of background signals, environmental sensitivity, is an ideal method to 
use for both ligand discovery and characterization of ligand-protein interactions. Herein, 
we describe the application of PrOF NMR to two proteins in particular, the KIX domain 
of CBP/p300 which is part of a larger transcriptional activation complex, and the first 
bromodomain of BrdT, an epigenetic “reader” protein that has been validated as a target 
for male contraception. We demonstrate the use of PrOF NMR as a primary screening 
tool for KIX, identifying key pharmacophores for KIX binding. We also demonstrate the 
use of PrOF NMR for characterizing ligand-protein interactions, uncovering a new 
binding site in KIX, distinct from its two native transcription factor binding sites. 
Validation of hits from other screening campaigns can also be followed via PrOF NMR, 
and the quantitative information obtained can be used to guide the structure-activity 
relationship (SAR) process for further ligand development. Beyond ligand discovery in 
proteins, fluorine magnetic resonance can also be applied as an imaging and oximetry 
tool. Given the sensitivity of fluorine and its applications in both biophysical and 
biomedical contexts, fluorine magnetic resonance serves as a new tool for small-molecule 
screening, ligand development, and oxygen sensing.  
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Preface 
Chapter 1 of this dissertation provides an overarching background to protein-
protein interactions, their significance, and how one can approach small-molecule 
discovery to specifically modulate these interactions. The KIX domain of CBP/p300 was 
selected as a model system due to its many native transcription factor binding partners. 
To study this protein, many biophysical tools, including circular dichroism and 
fluorescence polarization, were used. Fundamentals of NMR techniques and small-
molecule screening are also discussed to set up the subsequent chapters.  
In Chapter 2 of this dissertation, the first demonstration of a fragment screen 
against a protein target using our newly developed technique, protein-observed fluorine 
NMR spectroscopy (PrOF NMR) is presented. We incorporated 3-fluorotyrosine (3FY) 
into KIX, our model, system, and screened 508 fragment compounds to assess the 
feasibility of PrOF NMR as a screening tool. Hits are identified based on changes in 
chemical shift, and affinities are quantified by plotting the change in chemical shift as a 
function of ligand concentration. From this screen, we identified aromatic carboxylic 
acids as a minimum pharmacophore for binding to KIX. We were also able to assess the 
druggability of the different binding sites based on comparative hit rates and ascertained 
that the MLL site was more druggable than the CREB site. Due to the speed of the 
experiments, ease of interpretation, low amount of material consumed, and relatively low 
cost, we conclude that PrOF NMR is a useful, complementary tool for the screening 
community.  
 Chapter 3 is a follow-up to the work presented in Chapter 2 and encompasses two 
projects that stemmed from the previous work. With the newly discovered hit 
compounds, we began to synthesize derivatives of the lead compound, 3, 4-
dichlorophenyl acetic acid. Because our hypothesis from the initial paper was that this 
compound was binding to KIX in a non 1:1 manner, we sought to expand the compound 
while retaining both the dichlorophenyl group on one end and the acidic functionality on 
the other. Through amide bond coupling with amino acids, we developed a new 
compound with slightly improved affinity for KIX. Simultaneously, additional efforts 
were taking place to push the limits of fluorine labeling of proteins by seeking to 
 xix 
incorporate more than one type of fluorinated amino acid into a protein at the same time. 
These efforts produced KIX labeled with both 3FY and 4-fluorophenylalanine (4FF), 
providing an additional fluorine probe in the MLL site, the site occupied by the hits from 
Chapter 2. In putting these two projects together, we discovered a new binding site in 
KIX, distinct from the two used by native transcription factors. Through a combination of 
PrOF NMR, 
1
H-
15
N Heteronuclear Single Quantum Correlation (HSQC) NMR and 
computational methods (FTMap, Glide Docking), we propose the existence of a 
previously unreported ligand binding site.  
The protocol in Chapter 3 fully explains the entire process for establishing PrOF 
NMR in a new context, from the first steps of transforming plasmids into appropriate 
cells to fragment screening preparation. Using commercially available fluorinated amino 
acids or fluorinated amino acid precursors, we demonstrate the applicability of PrOF 
NMR with three different proteins, the KIX domain of CBP/p300, and the first 
bromodomains of Brd4 and BrdT. PrOF NMR is able to provide both quantitative 
information, through evaluation of binding affinity, and structural information, based on 
which resonances are perturbed in the presence of a ligand. This method provides a new 
tool that is complementary to existing screening tools. While experiments can already be 
run on the order of a few minutes, we also sought to improve the throughput with the 
addition of paramagnetic metal additives which shorten relaxation times. Shorter 
relaxation times allow for shorter experiment times. We identified an optimal metal-
chelate for application to PrOF NMR which is able to shorten experiment times by 
approximately 60%, making PrOF NMR even more efficient and accessible to a wider 
range of researchers.  
 In a collaborative effort, PrOF NMR was extended to a new protein target, BrdT, 
a bromodomain that is a validated target for male contraception and is discussed in 
Chapter 4. There is currently a market need for non-hormone based male contraceptive 
agents, and the inhibition of the epigenetic “reader” protein BrdT has been shown to 
exhibit the desired effects. BrdT knockout mice are viable but sterile, while mice that 
have been dosed with a bromodomain inhibitor regain spermatogenic function upon 
removal of treatment. Ligand development for this project took place through multiple 
 xx 
avenues including ligand deconstruction, fragment screening, and virtual screening. The 
goal in all three cases was to develop a ligand selective for BrdT over the other 
bromodomains in the same family. By deconstructing a kinase inhibitor that was 
previously reported to inhibit BrdT and assessing the structure-activity relationship 
(SAR), we sought to reconstruct a compound that would be selective for BrdT over Brd4. 
The SAR indicated the possibility of generating selectivity through an N-alkyl 
substitution pattern. However, the final compound failed to provide the desired 
selectivity. Fragment screening efforts identified several pharmacophores for binding to 
the BET bromodomains. The lead compound featured an indanone, a pharmacophore that 
had not yet been identified. Several analogs of this lead compound were synthesized, and 
SAR was guided through the use of PrOF NMR by providing affinities, ligand 
efficiencies, and lipophilic ligand efficiencies. A virtual screening campaign yielded 
several hits which were then evaluated by PrOF NMR. The lead compound identified by 
PrOF NMR was then further developed. While final compounds that were developed 
were not selective for BrdT, this project demonstrated the applicability of virtual 
screening in conjunction with biophysical assays.  
 A collaborative project utilizing my expertise in fluorine NMR is described in 
Chapter 6. Ultraporous mesostructured silica nanoparticles were synthesized and loaded 
with perfluorocarbons. Fluorine is extremely sensitive to its chemical environment. In 
particular, dissolved oxygen will significantly modulate the relaxation times of the 
fluorine nuclei. Fluorine NMR was used to both quantify the amount of perfluorocarbon 
that had been loaded into the particles and to monitor changes in relaxation as a function 
of oxygen concentration. Our idea was to take advantage of this property and use these 
loaded nanoparticles, termed PERFUMNS, as oximetry sensors with applications in the 
biomedical field. In collaboration with the Center for Magnetic Resonance Research 
(CMRR) we were able to obtain 
19
F MRI images of particles in solution demonstrating 
clinically-relevant concentrations of fluorine for imaging experiments.  
 The final chapter, Chapter 7, describes a new method for using standard 
colorimetric assays to measure protein concentrations. Smartphone colorimetry uses 
image analysis of the Red, Green, Blue (RGB) values in the place of absorbance in a UV-
 xxi 
Vis spectrophotometer. We demonstrate the applicability of smartphone colorimetry in 
two different protein colorimetric assays, the Bradford assay and the biuret assay, and 
provide instructions for both students and instructors to be able to utilize this experiment 
as part of a laboratory course, meeting some Next Generation Science Standards as well.  
In summary, the findings presented in this dissertation describe my contributions 
to the ligand discovery field through the development of protein-observed fluorine NMR, 
to the biomedical field through the development of a new oximetry measurement tool, 
and to the field of chemical education the development of a new application of 
smartphone colorimetry to protein-based assays.   
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Chapter 1. Introduction 
1.1 Protein-Protein Interactions 
 Protein-protein interactions, long classified as “undruggable” are now being 
targeted for their roles in various diseases.
1
 Under normal, healthy conditions, the 
putative 650,000 PPIs in the human body are vital for biological function, including the 
regulation of cell cycle and gene transcription.
2
  However, PPIs have also been 
implicated as drug targets in various diseases including cancer when they are 
dysregulated. Consequently, the ability to selectively and effectively target these 
interfaces is highly sought after.
1, 3-4
 
 In recent years there have been some successes in targeting PPIs with small 
molecules. Notable examples of PPIs that have been successfully targeted with small 
molecules include MDM2:p53,
5-7
 IL-2:IL-2 Rα,8-10 and Bcl-211-13 (Figure 1.1). These and 
other successes have been highlighted in recent reviews.
14,15
  Despite the rapid progress 
that has been made in the past 15 years, less than 0.01% of all PPIs in the human body 
have targeted inhibitors.
16
 In contrast, there are about 5,000 different human diseases of 
which the molecular cause is known.
17
 In light of these staggering statistics, clearly more 
work must be done to optimize the existing small molecules and discover new molecules 
for targeting these unreached PPIs.  
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Figure 1.1 Notable examples of small-molecule:PPI inhibitors  
A) MDM2:Nutlin 3a (PDB ID: 4HG7) B) IL-2:1 (PDB ID: 1M48) C) Bcl-xL:ABT-737 
(PDB ID: 2YXJ) 
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1.1.1 Protein Hot Spots 
 The interface between two proteins is often characterized as both large (1500-
3000 Å
2 
in total) and flat, lacking deep, hydrophobic pockets that could be considered as 
druggable sites.
18
 However, Clackson and Wells, in their seminal paper describing the 
interface between human growth hormone (hGH) and its receptor, hGHbp, were able to 
demonstrate through alanine mutagenesis that some amino acids are more important for 
binding than others. These protein “hot spots” are small regions within the interface, 
consisting of just a few residues which are essential for protein binding as demonstrated 
by the large change in binding free energy when mutated.
19
 While targeting the entire 
interface between two proteins may not be feasible, targeting a hot spot to modulate 
binding interactions is a reasonable task.
20
 Notably, in some cases protein hot spots are 
clustered together while in other cases hot spots are more distributed, which can make it 
more difficult to target these interactions.  
 Further investigation into protein hot spots have been carried out to determine 
which amino acids are overrepresented in hotspots. It was determined that the aromatic 
amino acids are enriched at protein-protein interfaces as evidenced by their 
overrepresentation in protein hotspots (Figure 1.2).
21-25
 If these hot spot residues could be 
labeled without perturbing the structure and function of the protein, one would have 
useful probes in position to monitor protein binding.  
 
Figure 1.2 Overrepresentation of aromatic amino acids at protein binding 
interfaces.  
Adapted from London et al.
21
 with permission from Elsevier.  
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1.1.2 Transcription Factors and Activators 
Transcription factors are of particular interest to cancer research due to their direct 
role in gene transcription.
26
 Transcription factors generally possess at least two distinct 
domains: a DNA binding domain (DBD) and a transcriptional activation domain 
(TAD).
27
 The DBD binds to specific recognition sequences in the DNA in order to 
activate transcriptions. This process requires the coordination of many proteins, termed 
the enhanceosome. One of the key components in the enhanceosome is a coactivator, 
which binds to its corresponding transcription factor at the TAD to form a bridge with the 
RNA polymerase II to promote transcription.
28
 
Transcription factors, due to their critical role in the regulation and transcription 
of genes, are therefore valuable therapeutic targets. In the case of cancer, genes are 
dysregulated to promote continued cell growth and prevent cell death. By targeting the 
specific transcription factors involved in the PPIs responsible for regulating these genes, 
one could selectively shut down cancer cell growth.
29
 However, because transcription 
factors are involved in several different PPIs, effective targeted therapeutics would need 
to inhibit specific PPIs while not perturbing other beneficial functions of the proteins, 
allowing for normal function of the proteins.   
1.1.3 CREB-CBP: a model transcription factor-coactivator interaction 
The cyclic adenosine monophosphate (cAMP) response element (CRE) binding 
protein (CREB) is a biologically important protein due to its implications in neuronal 
plasticity and long term memory formation as well as its role in hematopoiesis, immune 
function, cell cycle regulation, gene transcription, and consequently, cancer.
30-34
 This 43 
kDa protein is a transcription factor that is conserved across multiple species from insects 
to humans, indicating its significance for biological function.
35
  
CREB was first discovered as a transcription factor related to long term memory 
formation and has now been established to have than 100 target genes controlling a 
variety of functions including neurotransmission, cell growth, neuronal structure, cellular 
metabolism, and signal transduction.
34
 Each of these genes possesses the same 
octanucleotide cAMP response element (CRE) sequence, TGANNTCA where N 
represents any of the four nucleotides.
29, 35
 CREB binds as a homodimer to the CRE 
  5 
sequence and its TAD is subsequently activated by phosphorylation which is performed 
by various kinases, including protein kinase A and calmodulin-dependent kinase. Upon 
phosphorylation at Ser133, CREB is able to recruit its coactivator, CREB binding protein 
(CBP).
36
 This binding event between the two proteins allows for the recruitment of RNA 
polymerase II (RNApolII) to activate transcription of target genes 
29-31, 35, 37
 (Figure 1.3). 
 
Figure 1.3 Cartoon schematic of CREB:CBP Transcriptional Complex.   
CREB binds as a homodimer to the CRE sequence. Interaction between the KID domain 
of CREB and the KIX domain of CBP is  activated by phosphorylation of KID at Ser133, 
allowing the recruitment of RNApolII for transcription of target genes such as Bcl-2, 
cyclin A, and egr-1.  
 
CREB has been implicated in the proliferation of AML in which CREB’s 
dysregulation leads to improper transcription of several target genes including the 
antiapoptotic gene Bcl-2, the cell cycle regulating gene cyclin A, and the differentiation 
gene early growth factor-1 (egr-1). 
29, 35
 With Bcl-2 upregulated, apoptosis is inhibited, 
allowing cells to survive.
11, 13
 Likewise the upregulation of cyclin A allows cells to 
bypass the natural death stage and continue proliferating. The dysregulation of egr-1, 
causes cells to differentiate improperly, meaning that instead of cells becoming blood 
cells or neuronal cells, they become cancer cells.
38
 Because CREB holds an integral role 
in the proliferation of leukemia cells, it is an attractive, albeit a difficult, therapeutic 
target. 
29, 35
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1.1.4 KIX – Structure and Function 
The CREB-CBP interaction takes place through specific binding domains. CREB 
features a kinase inducible domain (KID) which is phosphorylated at Ser133, hereafter 
referred to as pKID. The 256 kDa protein CBP features a 12 kDa KID interacting (KIX) 
domain, which can be expressed as a minimal protein construct modeling interactions of 
CREB at the KIX domain. KIX also binds several other transcriptional activators in 
addition to CREB, including BRCA1, c-Jun, c-Myb, mixed lineage leukemia (MLL) and 
human papillomavirus E2.
36, 39-40
 
The solution structure of KIX consists of three α helices (α1, α2, α3) and two 310 
helices. Two α helices, α1 and α3, are coplanar and interact with two of the α helices 
from pKID, αA and αB (Fig) which form a 90° angle around α3.  In contrast, the MLL 
binding site lies between α2 and α3 away from α1 while c-myb has been found to bind in 
a similar site as KID (Figure 1.4). 
40
 
 
Figure 1.4 Solution structure of KIX with binding partners.  
(A) A ribbon diagram of KIX bound to pKID (PDB ID: 1KDX). (B) A ribbon diagram of 
KIX bound to both MLL and Myb (PDB ID:2AGH) (Structures were generated in 
PyMOL) 
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1.1.5 Known Small Molecule and Peptide Ligands for KIX 
PPIs involving KIX, unlike most PPIs, do have some known, well-characterized 
small-molecule and peptide ligands. One of the most prominent small-molecule inhibitors 
of the KIX-KID interaction is naphthol AS-E phosphate, also known as KG-501,
36
 which 
selectively inhibits the KIX-KID interaction with an initially reported Ki of 90 µM. Other 
known KIX ligands are listed in Table 1.1.   
Table 1.1 Known small-molecule and peptide KIX Ligands  
 
While there has been significant investigation into identifying KIX-KID inhibitors 
44-46
 as well as inhibitors for MLL
47-48
 and Jun
48
, there is still a need for identifying more 
high-affinity molecules that demonstrate significant efficacy in selectively targeting the 
interactions between KIX and its binding partners.  
1.1.6 Current Methods to Observe and Characterize Protein-Protein Interactions 
Several different yet complementary characterization methods are available for 
characterizing and obtaining binding information regarding both PPIs and protein-ligand 
interactions. X-ray crystallography provides angstrom level image resolution of a protein, 
but the drawback is that this snapshot may not accurately represent its behavior in 
solution. Forster resonance energy transfer (FRET) can provide useful binding 
information but necessitates the use of bulky fluorophores which may alter natural 
protein function.  Surface plasmon resonance (SPR), while being label-free, requires the 
Compound Inhibition Affinity Method/Technique Citation 
Naphthol AS-E 
Phosphate (KG-501) 
KID 
 
90 µM 
†
 
115 ± 15 µM * 
FBS/SAR by NMR 
Best et al.
36
 
Pomerantz et 
al.
41
 
Sekikaic Acid 
MLL 
KID 
34  µM 
‡
 
64 µM 
‡
 
HTS/FP 
Majmudar et 
al.
42
 
Lobaric Acid 
MLL 
KID 
17 µM 
‡ 
25 µM 
‡  
Majmudar et 
al.
42
 
1G7 
 
---------------- FBS/PrOF NMR 
Pomerantz et 
al.
41
 
1-10 
 
220 ± 50 µM * FBS/Tethering (MS) 
Pomerantz et 
al.
41
 
KBP 2.20 
 
16.1 µM* Phage Display 
Frangioni et 
al.
43
 
Affinity reported as Kd, Ki, or IC50. (†Ki, *Kd, ‡IC50). Lobaric acid was derived as a 
conformationally constrained version of Sekikaic acid based on computational modeling which 
predicted improved binding 
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target protein to be immobilized on a surface which could lead to unnatural binding and 
function. Isothermal titration calorimetry (ITC) uniquely enables the simultaneous 
determination of binding constants and thermodynamics by measuring the heat release 
associated with binding but lacks structural information.
49
 For these reasons, multiple 
characterization techniques are used in tandem to provide a fuller understanding of 
protein binding.    
Fluorescence polarization (FP) is a fluorescence-based technique that monitors 
the change in the light’s polarization based on molecular size and tumbling rate in 
solution. A smaller molecule that is tumbling faster will exhibit low polarization while a 
large molecule that tumbles slower will exhibit high polarization. A fluorophore-labeled 
molecule or peptide that binds to a protein can take advantage of this effect as it will 
exhibit a significant change in polarization when it is bound versus when it is unbound. 
50
 
For this reason, FP is often used to determine binding constants for protein-ligand 
binding. These constants can either be found by direct binding experiments yielding the 
Kd or indirect competition experiments, yielding the Ki. In either case, a fluorophore is 
attached to a tracer molecule that will bind to the target. In a direct binding experiment, 
the Kd of a tracer is determined by observing the change in polarization as it relates to its 
concentration of the tracer.  At a high concentration of tracer, low polarization will be 
detected while at low concentrations, there will be high polarization. (Figure 1.5A, B, 
Equation 1) For an indirect competition experiment, the tracer is used as a way to 
measure the binding affinity of another ligand which will displace the tracer from binding 
to the target protein. As the concentration of the molecule of interest increases, it 
displaces more of the tracer resulting in a decrease in polarization (Figure 1.5C, D, 
Equation 2).
50
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Figure 1.5 General schematic for fluorescence polarization experiments.  
A) Schematic of a direct binding experiment in which a fluorescently-labeled ligand is 
added to a protein, leading to an increase in fluorescence polarization. B) Sample direct 
binding curve by FP. C) Schematic of a competition experiment in which a fluorescently-
labeled ligand is competed away from its protein target by an inhibitor molecule, leading 
to a decrease in fluorescence polarization. D) Sample FP competition curve with the IC50 
being noted at the inflection point of the curve.   
 
Kd values in a direct binding experiment are calculated using the equation below: 
                                         𝑦 = 𝑐 + (𝑏 − 𝑐) ∗  
√(𝐾𝑑+𝑎+𝑥)2−4𝑎𝑥
2𝑎
                                         (1) 
In the above equation, y corresponds to the observed anisotropy, c and b correspond to 
the minimum and maximum observed entropies, respectively, Kd is the dissociation 
constant, and a and x are the concentrations of fluorescent ligand and protein, 
respectively. The Ki can be calculated from the IC50 values using a variant of the Cheng-
Prusoff equation where the Ki is the indirectly determined dissociation constant of the 
competitor ligand.
51
        
                                          𝐾𝑖 =  
(𝐿𝑏)(𝐼𝐶50)(𝐾𝑑)
(𝐿0)(𝑅0)+[𝐿0(𝑅0+𝐿𝑏−𝐿0−𝐾𝑑)]
                                               (2)  
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Each of the aforementioned techniques has strengths and weaknesses which 
typically necessitates the use of complementary methods. A further explanation of these 
and other techniques for small-molecule screening will be discussed in section 1.4. 
However, the following section will describe how Nuclear Magnetic Resonance may 
serve as an ideal technique by simultaneously providing structural information, allowing 
the evaluation of binding affinity, and accurately reflecting solution conditions.  
1.2 Nuclear Magnetic Resonance Spectroscopy 
1.2.1 Protein NMR 
Nuclear magnetic resonance (NMR) spectroscopy is an effective tool for 
analyzing not only small molecules but also large biomolecules like proteins.  High field 
NMR spectrometers have made biomolecular structural studies via NMR not only 
possible but efficient as well. More powerful magnets provide a higher signal-to-noise-
ratio (S/N), allowing for shorter data acquisition or higher resolution data in the same 
amount of time. The development of cryogenically cooled probes has also provided 
significant S/N improvement by reducing thermal noise. Cryoprobes increase the S/N 
three to four-fold. Because S/N is proportional to the square root of the number of scans, 
a cryoprobe allows data acquisition nine to sixteen times faster than a typical probe. 
Alternatively, one could have a sample that is significantly less concentrated (mid µM 
range) and still acquire good quality data in a reasonable amount of time.
52
  
Since the advent of the two-dimensional (2D) NMR experiments in 1971, 
researchers have found numerous uses for application multidimensional NMR in 
providing structural information.
53
 2D NMR experiments can be classified in one of two 
categories: correlations between the same types of nuclei (homonuclear) or different 
types of nuclei (heteronuclear). For proteins, heteronuclear single-quantum correlation 
(HSQC) or Nuclear Overhauser Effect spectroscopy (NOESY) are often used. Most 
commonly the HSQC experiments examine the correlation between 
15
N in the amide 
backbone and its corresponding 
1
H or the correlation between 
1
H and 
13
C in the 
sidechains. NOESY determines coupling between two nuclei through space, making it a 
useful tool for secondary structure determination in proteins.
54
 To obtain even more 
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detailed structural information, three dimensional (3D) and four dimensional (4D) NMR 
experiments were developed to analyze the correlations among three or four distinct 
nuclei. This tool revolutionized the protein NMR field, allowing for the acquisition of 
even more structural information.
55
  
 
Figure 1.6 Sample 
1
H-
15
N HSQC Spectrum of KIX 
 
Traditionally protein observed NMR has studied either the backbone or the side 
chains. The 
1
H-
15
N HSQC experiment is performed by isotopically labeling each of the 
nitrogen atoms in the amide backbone and observing the correlation to its corresponding 
hydrogen, providing the overall framework of the protein (Figure 1.6).
56
 Two key 
developments have aided in the more effective application of HSQC experiments. The 
first is the band-selective optimized flip-angle short-transient (SOFAST) pulse sequence 
in which the band-selective pulses and short recycle delays allow for faster experiments 
without loss of S/N.
57
 
A powerful innovation was the invention of the transverse-relaxation optimized 
spectroscopy (TROSY) pulse sequence which makes characterization and structural 
  12 
determination of larger proteins (> 60 kDa) a reasonable task.
56, 58-59
 Under normal 
conditions, it is difficult to determine the structure of large proteins via NMR due to 
complex coupling signals that often obscure the important peaks. Due to dipolar coupling 
and chemical shift anisotropy, relaxation times are also significantly affected as a 
function of molecular size leading to broad resonances. By eliminating the cross-
correlated components with a fast relaxation and retaining the ones with a slow 
relaxation, TROSY provides improved peak resolution and better quality spectra 
overall.
56
 By coupling TROSY with other NMR experiments like HSQC as well as 
NOESY and HNCA, large proteins or protein complexes as high as 900 kDa can be 
analyzed.
58, 60
  
Protein NMR can be applied not only for structural determination but also for 
small molecule discovery. Fesik et al. developed the technique known as structure-
activity relationship (SAR) by NMR to identify potential leads for drug discovery.
61
 SAR 
by NMR, which uses the HSQC experiment, was able to identify a trimethoxyphenyl 
pipecolinic acid derivative and a benzanilide derivative that bound to the FK506 binding 
protein.
61
 Once two ligands that bind nearby sites in the protein, as judged by 
perturbations in the HSQC NMR spectra, the two fragments can be chemical linked and 
functionalized, resulting in a synergistic effect on binding affinity in the final 
compound.
61
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Figure 1.7 Protein labeling for NMR. 
 (Structures were generated in PyMOL, PDB: 1KDX) 
 
The alternative to isotopically labeling the backbone with 
15
N is to label the side 
chains with 
13
C. Most commonly, the five side chains that are labeled are alanine, valine, 
leucine, isoleucine, and methionine due to the prominent methyl group in each which 
allows for methyl-TROSY NMR experiments to be performed.
62-65
 Protein 
characterization through methyl group analysis is advantageous due to their ability to 
probe structure
66-68
 and dynamics.
69
 Furthermore, the acquired spectra are well resolved 
and feature residues that are spread throughout the hydrophobic core of a given protein.
62
 
Each of the protein labeling techniques (Figure 1.7) has its benefits and provides 
complementary information for protein structure and function. 
1.2.2 Fluorine (19F) NMR 
While many advances have been made in NMR, wide application 2D and 3D 
experiments are still limited by their long experimental times and complicated results. 
Because these experiments often rely on correlation to 
13
C or 
15
N, they are inherently 
slow due to the need for a high number of scans.
70-71
 This temporal challenge has been 
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diminished by advanced pulse sequences such as SOFAST-HMQC and magnetization 
transfers allowing for detection of 
13
C or 
15
N signals through the proton channel.  
In recent years, fluorine (
19
F) has become more popular due to its powerfully 
sensitive and versatile nature as an NMR active nucleus.
52
 The 
19
F nucleus is 100% in 
natural abundance with a gyromagnetic ratio of 25.1815 x 10
7
 rad T
-1
s
-1
, making it 83% 
as sensitive as 
1
H and the second most signal-sensitive NMR active nucleus. It also has a 
spin quantum number of ½, which means unlike quadrupolar nuclei (spin > ½), it only 
has two possible spin states which keeps interpretation relatively simple.
71
 The Bruker 
Corporation regards 
19
F as one of the three most important NMR active nuclei along with 
1
H and 
13
C.
72
 Furthermore, because fluorine is not found in natural biomolecules or in 
physiological conditions, there are no background signals to obfuscate the 
19
F
 
NMR 
spectrum. In addition fluorine’s chemical shift window is significantly larger than that of 
either 
1
H or 
13
C. While the chemical shift range for 
1
H and 
13
C is typically 12 and 220 
ppm respectively,
54
 
19
F can span nearly 800 ppm,
73
 allowing for widely separated 
chemical shifts corresponding to fluorine’s hyper-responsiveness to slight changes in its 
chemical environment.
74
 Urick et al. reported a 6-20 fold higher responsiveness of 
fluorine to ligand binding, relative to 
1
H.
75
 For these reasons, 
19
F NMR can be used as a 
powerful characterization tool.  
1.2.3 Protein Observed Fluorine NMR (PrOF NMR) 
While the term protein observed fluorine NMR (PrOF) NMR was coined recently, 
proteins have been fluorine-labeled and analyzed previously.
74
 Due to fluorine’s hyper-
responsiveness to changes in its chemical environment, fluorinated amino acids within a 
protein can serve as effective molecular probes. Even subtle changes in a protein’s 
tertiary structure can result in drastic differences between chemical shifts for the same 
fluorinated amino acid in different positions within the protein. One such example is the 
19
F NMR spectrum of the fatty acid binding protein (Figure 1.8), which was labeled with 
both 4-fluoro-phenylalanine (4FF) and 6-fluoro-tryptophan.
76
 Each 4FF residue is 
distinguished from the other over a 10 ppm window.  One key benefit PrOF NMR holds 
over other protein NMR techniques is the fact that it is a one-dimensional technique, 
making it inherently simpler to interpret, easier to acquire.
74
 While other NMR 
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techniques provide more structural information, PrOF NMR can serve as a 
complementary technique to supplement characterization data.   
 
Figure 1.8 
19
F NMR spectrum of 4FF/6FW labeled IFABP.  
Adapted from Li et al.
76
 Copyright 2007 National Academy of Sciences 
 
  Because aromatic amino acids are highly enriched at PPI interfaces, they are well 
suited positionally to serve as NMR probes. By incorporating fluorinated aromatic amino 
acids, activity at protein-protein interfaces, including protein-protein and protein-small 
molecule binding, can be monitored. PrOF NMR can also be used to generate unique 
binding footprints for a protein depending on the binding partner. The 3FY 
19
F NMR 
spectra from KIX bound with MLL, pKID, and c-Myb have been reported in the 
literature in which each spectrum is clearly distinguishable from the other based on the 
shifting or broadening of resonances (Figure 1.9).
41
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Figure 1.9 
19
F NMR of 3FY KIX with different binding partners MLL, c-Myb, and 
pKID. 
Adapted with permission from Pomerantz et al.
41
 Copyright 2012 American Chemical 
Society  
 
The use of PrOF NMR is not limited to a few isolated cases. Rather, it has been 
used to study a wide variety of proteins including receptor proteins, DNA binding 
proteins, membrane proteins, enzymes, and even some disordered proteins.
77-78
 Some 
membrane proteins whose structure and function have been characterized by PrOF NMR 
include the β2-adrenergic receptor,
79-82
 rhodopsin,
83-84
 gramicidin A,
85-86
 and the M13 
phage coat protein.
87-88
 For their role in catalyzing various biological processes, enzymes 
such as purine nucleoside phosphorylase and adenosine deaminase, have been 
characterized using PrOF NMR. Likewise, disordered proteins, like the Aβ protein 
aggregate
78
 and the SH3 domain of the Drosophila signal transduction protein,
89
 have 
been characterized by PrOF NMR to better understand their activity in solution. Notably, 
due to the importance of the disordered protein α-synuclein in neurodegenerative 
diseases, Pielak and colleagues have characterized its conformational changes and 
binding interactions also using PrOF NMR.
90-92
  
Kinetic information regarding protein folding, denaturation, and refolding is also 
acquirable through the use of PrOF NMR which not only demonstrates its versatility but 
also its speed.
93
 Frieden and colleagues reported the use of stopped-flow 
19
F NMR and 
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two different proteins (E. coli Dihydrofolate Reductase and PapD) labeled with 6-fluoro-
tryptophan (6FW)
93-96
 or 4-fluoro-phenylalanine (4FF)
97
 to monitor protein folding in 
solution under various conditions. By observing the relationship between peak area and 
mixing time, they could better understand the dynamics of proteins in solution as they 
fold in their native state, denature under specific conditions, and refold when denaturing 
conditions have been removed.
95
 Some of their spectra were acquired as fast as 1.5
93
 and 
2.74 seconds
97
 demonstrating the speed of PrOF NMR.  
PrOF NMR has been used to characterize ligand binding and to screen libraries of 
compounds in multiple cases in recent years. Gee et al. screened 508 fragments against 
the transcriptional coactivator KIX and were able to identify several new small molecule 
ligands for KIX. These results and their follow-up will be further discussed in chapters 2 
and 3. PrOF NMR has also been used to characterize ligand binding to a number of 
bromodomains,
98
 was used in a dual screening format to identify a selective 
bromodomain ligand,
99
 and been compared to 
1
H-CPMG NMR, a standard industry NMR 
screening technique.
75
 
1.2.4 Fluorine Side-Chain Resonance Assignment 
Once a protein has been labeled with fluorinated amino acids, it is important to 
determine which resonances correspond to which amino acids. Several methods to 
accomplish this goal are used, including site directed mutagenesis,
41
 site-specific 
labeling,
100
 ligand binding experiments, and solvent exposure experiments with 
broadening agents
41
 as well as multidimensional NMR experiments.
101-102
 Further 
descriptions, procedures, and anticipated results for site directed mutagenesis will be 
discussed in Chapter 4.  
The use of several sequential multidimensional NMR techniques for assigning the 
spectrum of 
19
F-labeled side-chain resonances in proteins was pioneered by the lab of 
Scott Prosser.
101
  These techniques seek to avoid the challenges inherent in mutagenesis 
approaches such as difficulty of expression and spectral overlap. Prosser’s method 
utilizes several through-bond correlations to link the fluorine resonances to their 
corresponding amide nitrogen and consequently their position within the primary 
sequence. 
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Figure 1.10 Example spectra demonstrating the use of multidimensional NMR 
experiments to assign fluorine resonances.  
A) F-H COSY correlating the fluorine and its neighboring proton. B) Correlation of 
aromatic (δ) and β protons. C) HNCACB to correlating the β proton to the amide 
backbone. Reprinted with permission from Kitevski-LeBlanc et al.
101 
Copyright 2009 
American Chemical Society.  
 
Using 3-fluorotyrosine-labeled calmodulin (CaM) as the example, the first 
experiment uses a CT-HCCF-COSY pulse sequence which is a slightly modified COSY 
experiment to correlate the fluorine to its neighboring proton on the aromatic ring.
101
 The 
second experiment correlates that proton to the ones on the β carbon using an 
(Hβ)Cβ(CγCδ)Hδ pulse sequence. Lastly, the β protons are correlated to the amide 
backbone using a standard HNCACB experiment. Through this method, each fluorine 
resonance can be assigned to its corresponding amino acid position based on the 
correlation data obtained through multidimensional NMR.
101
 A similar method has also 
been used for the assignment of 3-fluorophenylalanine-labeled CaM.
102
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While this method does remove the challenges of the mutagenesis approaches, 
this multidimensional technique requires the protein to be labeled with 
15
N and 
13
C in 
addition to the fluorinated aromatic amino acids. Furthermore, this method is only 
effective if the 
1
H-
15
N HSQC assignments have already been obtained. It does, however, 
provide an alternative when mutagenesis approaches are unsuccessful. 
As an additional alternative to site-directed mutagenesis, Isley et al. demonstrated 
the possibility of computationally predicting the chemical shifts of fluorine resonances in 
a given protein based on its environment, orientation, neighboring water molecules, and a 
range of other factors.
103
 While this method is not yet accurate enough to perfectly 
predict chemical shifts of each resonance, it is a proof-of-concept that chemical shifts of 
fluorinated amino acids in proteins may be able to be predicted in the future.  
1.2.5 Paramagnetic Metals and Relaxation Times 
The transition from 2D or 3D NMR experiments to a 1D 
19
F experiment 
significantly reduces the total experimental time, but there are still two limitations: 
relaxation time and chemical shift dispersion. Even short 1D experiments are limited by 
the delay time in the pulse sequence which is typically 3-5 times the longitudinal (spin-
lattice) relaxation time (T1).
53
 In addition, NMR data interpretation can be hindered if 
there are overlapping or poorly resolved peaks. Both of these challenges can be addressed 
through the addition of paramagnetic metals, most commonly the paramagnetic 
lanthanides.
54
  
Paramagnetic compounds such as O2 and certain metals, such as Ni
2+
, Dy
3+
, Ho
3+
, 
Cu
2+
 and Tm
3+
, have a profound effect on the relaxation of nuclei in magnetic resonance 
experiments.
70, 104-106
 Therefore, paramagnetic agents can be used to intentionally 
modulate relaxation properties as described below and in Chapter 4.
107
 Hawk et al. 
demonstrated that the addition of 20 mM Ni-DTPA could shorten T1 relaxation times by 
approximately 75%, thereby shortening the overall experiment time by approximately 
60%. The inverse principle is also useful i.e., monitoring changes in relaxation to 
determine the amount of paramagnetic agent present, as we reported in ACS Nano and as 
described in Chapter 6.
108
 Historically lanthanides have been used as Magnetic 
Resonance Imaging (MRI) contrast agents. By shortening relaxation times, the contrast in 
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the MRI readout improves.
109
 It is also well known that lanthanides are capable of 
changing the chemical shifts of different peaks in an NMR spectrum such that formerly 
overlapping peaks can be resolved.
110
 The degree to which each metal alters the chemical 
shift and the relaxation times differs and is portrayed in Figure 1.11.
104
  
The use of paramagnetic metals in shortening relaxation times applies not only to 
small molecules but also has literature precedence to aid in protein NMR. Ramamoorthy 
and colleagues have frequently utilized the paramagnetic properties of the Cu
2+
 to shorten 
relaxation times in their studies of protein structure and function.
111-114
 They have 
observed a 3-10-fold decrease in T1 relaxation with no significant change in T2 relaxation 
at concentrations as low as 3 mM Cu
2+
.
111, 113
 Similarly Ishii et al. reported a 4 fold 
decrease in T1 relaxation with the addition of Cu
2+
.
115
  
 
 
Figure 1.11 Effect of various metal ions on 
19
F NMR signals.  
(A) Chemical shift in the presence of metal ions (B) Impact on T1 and T2 relaxation 
times. Adapted from Jiang et al.
104
 with permission of the Royal Society of Chemistry. 
 
Both the T1 and the T2 relaxation times are important to understand and play a 
significant role in data acquisition. The T1 relaxation time, also called the spin lattice or 
the longitudinal relaxation time, is qualitatively described as the amount of time required 
for a signal to precess back to its original position (M0) in the Z axis after being radiated 
with the radio frequency (RF) pulse. The faster the nuclei return to their original 
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magnetization, the sooner they can be pulsed again, meaning the experiment can be 
completed in a shorter time.
53
  
The T2 relaxation time, also known as the spin-spin or transverse relaxation time, 
describes the amount of time required for the nuclei to lose phase coherence.
53
 T2 can 
also be thought of as the time required for the net magnetization vector in the XY plane 
to return to zero.
116
 As the nuclei precess back to their original position in the Z-axis, they 
do so in a circular manner around the Z axis. As they precess around the Z axis, the XY 
magnetization slowly starts to lose phase coherence which results in a broader signal.
53
 
Ideally when altering the relaxation properties of a given compound, the change would 
balance the shortest T1 possible with the longest T2 possible.  
The relaxation process is heavily dependent on its surrounding environment and is 
carried out through a variety of mechanisms including dipole-dipole, chemical shift 
anisotropy (CSA), spin-rotation, and quadrupolar relaxation. Generally the most 
significant of these four is the dipole-dipole interaction in which the dipole from a nearby 
nuclei interacts with the nuclei of interest.
53
 According to the Solomon-Bloembergen 
equations, the magnitude of the effect of the dipole-dipole interaction is directly 
proportional to the magnetic moments created by both spinning nuclei and inversely 
proportional to the distance between the two nuclei in an r
-6
 manner.
117
 Unpaired 
electrons, such as those in paramagnetic metals, can generate a magnetic moment that is 
over 600 times the magnetic moment of a neighboring proton which results in an even 
more significant reduction in relaxation time. This paramagnetic relaxation effect can 
occur at distances up to 35 Å away in some cases.
53, 110, 118
 Because the T1 and T2 
relaxation times are described by different equations (Eq 3 and 4) as noted by Solomon
117
 
and Bloembergen,
119
 a reduction in one will not result in an identical reduction in the 
other.  
  𝑇1 =  
2
5
(
𝜇0
4𝜋
)
2
𝛾1
2𝑔2𝜇𝐵
2𝑆(𝑆 + 1)𝐽𝑆𝐵(𝜔1)                                         (3) 
                                  𝑇2 =  
1
15
(
𝜇0
4𝜋
)
2
𝛾1
2𝑔2𝜇𝐵
2𝑆(𝑆 + 1)[4𝐽𝑆𝐵(0) + 3𝐽𝑆𝐵(𝜔1)]                           (4) 
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where µ0 is the permeability of free space, γ1 is the gyromagnetic ratio, g is the electron 
g-factor, µB is the magnetic moment of the free electron, ω1/2π is the Larmor frequency 
and JSB is described as follows: 
                                                      𝐽𝑆𝐵 =  𝑟
−6 𝜏𝑐
1+ (𝜔𝜏𝑐)2
                                      (5) 
where τc  is the correlation time.
118
  
To measure the T1 relaxation time for a given compound, the inversion recovery 
(IR) experiment is used. In this NMR experiment (Figure 1.12), the time delay, denoted 
by τ, is arrayed from small to large values. At a shorter time, τ, the magnetization of the 
nuclei has not adequately relaxed back to its equilibrium position (M0) resulting in a 
reduced signal following the 90° pulse. As τ increases, the signal intensities of the peaks 
in the NMR spectrum also increase. The integrals of the peaks from the array are then fit 
to an exponential equation to determine the T1 (Eq. 6).
53, 71, 116
  
 
Figure 1.12 T1 relaxation measurements. 
A) NMR pulse sequence with a 180° pulse followed by a 90° pulse with a variable delay 
time (vd). B) Sample T1 data and corresponding equation to fit the data. 
 
The T2 relaxation time can be evaluated by two different methods.  An 
approximation utilizes the relationship between line broadening and T2 as described in 
the following equation: 
𝑇2 =  
1
𝜋∗𝐿𝑊
                                     (7) 
where LW is equal to the linewidth at half height. This approximation assumes perfect 
homogeneity within the NMR sample which is often times not the case.
53, 71, 116
 Because 
that method is only an approximation, other techniques were developed to more 
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accurately measure the T2. The first pulse sequence for T2 determination was developed 
by Carr and Purcell
120
 but was later modified by Meiboom and Gill, yielding the now 
standard Carr-Purcell-Meiboom-Gill (CPMG) experiment.
121
 This method provides a 
more accurate measurement of the T2 relaxation time by examining a data array in a 
similar manner to the T1 IR experiment. Delay times, or number of repetitions of the 
cycle, are arrayed such that at a shorter delay there is a larger signal and at the longer 
delay the signal is significantly reduced or nonexistent. The data can be fit using a first 
order exponential decay equation. (Figure 1.13) 
 
Figure 1.13 T2 relaxation measurements. 
A) NMR pulse sequence with a 90° pulse followed by a 180° pulse with a set echo time 
(D20). The D20-180° pulse-D20 sequence will be repeated c times. Total experiment 
time will be determined by the vc list. B) Sample T2 data and corresponding equation to 
fit the data. 
 
The lanthanide induced shift (LIS) effect arises from the paramagnetic property 
known as pseudocontact shift (PCS) in which the magnetic field generated by unpaired 
electrons affects the nuclei of interest in a r
-3
 distance dependent manner.
118, 122-123
 This 
effect is only possible in an anisotropic environment, meaning there is an uneven 
distribution of electrons in the magnetic field.
124
 The necessity of anisotropy for LIS 
stands in contrast with the paramagnetic relaxation effect which can be induced with 
either isotropic or anisotropic magnetic fields. For this reason not all paramagnetic metals 
can be used as shift reagents.  
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1.2.6 NMR physics of spin relaxation and molecular motion 
Nuclear magnetic resonance (NMR) spectroscopy experiments are dependent on 
the relaxation properties of the nuclei being investigated. Nuclear spin relaxation is a 
process by which a nuclear spin interacts with any external magnetic field, whether that is 
the magnetic field from the spectrometer, neighboring nuclei, or free unpaired electrons. 
When the nuclear spin of interest is perturbed, it relaxes back to its equilibrium spin state 
in accordance with its own magnetic properties and the properties imparted to it. Some 
examples of these interactions include dipolar coupling, quadrupolar interactions, spin-
rotation, and chemical shift anisotropy (CSA).
53
 One commonality among all of these 
relaxation mechanisms is their dependence on molecular motion which is described by 
various spectral density functions. CSA relaxation can have a dominating effect on 
19
F 
NMR spectra, so it is important to understand its origins and implications.
125
  
Chemical shift or chemical shielding anisotropy (CSA) in its simplest conceptual 
description arises from asymmetric or anisotropic dispersion of electrons in a given 
system. Nuclei with more electrons, like 
19
F, are anisotropic and more susceptible to 
effects from CSA than nuclei that have fewer electrons, like 
1
H which are isotropic.
53
 
Molecular tumbling in solution allows local magnetic fields to be generated which aid in 
spin relaxation. The magnitude of the effect of these generated fields will depend on the 
degree of anisotropy present in the nucleus of interest. 
The most noticeable effect on an NMR spectrum from CSA is line broadening 
due to the dependence of T2 relaxation on the square of both the shielding anisotropy 
value 
                
1
𝑇2
=  
2
15
 (𝜎∥ − 𝜎⊥)
2𝜔𝐹
2𝜏𝑐 [
2
3
+
1
2
1
(1+𝜔𝐹2𝜏𝑐2)
]                                       (9) 
where T2 is the spin-spin relaxation time, (𝜎∥ − 𝜎⊥) is the CSA, ωF is the strength of the 
magnetic field, and τc is the rotational correlation time.
125
 While CSA for any given 
nucleus will vary depending on its chemical environment such as nearby functional 
groups or position within a protein, the values for each nucleus tend to fall within 
predictable ranges. Since 
1
H is mostly isotropic, its CSA is typically between 0 and 20 
ppm. The CSA for 
13
C tends to fall between 80 and 120 ppm but can be as low as 15 
ppm.
126
 The CSA for 
15
N varies significantly depending on its environment, but in the 
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peptide backbone of a protein, it tends be between 160 and 180 ppm.
127
 
19
F also has a 
large CSA (50-100 ppm).
128-130
 In a direct detection experiment of these nuclei, 
15
N 
resonances would be the broadest on the basis of CSA. This effect is partially mitigated 
and some signal sensitivity is recovered, however, by the fact that for an HSQC, 
15
N is 
indirectly detected through the 
1
H nucleus. Consequently, the 
15
N resonances retain the 
signal sensitivity and some sharpness from 
1
H due to dipolar relaxation and low CSA.
53
 
With the advent of transverse relaxation-optimized spectroscopy (TROSY) NMR 
methods, the CSA challenge for 
15
N labeled proteins is surmountable.
58
 In contrast, there 
are currently no TROSY methods available for direct-detected 
19
F experiments, and 
therefore nuclei experience the full effects of CSA. 
The T2 relaxation is also dependent on the square of the magnetic field strength. 
(Equation 7) Therefore, nuclei whose relaxation mechanisms are dominated by CSA 
experience an even greater broadening effect at higher magnetic fields (Figure 1.14).
131
 
Consequently, these nuclei can be more efficiently analyzed at lower magnetic fields (e.g. 
500 MHz instead of 900 MHz). The rotational correlation time (τc) can further compound 
the broadening of linewidths as an increased τc also results in increased linewidths, as is 
the case in a protein backbone. However, internal rotational motion within a protein side 
chain can lead to line narrowing, allowing for the possibility of analyzing large proteins 
by NMR.
63
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Figure 1.14 Predicted effect of CSA and dipole-dipole relaxation on 
19
F linewidths at 
varying magnetic field strengths.   
A) Rotational correlation was 0.4 ns B) Rotational correlation time was 16 ns. ····· 
Extrapolation of the linear region of CSA.   - - - - - Optimal magnetic field strength 
before CSA effects take over. Adapted from Gerig et al.
131
  
 
In its basic mathematical form, chemical shift anisotropy, is a tensor, which means it is 
calculated relative to three components in a coordinate axis system. The chemical shift 
tensor is denoted as σ while its component parts are designated σ11, σ22, and σ33.
125
  For 
an isotropic system like 
1
H, these values are equivalent (Equation 10). 
                                𝜎𝑖𝑠𝑜 =
1
3
[𝜎11 + 𝜎22 + 𝜎33]                                                    (10) 
For systems that deviate from the ideal isotropic sphere, the anisotropy can be calculated 
using equation 11 and abbreviated as equation 12. 
                               ∆𝜎 = 𝜎11 −
1
2
(𝜎22 + 𝜎33)                                                     (11) 
                                      ∆𝜎 = 𝜎∥ − 𝜎⊥                                                                (12) 
using the standard convention that  σ11 ≥ σ22 ≥ σ33.
129
 
These tensor components can be predicted through computational studies using 
quantum mechanics, but they also can be measured or calculated from experimental 
data.
126, 128
 Using solid state NMR, measurements can be taken on single crystal samples, 
static powder pattern spectra from polycrystalline samples, and spinning side bands 
undergoing magic angle spinning (MAS), in addition to CSA recovery experiments that 
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measure CSA when it is normally cancelled out.
132
 In solution NMR, the CSA tensors 
can be calculated based on examining T1 and T2 relaxation data provided that CSA is the 
predominant relaxation mechanism relative to dipolar interactions. Cross correlated spin 
relaxation between CSA and dipole-dipole (DD) relaxation can also provide information 
regarding the tensor values.
133-134
 
 
Figure 1.15 Molecular motion of a protein. 
A) The overall tumbling of a protein in solution is represented by τc while the internal 
rotation of side chains is represented by τi. B) Internal side-chain rotation occurs around 
the Cα-Cβ bond and the Cβ-aromatic bond. 
 
In addition to CSA, another key contributor to resonance linewidths is molecular 
motion in solution.
131
 In the case of proteins both the overall tumbling in solution and the 
internal side-chain rotation must be taken into consideration (Figure 1.15 A). The 
rotational correlation time, τc, is a function of molecular weight such that larger 
molecules tumble slower in solution, leading to line broadening. Internal correlation time 
τi corresponds to internal side chain rotational motion which most often leads to line 
narrowing, as calculated using spectral density functions.
125
 
For aromatic amino acids, the dominant source of internal rotation is around the 
Cβ-aromatic bond (Figure 1.15 B). Some internal rotation also occurs around the Cα-Cβ 
bond. In the case of phenylalanine, this effect can result in narrower linewidths due to τi 
being faster than τc. Tryptophan, due to its large size, and tyrosine to an extent, have very 
limited rotation around this bond when they are buried within a protein. In these cases τi 
can be approximated to be equal to the τc of the protein as a whole.
135-137
 This 
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phenomenon was estimated by Hull and Sykes
125
 (Table 1.2) and later calculated based 
on experimental data by Dürr et al.
129
 ( 
Table 1.3). This same approximation cannot be made, however, when the residues 
are more surface or solvent exposed.   
 
Table 1.2 Predicted 
19
F linewidths of 3FY and 4FF at varying field strengths, molecular 
weights, and internal side chain rotational correlation times 
Linewidths are reported in Hz, and 7 x 10
-8
 s was used for the overall rotational 
correlation time, τc.  “Isotropic” is used to denote no internal motion. Adapted from Hull 
and Sykes
125
 with permission from Elsevier.
 
 
 
NMR 
Frequency 
log τi 
3-fluoro-tyrosine 4-fluoro-phenylalanine 
MW=86,000 MW=20,000 MW=86,000 MW=20,000 
94 
-11 3.2 0.46 0.07 0.01 
-10 3.2 0.46 0.08 0.01 
-9 3.2 0.50 0.11 0.04 
-8 3.4 0.69 0.34 0.24 
-7 4.8 1.1 1.7 0.67 
-6 7.7 1.3 4.9 0.88 
Isotropic 8.8 1.3 6.3 0.92 
254 
-11 23.0 3.3 0.5 0.08 
-10 23.0 3.3 0.6 0.11 
-9 23.3 3.6 0.8 0.34 
-8 24.8 4.7 2.2 1.5 
-7 35.0 7.6 12.5 4.7 
-6 55.8 9.0 35.9 6.3 
Isotropic 64.3 9.2 45.8 6.6 
339 
-11 40.9 5.9 1.0 0.14 
-10 41.0 5.9 1.0 0.19 
-9 41.4 6.3 1.4 0.58 
-8 44.1 8.3 3.8 2.5 
-7 62.2 13.5 22.2 8.4 
-6 99.2 16.0 63.9 11.2 
Isotropic 114.2 16.3 81.5 11.7 
 
The linewidths in Table 1.2 were calculated using reported tensor values for 
fluorobenzene compounds, with monofluorobenzene and 1,2-difluorobenzene serving as 
approximations for 4-fluorophenylalanine (4FF) and 3-fluorotyrosine (3FY) 
respectively.
125
 As expected, both amino acids show an increase in linewidth as a 
function of both increasing field strength and increasing molecular weight, which, as 
mentioned above, relates to the rotational correlation time of the protein as a whole. For 
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both amino acids, there is also significant line broadening as the amount of internal side-
chain motion decreases. For 3FY the linewidth experiences a 3-4 fold increase from 
comparing fast internal rotation to no internal rotation. For 4FF, this effect was even 
more pronounced where the linewidths increased by almost two orders of magnitude 
when the residue was calculated to have no internal motion. In comparing the two amino 
acids, 4FF has significantly narrower linewidths than 3FY, which serves as evidence that 
4FF labeling of a protein may provide the narrowest resonances.   
 
Table 1.3 CSA and relaxation data obtained by solid state 
19
F NMR, Adapted from Dürr 
et al.
6
  
Amino 
Acid 
CSA (ppm) T2 (µs) 
4FF 60.5 40.6 ± 7.2 
3FY 74.6 25.4 ± 5.4 
5FW 47.1 42.0 ± 1.1 
 
Using solid-state NMR data of polycrystalline amino acids, Dürr et al compared 
the CSA and relaxation times of various fluorinated amino acids that have been 
incorporated into poly peptides and proteins.
129
 Key results have been summarized in  
Table 1.3. This data corroborates the predictions made by Hull and Sykes with 
3FY being more affected by CSA and consequently having as shorter T2 relaxation time 
than 4FF. Given the relationship between T2 and linewidth, it is also reasonable to 
postulate that the 3FY resonances will be broader than those of 4FF. 5FW has the lowest 
CSA and the longest T2 of the three amino acids being compared which would make it an 
ideal candidate for studying a protein. However, as established above, the internal side-
chain rotational motion must also be taken into consideration. Both 4FF and 5FW are 
comparable in regards to their T2 relaxation, but their internal motion will be heavily 
dependent on their location within a protein in regards to whether it is more surface 
exposed or buried in the interior of the protein.  
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Figure 1.16 3FY labeled alkaline phosphatase obtained on a 250 mHz NMR. 
Fluorine incorporation was approximately 70%. Adapted from Hull and Sykes
125
 with 
permission from Elsevier. 
 
When considering linewidths in NMR, it is important to understand the many 
components that contribute, including the chemical shift anisotropy of the nucleus being, 
the rotational correlation time of the protein as a whole, and the internal side-chain 
rotation. While 
19
F may have more CSA than 
15
N, by labeling side chains rather than the 
backbone it is still possible to obtain distinct resonances even at large molecular weights. 
Even though 3FY is expected to be the least favorable aromatic amino acid to be 
incorporated into a protein due to broadening and poor mobility, it is still feasible to 
discern the individual residues on alkaline phosphatase (MW 86 kDa) (Figure 1.16). 
While some resonances overlap, most are distinguishable. To summarize, even though 
CSA has significant effect on line broadening, PrOF NMR is still well suited to study 
proteins as demonstrated by its use for various proteins encompassing a wide range of 
molecular weights, its sensitivity to its chemical environment, and its ease of use and 
interpretation.
41, 79, 90, 138-140
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1.3 Small Molecule Screening 
The identification of viable compounds for drug use is a difficult process that has 
been addressed by screening large libraries of compounds against a target of interest. To 
efficiently select potential drug compounds, Lipinski’s “Rule of 5” (RO5) is often used as 
a guideline.
141
 The RO5, as well as other iterations like the Rule of 3 (RO3)
142
 provide 
guidelines regarding size and chemical properties for selecting compounds that will have 
a greater likelihood of success as drug compounds. High throughput screening (HTS) has 
been the dominant method for drug discovery, but recent years have also seen the rise of 
fragment based screening (FBS) as an alternative and potentially more efficient 
method.
143-144
  
1.3.1 High Throughput Screening 
HTS is characterized by the ability to screen more than 10,000 compounds within 
one week, although with advances in technology it is not unreasonable to now expect 
10,000 compounds per day. By nature of the screening method, any analysis technique 
for HTS must be extremely fast. This lends itself best to optical methods which can be 
examined quickly with a camera or other optical detector. These techniques include 
biochemical assays such as fluorescence polarization and cell based assays such as 
reporter gene assays. The application determines both the types of compounds that are 
screened as well as the technique used for screening.
145-146
 
 While HTS has been well optimized, there are intrinsic shortcomings that it has 
yet to address. One major challenge is the size of chemical space, which is a description 
of the number of molecules possible given certain conditions. In HTS, chemical space is 
estimated to be composed of 10
60
 unique molecules.
147
 Even screening at a rate of 
200,000 compounds per day for a year does not come close to covering all of chemical 
space. While HTS has had many success stories for a variety of protein classes, most 
notably enzymes, the challenge of low hit rates for PPIs is sufficient cause for seeking a 
more efficient method for small molecule discovery.
143
 HTS faces a qualitative challenge 
as well in that it seeks to identify high affinity compounds (Kd ≤ 1µM).
147
 The number of 
lead compounds with this level of affinity is extremely low, which adds to the problem of 
already not covering very much of the available chemical space. These challenges may 
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indicate that the types of compounds in HTS libraries are not fit for targeting PPIs. If 
there was a way to simultaneously reduce the size of chemical space and increase the hit 
rate, the efficiency of the entire process would be greatly improved.  
1.3.2 Fragment Based Screening 
Fragment based screening (FBS), developed as an alternative to HTS, differs in 
the types of molecules that are screened. FBS examines low molecular-weight, low 
affinity fragments of drug-like molecules rather than full size drug molecules. A hit in 
FBS typically has a Kd in the mid µM to low mM range.
147
 These fragments that bind in 
nearby locations in the protein can then be pieced together to form active drug 
compounds possessing higher affinities than any of the component fragments.
148
  In 
addition to a higher hit rate, chemical space in FBS is significantly smaller than it is in 
HTS. The number of potential fragment molecules in chemical space for molecules less 
than 160 Da is estimated to be on the order of 10
7
 in contrast with 10
60
 as is estimated for 
complete chemical space in HTS.
147
 This drastic reduction in the size of chemical space 
makes exploring the entirety of chemical space far more feasible.  
 NMR is an ideal FBS technique and holds numerous advantages over other 
methods. It requires no immobilization or bulky fluorophores. It is also a non-destructive 
technique, allowing the protein to be reused. Additionally, NMR is performed in a 
buffered solution at a physiological pH which allows the proteins to orient and fold 
naturally as it would in a biological system. It also provides structural information 
regarding the protein of interest. Sample preparation is also significantly easier in NMR 
than it is for most other screening techniques. Using SAR by NMR, as discussed earlier, 
Fesik and colleagues have been able to discover small molecule fragments that bind to 
proteins. As a proof-of-concept, Pomerantz et al. used PrOF NMR for a preliminary 
fragment screen of 50 small-molecule fragments which recognized one hit as determined 
by a Δδ of 0.100 ppm in the 19F NMR spectrum. The conclusion was that not only can 
PrOF NMR be used for FBS but that it could be done within a reasonable amount of time 
(5-10 min/fragment mixture).
41
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1.3.3 Screening Metrics for Ligand Development 
In a screening campaign, there are a range of metrics that can be used to prioritize 
which compounds should be carried on to development and which should be triaged. 
Affinity is just one of many metrics that is utilized to evaluate hit compounds from a 
screen. Beyond principles avoiding pan-assay interfering compounds (PAINS)
149
 or 
identifying compounds that will be easier to synthetically derivatize, there are several 
versions of what has become commonly known as ligand efficiency. Here we will 
describe just two of them.  
A compound’s ligand efficiency (LE) is defined as the its change in free energy 
per non-hydrogen atom. Essentially it is a measure of how much each atom in the 
molecule contributes to the overall binding energy and is calculated using Equation 13 
where HA denotes the number of heavy or non-hydrogen atoms. This equation can be 
modified to be calculated from a Kd, as shown in Equation 14 where R is the ideal gas 
constant, T is the temperature in Kelvin, and Kd is the dissociation constant.  
                                           𝐿𝐸 =  ∆𝐺/𝐻𝐴                                                          (13) 
                                     𝐿𝐸 =  −𝑅𝑇 ln 𝐾𝑑/𝐻𝐴                                                    (14) 
Each atom in a compound will either contribute to or take away from the binding energy 
of the compound to the protein target. Therefore it is advantageous to start with a 
compound that has a high LE as opposed to a low LE because a low LE makes the 
development process more difficult. In a case study of 480 target-assay pairs, the median 
LE was found to be 0.32 kcal mol
-1
 HA
-1
  with a range of 0.2 to 0.6 kcal mol
-1
 HA
-1
.
150
   
A compound’s lipophilic ligand efficiency (LLE) is calculated using equation 15 
and describes the specificity of a compound to bind to the target relative to its affinity to 
partition into 1-octanol. Note that in this case the LLE can be calculated using any 
variation of an affinity measurement (e.g., Ki, IC50, EC50).  
                                                    𝐿𝐿𝐸 = 𝑝𝐾𝑑 − 𝑐𝑙𝑜𝑔𝑃                                                   (15) 
The LLE accounts for not only affinity but also for hydrophobicity. It is not uncommon 
for developed compounds to be triaged due to unfavorable adsorption, distribution, 
metabolism, excretion, and toxicity (ADMET) properties.
151
 Analyzing a hit’s LLE is a 
method to preemptively avoid these types of issues later on since lipophilicity is often 
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closely related to other ADMET properties. In the same study cited above, the median 
LLE for the 480 target-assay pairs was 2.83 with a range from -3 to 9.
150
 An ideal drug 
candidate is estimated to have an LLE greater than 5, but it is common for HTS hits to 
have an LLE ≤ 2. Further discussions of both LE and LLE will be presented in chapters 2 
and 5.  
1.4 Additional Techniques for Ligand Screening 
1.4.1 NMR spectroscopy 
While protein-observed NMR techniques have been discussed at length above, it 
is worth noting that ligand-observed techniques such as saturation transfer difference 
(STD), Water-Ligand Observed via Gradient Spectroscopy (WaterLOGSY), and Carr-
Purcell Meiboom-Gill (CPMG) are standard screening tools utilized by industry and 
pharmaceutical companies.
144, 152-154
 These ligand-based techniques have the distinct 
advantage of removing the need for a deconvolution step when screening mixtures of 
compounds. Because resonances corresponding to specific ligands are monitored, it is 
clear which ligands are undergoing binding events and which are unaffected.  
Urick et al. performed a comparative screen using PrOF NMR and 
1
H CPMG 
NMR against the protein Brd4.
75
 They compared the hit rates, speed, material 
consumption, propensity for false results (positive or negative), the ability of each 
method to triage compounds, and the responsiveness of the each method. Results were 
confirmed by thermal shift assays (Section 1.4.2) and ITC. Urick et. al. reported an 80% 
overlap between the two assays, demonstrating the complementary nature of the two 
techniques.  
It has also been common to use 
19
F NMR to perform ligand observed experiments 
in the cases where libraries of fluorinated compounds are available.
155-156
 Much of this 
work has been pioneered by Dalvit and coworkers over the past 15 years in performing 
both 1D and 2D 
19
F NMR experiments for small molecule discovery. Of relevance is the 
fact that almost 30% of all FDA approved drugs contain at least one fluorine, making the 
screening of fluorine-containing small-molecule libraries even more attractive.
157
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1.4.2 Thermal Shift Assays 
Thermal shift assays, such as differential scanning fluorimetry (DSF), are another 
class of biophysical assays commonly used as screening platforms.
158-160
 Their rapid 
throughput and low material requirements make them an attractive starting point for a 
screening campaign. The premise of a thermal shift assay is that as a ligand associates 
with a protein of interest, it will stabilize or destabilize the structure of the protein, 
thereby changing or shifting the melting point (Tm) of the protein. Conversely compounds 
that do not bind to the protein will have no effect on the melting point of the protein. 
Typically a fluorescence of a dye is monitored as a function of temperature. As the 
temperature increases and the protein begins to unfold, hydrophobic regions of the 
protein are then exposed, to which the fluorescent dye binds. This association increases 
the fluorescence signal that is measured. The more stabilized a protein is by a ligand, the 
higher the temperature will need to be to achieve the same fluorescence signal.  
Molina and coworkers. have reported on methods for a cellular thermal shift assay 
(CETSA) in which the same principles discussed above are performed but in a cellular 
context.
161-162
 The consideration of the cellular environment is important because a drug 
compound may have a different on- or off-target effect in cells than it does in an in vitro 
system. This method has significant potential to help triage compounds in the pre-clinical 
drug development stage and further aid in the process of studying drug efficacy at 
biologically relevant levels. 
Thermal shift assays provide incredibly rapid screening results, but its main 
limitation is in its inability to provide any quantitative or structural information about the 
newly discovered ligand. Loose correlations can be drawn between the magnitude of 
change in a protein’s melting temperature and the affinity of a given compound. There is 
also a significant amount of debate regarding the relevance of destabilizing compounds 
i.e., compounds that decrease rather than increase the Tm. While most people tend to 
favor compounds that stabilize a protein target, Gestwicki and coworkers have 
demonstrated uses for destabilizing compounds as well.
163
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1.4.3 Surface Plasmon Resonance 
SPR is one of the more common screening techniques available due to its rapid 
throughput and low material consumption. 
164
 In SPR, a protein of interest is immobilized 
on the surface of a chip, and ligands are flowed over the protein, often using a 
microfluidics platform. On the other side of the surface to which the protein is attached is 
a layer of gold. This layer is excited by plane polarized light, which releases a plasmon 
wave. The frequency of this wave will change as a function of changes on the surface, 
such as ligand binding to a protein. The altered plasmon wave also changes the light that 
is reflected from the surface. Consequently, binding events can be monitored in real time, 
allowing the measurements of on-rates (Kon) and off-rates (Koff).  
One of the key advantages of SPR is that it is a label-free technique. However, the 
protein does have to be immobilized on a surface which can still potentially alter ligand 
binding, either positively or negatively. This consideration  further emphasizes the need 
for orthogonal methods of evaluation of hit compounds.  
1.4.4 Virtual Screening 
A relatively recent tool that has been gaining popularity and utility is virtual 
screening, which computationally predicts ligand binding.
165
 A range of softwares and 
methods are available, but they all operate under similar principles. At a basic level, these 
“docking” studies will take a molecular mechanics approach to analyzing whether or not 
a small molecule will fit into a binding pocket. Its fit will be evaluated on criteria such as 
steric hindrance and charge interactions. More advanced methods utilize quantum 
mechanics for more precise calculations. Because virtual screening is a computational 
method, the throughput and capacity of compounds that can be screened is unparalleled 
in biophysical assays. We reported on SAR development that came from a six million 
compound virtual screen against Brd4.
166
 This work is also highlighted in Appendix 4.  
The main drawback to virtual screening is the fact that it is virtual. As good as 
computational predictions are, they do not perfectly reflect what happens in a physical 
experiment. As such, it is a very useful tool for initial screening and for brainstorming 
new compounds and analogs, but it must be followed up with biophysical assays.  
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1.5 Brief descriptions of chapters 
The following chapters describe my role in various projects in the development and 
application of fluorine-based magnetic resonance experiments. Chapters 2 and 3 focus on 
the application of PrOF NMR to the protein KIX in a full fragment screen (Ch. 2) and in 
the discovery of a new ligand binding site (Ch. 3). Chapter 4 is a description of our PrOF 
NMR protocol, covering the entire process from bacterial transformation to fragment 
screening. Chapter 5 shifts in focus to bromodomains, a class of proteins that are 
biologically of interest as epigenetic “reader” proteins. This chapter encompasses three 
separate projects for targeting the bromodomain BrdT from a ligand deconstruction 
approach and from a fragment screening approach. Chapter 6 describes the application of 
19
F NMR and MRI as an oximetry tool using ultraporous mesostructured silica 
nanoparticles loaded with perfluorocarbons. Finally, Chapter 7 features an educational 
report on protein quantification using a technique known as smartphone colorimetry, 
making experiments like the Bradford assay accessible even in situations when a UV-Vis 
spectrophotometer is not available. Appendix 1 is an extension of Chapter 6, describing 
more of the details in the synthesis and characterization of the nanoparticles. Appendix 2 
features both a student worksheet and instructor guide for the experiments outlined in 
Chapter 7.  
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Chapter 2. Fragment Screening and Druggability Assessment for the 
CBP/p300 KIX Domain Via Protein Observed 19F NMR 
 
Reproduced with permission from “Fragment Screening and Druggability Assessment for the 
CBP/p300 KIX Domain Via Protein Observed 
19F NMR,” C. T. Gee, E. J. Koleski,  W. C. 
Pomerantz, Angewandte Chemie International Edition 2015, 3735-3739. Copyright 2015 Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
Motivation: The motivation for this manuscript was to address the question of whether or 
not Protein Observed Fluorine NMR could be useful as a ligand discovery tool in a 
fragment screening capacity. Screening techniques using structure-based methods ideally 
address the three following questions in varying degree: 1) Does a particular compound 
bind to the protein target? 2) How well does it bind? And 3) Where on the protein does it 
bind? This manuscript sought to establish that PrOF NMR could be sufficiently used to 
address all three of these questions. Further, we sought to evaluate the efficacy of using 
PrOF NMR as a method for assessing the druggability of different binding sites by 
comparing hit rates for each site to other established screening tools. KIX, the model 
protein system that we used in this study, features two native transcription factor binding 
sites, which are both biologically relevant targets of interest.  
2.1 Introduction 
Protein-protein interactions (PPIs) are essential nodes in almost all biological 
processes within the cell. Modulation of these biomolecular interactions via small 
molecules is now a validated approach for therapeutic intervention
167-168
 and chemical 
probe development to improve our understanding of biological systems.
169
 Despite this 
validation, disruption of these interactions is difficult due to the large and plastic 
interfaces at the protein surface and lack of deep hydrophobic binding sites for 
accommodating traditional drug-like molecules.
16
 This is particularly the case for the 
  39 
transient and dynamic interactions found for many transcription factor-protein binding 
events that occur with modest affinity (Kd = 0.1-100 µM).  
We recently reported on a protein-observed fluorine NMR method (PrOF NMR) 
for characterizing ligand binding at PPI sites.
41, 98
 We employed singly-labeled 
fluorinated aromatic amino acids due to the enrichment of aromatic amino acids at PPI 
interfaces.
23, 170
  In many cases, the modest protein structural perturbations from a single 
aryl hydrogen to fluorine substitution, the fast data acquisition for small to medium sized 
proteins, and the orthogonality of fluorine with biological nuclei, lead to a simplified and 
readily obtainable 1D-NMR spectrum reporting directly on protein structure.
74, 171
 We 
used this method to characterize small molecule binding to three different epigenetic 
effector domains: bromodomains Brd4, BrdT, and BPTF.
98
 We also studied the protein 
interaction domain of CBP/p300, KIX, by PrOF NMR and identified small molecule 
ligands 1-10 and 1G7.
41
 Beyond model studies, PrOF NMR has yet to be tested in a full 
discovery format. Herein, we report the first full small molecule screen using PrOF 
NMR, evaluate its effectiveness for assessing protein druggability at two different 
binding sites within the same protein, KIX, and report structure activity relationships 
(SAR) from several newly discovered small molecules. 
Molecules of low molecular weight and complexity, called fragments, have 
helped increase successful screening outcomes against difficult protein targets.
147
 NMR 
has become a preferred method for screening for identifying low affinity ligands, in many 
cases using 1D-NMR ligand-based methods.
172-174
 Analysis of fragment screen hit rates 
provides valuable information into the ligandability or “druggability” of the proteins,175 
and further development of fragments has led to molecules with more efficacious binding 
affinity and improved physicochemical properties than molecules obtained from 
traditional high-throughput screening.
176
 To test the feasibility of using PrOF NMR in a 
fragment screening format, we chose the KIX domain.  
KIX is a useful model protein for characterizing protein-small molecule 
interactions and studying the conformational plasticity of this dynamic protein domain. 
KIX binds to over a dozen transcription factors (e.g., MLL, E2A-PBX1, and CREB) 
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through two binding sites.
40, 177-178
 These sites as well as new cryptic sites cannot readily 
be distiguished in a direct binding 1D-NMR ligand-based experiment. Prior screening 
efforts offer valuable ligand information for comparison with our PrOF NMR 
experiments. Two natural product depsides, sekikaic acid and lobaric acid, are reported as 
the most potent KIX inhibitors at the MLL-KIX PPI site (IC50 = 34 and 17 µM 
respectively). These compounds isolated from natural products were discovered after a 
screen of 50,000 commercial library compounds had resulted in no hits.
42
 The only 
HSQC NMR screen resulted in two lead compounds, KG-122 (pamoic acid) and KG-501 
from a 762-member peptidomimetic library (Fig. 1).
36, 179
 Isoxazolidine derivatives, 
discovered first as general transcriptional activation domain mimics,
180
 were later shown 
to also be KIX ligands.
181
 Despite the paucity of potent ligands, both CREB-KIX, and 
E2A-KIX interactions have been proposed as important PPI targets for treating blood 
cancers due to their regulatory role in blood cell proliferation further motivating our 
research.
35, 177
  
 
Figure 2.1 Solution structure of KIX and known ligands.  
A) NMR solution structure of KIX (PDB: 2LXT) with natural peptides MLL and pKID 
(CREB). Tyrosine residues are shown as spheres. B) Structures of KIX ligands and their 
corresponding methods of discovery. 
 
PPIs involving the KIX domain occur through two distinct and allosterically-
coupled binding sites on this 3-helical bundle protein. These sites are often referred to as 
the MLL and CREB/c-Myb sites.
42
  To conduct the NMR screen, we replaced native 
tyrosine residues of KIX with 3-fluorotyrosine (3FY). The MLL site contains one 
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tyrosine (Y631), which makes a critical contact with the native protein. A sequence 
analysis by Näär et al. of KIX domains shows this residue is conserved in humans, C. 
elegans and drosophila.
182
 Y649 is evolutionarily conserved in all KIX domains. Fluorine 
resonances from Y649, Y650, and Y658 experience significant chemical shifts when 
CREB binds to KIX as well as Y631 from allostery.
41
 Consistent with natural ligands, our 
computed druggability analysis using SiteMap identified two druggable sites near the 
tyrosine residues at both the MLL (10.8 Å from Y631) and CREB/Myb sites (4-10 Å 
from Y649, Y650, and Y658).
183
 Y640, which structurally stabilizes KIX via a cation-π 
interaction with R600,
184
 is found in 97% of KIX domains, and may represent a new 
small molecule site for regulating protein conformation.
182
 Importantly, singly fluorinated 
aromatic residues in KIX only modestly perturb secondary structure and ligand binding.
41
  
 
Figure 2.2 SiteMap analysis of KIX (PDB 2AGH). 
Tyrosine and phenylalanine are shown as sticks. Binding sites identified by SiteMap are 
represented as spheres. Native peptides MLL and Myb are shown as ribbons. A) Full 
protein view portraying both native binding sites identified by SiteMap. B) MLL binding 
  42 
site showing both F612 and Y631 in close proximity to the binding site. C) CREB/Myb 
binding site showing Y649, Y650, and Y658 in close proximity to the identified binding 
site. 
 
Figure 2.3. The deconvoluted ESI-mass spectrogram of a 3FY KIX sample 
demonstrating high fluorine incorporation.  
The peak at 12004.6 is an 80% labeled protein, the peak at 12021.8 is the 100% labeled 
protein containing all five 3FY residues, and the peak at 12037.0 is consistent with a 
small percentage of an oxidized product that was presumed to occur from methionine 
oxidation. For high labeling, 80 mg 3FY per liter is added to the defined media.   
2.2 Results and Discussion 
We expressed 3FY-labeled KIX (12 kDa) in good yield (70 mg/L) with high 
labeling efficiency (>98%) for the screen.
183
 Our fragment library was generated from the 
Maybridge rule of 3 commercial set, combining compounds into 85 mixtures of five or 
six compounds at a total stock concentration of 33.3 mM per compound in DMSO. As a 
positive control, we tested a known ligand, KG-501 (833 µM), and identified a binding 
interaction, both in isolation, consistent with prior results,
41
  and in a mixture based on 
chemical shift perturbation of Y631 (Fig. 2B). For the NMR screen we used 40 µM KIX 
(~20 mg protein total). Chemical shift information was acquired in five minutes yielding 
approximately 510 minutes of experiment time for screening the 85 mixtures, including 
additional short reference experiments for each mixture. This experiment time is faster 
than 
1
H-
15
N SOFAST HMQC NMR experiments for similar sized proteins.
185
  All 
mixtures were screened at 833 µM small molecule and 2.5% DMSO. Statistical cut-offs 
for chemical shift perturbation were set to two standard deviations from the average 
perturbations from the screen yielding 15 mixtures (Fig. 2C). Each mixture was 
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subsequently deconvoluted by individual analysis of each compound leading to four 
verified ligands (1-4, 0.8% hit rate). The reduction in hits was due to apparent additive 
effects of fragments which prevented the identification of a sole compound responsible 
for chemical shift perturbations in a given mixture. 
 
Figure 2.4 Fragment screening by PrOF NMR.  
A) Flowchart for screening of fragment library for KIX ligands. 508 fragments were 
screened using PrOF NMR, yielding 15 mixtures hits and seven final ligand after 
deconvolution and SAR studies. B) KG-501 was used to test for KIX ligand identification 
in isolation or a mixture of six total compounds. C) Statistical cut-offs for chemical shift 
perturbations found in the screen. Samples with chemical shift pertubations greater than 
two standard deviations were identified as hits. 
 
Ligand titration experiments via PrOF NMR were performed to determine the 
dissociation constants for the small molecule obtained by monitoring changes in chemical 
shift (Δδ). Three of the four ligands (2, 3, and 4) discovered from the screen were found 
to have low mM binding affinities for KIX. These compounds contained either an aryl or 
phenylacetic acid group (Table 1).  Small molecules 3 and 4 exhibited a binding isotherm 
consistent with one-to-one binding while 2 potentially exhibited higher-order binding 
above 2 mM based on the binding isotherm generated. Consequently the Kd for 2 was 
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estimated based on fitting the data up to 2 mM. We ruled out activity due to small 
molecule aggregation above 2 mM based on well resolved small molecule resonances in 
the presence and the absence of detergent.
183
  
 
Figure 2.5 Aromatic region of 2 in the presence and absence of detergent in aqueous 
buffer.  
Buffer contains 50 mM HEPES and 100 mM NaCl at pH 7.2. Linewidths are not 
significantly perturbed in the presence of detergent, suggesting a lack of small molecule 
aggregation. 
 
Given that KG-122 is a diacid compound that binds to KIX in the MLL site, it is 
possible that multiple copies of the monoacid 2 could bind in the same region on the 
protein. Y631, which is featured in the MLL site, was the most sensitive reporter for 
binding and was therefore used to calculate the Kd for 2, 3, and 4.  In contrast, Y649, 
Y650, and Y658, which are featured in the CREB binding site, were significantly less 
responsive to ligand binding with the exception of 1 which perturbed resonances for 
Y649, Y650, and Y631, potentially indicating binding at the CREB site.   
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Figure 2.6 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of 1.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. Tyrosine residues shown as sticks experienced statistically significant 
perturbations at low concentrations (833 µM) but failed to approach saturation, were not 
significantly perturbed, or were significantly perturbed and approached saturation. B) 
Absolute value of chemical shift perturbations for all 3FY KIX tyrosine resonances at 5 
mM 1. C) Binding isotherm of Y631 perturbation for the titration of 1. 
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Table 2.1. 3FY-KIX 19F NMR chemical shift perturbations at varying 1 concentrations  
[1] (µM) 
Chemical 
shift (ppm) 
Y649 Y650 Y658 Y640 Y631 
0 
Chemical 
shift (ppm) 
-134.6690 -138.2668 -138.6544 -138.9044 -139.5114 
104 Δδ (ppm) 0.0212 0.0076 0.0090 0.0091 0.0214 
208 Δδ (ppm) -0.0076 0.0182 0.0055 -0.0080 0.0201 
416.5 Δδ (ppm) -0.0060 0.0161 0.0060 0.0092 0.0427 
833 Δδ (ppm) -0.0032 0.0238 0.0135 0.0044 0.0656 
1666 Δδ (ppm) 0.0321 0.0523 0.0213 0.0160 0.1280 
5000 Δδ (ppm) 0.1291 0.1300 0.0424 0.0342 0.3078 
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Figure 2.7. 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of 2.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. Tyrosine residues shown as sticks experienced statistically significant 
perturbations at low concentrations (833 µM) but failed to approach saturation, were not 
significantly perturbed, or were significantly perturbed and approached saturation. B) 
Absolute value of chemical shift perturbations for all 3FY KIX tyrosine resonances at 5 
mM 2. C) Binding isotherm of Y631 perturbation for the titration of 2. 
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Figure 2.8. Full titration of 2, demonstrating non-first order binding behavior above 2 
mM. 
 
Table 2.2. 3FY-KIX 19F NMR chemical shift perturbations at varying 2 
concentrations 
 
 
[2] (µM) 
Chemical 
shift (ppm) 
Y649 Y650 Y658 Y640 Y631 
0 
Chemical 
shift (ppm) 
-134.6690 -138.2668 -138.6544 -138.9044 -139.5114 
104 Δδ (ppm) -0.0066 0.0054 0.0030 -0.0161 -0.0208 
208 Δδ (ppm) -0.0259 0.0051 0.0052 0.0037 -0.0284 
416.5 Δδ (ppm) -0.0962 -0.0077 -0.0057 -0.0040 -0.0560 
833 Δδ (ppm) 0.0051 0.0137 0.0156 0.0046 -0.0797 
1666 Δδ (ppm) -0.0477 0.0053 0.0163 -0.0090 -0.1277 
1978 Δδ (ppm) -0.0476 0.0065 0.0196 -0.0134 -0.2154 
2499 Δδ (ppm) -0.0333 0.0158 0.0341 -0.0169 -0.2621 
2916 Δδ (ppm) -0.0523 0.0158 0.0391 -0.0319 -0.3297 
5000 Δδ (ppm) -0.0434 0.0158 0.0368 -0.0272 -0.3510 
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Figure 2.9. 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of 3.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. Tyrosine residues shown as sticks experienced statistically significant 
perturbations at low concentrations (833 µM) but failed to approach saturation, were not 
significantly perturbed, or were significantly perturbed and approached saturation. B) 
Absolute value of chemical shift perturbations for all 3FY KIX tyrosine resonances at 5 
mM 3. C) Binding isotherm of Y631 perturbation for the titration of 3. 
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Table 2.3. 3FY-KIX 19F NMR chemical shift perturbations at varying 3 
concentrations 
 
Table S4.  3FY-KIX 
19
F NMR chemical shift perturbations at varying 3 concentrations. 
[3] (µM) 
Chemical 
shift (ppm) 
Y649 Y650 Y658 Y640 Y631 
0 
Chemical 
shift (ppm) 
-134.6690 -138.2668 -138.6544 -138.9044 -139.5114 
104 Δδ (ppm) -0.0183 0.0000 0.0056 0.0185 -0.0008 
208 Δδ (ppm) -0.0306 0.0015 0.0062 0.0164 -0.0115 
416.5 Δδ (ppm) 0.0142 -0.0110 0.0001 0.0067 -0.0388 
833 Δδ (ppm) 0.0158 -0.0226 0.0018 0.0112 -0.0582 
1666 Δδ (ppm) -0.0602 -0.0579 -0.0090 -0.2816 -0.1105 
5000 Δδ (ppm) -0.0003 -0.1686 -0.0149 0.0406 -0.2193 
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Figure 2.10. 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of 4.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. Tyrosine residues shown as sticks experienced statistically significant 
perturbations at low concentrations (833 µM) but failed to approach saturation, were not 
significantly perturbed, or were significantly perturbed and approached saturation. B) 
Absolute value of chemical shift perturbations for all 3FY KIX tyrosine resonances at 5 
mM 4. C) Binding isotherm of Y631 perturbation for the titration of 4. 
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Table 2.4. 3FY-KIX 19F NMR chemical shift perturbations at varying 4 
concentrations.  
 
As a follow-up to the screen, the SAR from the four hits were examined to 
identify structural motifs important for binding. Four trifluoromethylquinoline derivatives 
of 1 were purchased. These compounds were of interest due to small but significant 
chemical shift perturbations from 1 of Y649, Y650, Y658, and Y631, which were similar 
to the chemical shift effects observed upon CREB  binding to KIX suggesting a possible 
allosteric binding mode.
[4a]
 One of the four compounds (KM07508) yielded comparable 
chemical shift perturbations as 1.
183
 However, as 1 displayed poor binding behavior in 
titration experiments (Kd > 10 mM) due to lack of saturated binding and in 2D NMR 
experimental results explained below, SAR studies with this ligand class were not 
pursued further in lieu of the investigation into aryl and phenylacetic acids.  
 
[4] (µM) 
Chemical 
shift 
(ppm) 
Y649 Y650 Y658 Y640 Y631 
0 
Chemical 
shift 
(ppm) 
-134.6653 -138.2711 -138.6618 -138.8869 -139.5090 
104 Δδ (ppm) -0.0255 -0.0038 -0.0037 -0.0062 -0.0310 
208 Δδ (ppm) -0.0225 0.0017 -0.0035 0.0061 -0.0254 
416.5 Δδ (ppm) -0.0329 -0.0056 -0.0049 0.0071 -0.0684 
833 Δδ (ppm) -0.0448 -0.0049 0.0006 -0.0194 -0.1158 
1666 Δδ (ppm) -0.0776 -0.0223 -0.0001 -0.0057 -0.1690 
  53 
 
Figure 2.11 SAR analysis of 1 analogs.  
A) Structures of 1 and corresponding analogs from Maybridge. B) Stacked PrOF NMR 
spectra with 5 mM ligands. Intensity scale for 3FY KIX and 1 spectra were increased to 
compensate for a larger number of scans for the other three experiments.  * denotes a 
partial degradation peak of KIX. C) Absolute value of chemical shift perturbations of all 
tyrosine residues with 5 mM ligands. 
  
The other three discovered ligands contained an aryl or phenylacetic acid motif as 
a potential pharmacaphore. The presence of a carboxylic acid has been found in other 
KIX ligands that bind to the MLL site (sekikaic acid, lobaric acid, KG-122, and 1G7, Fig 
1). To evaluate specificity over other acidic molecules and to probe for false negatives, 
several compounds from library mixtures were retested. One of the four compounds 
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(9B11, 5), a biaryl carboxylic acid, was anticipated to have been a false negative due to 
its similar structure to KIX ligand 1G7. The other three carboxylic acids were selected to 
test if these aryl and phenylacetic acids represented a class of ligands that bound KIX 
while other carboxylic acids would not (i.e., an aliphatic (6), a phenethyl (7), and a 
thiazole (8) carboxylic acid). Only 5 yielded significant changes in chemical shift, while 
the other three exhibited minimal to no apparent binding. Titration of 5 yielded a Kd of 
1.6 ± 0.3 mM (Table 1). Low mM Kd values and ligand efficiencies from 0.19 to 0.32 
kcal mol
-1
 non-hydrogen atom
-1
 were calculated for each fragment. As a comparison, the 
reported median ligand efficiency was 0.32 for a sample set of 480 ligand-target pairs.
150
 
Our ligand efficiencies are equal to or slightly lower than this value, supporting the 
difficulty of this target site.
42
 
  55 
 
Figure 2.12 SAR analysis of carboxylic acids from screen.  
A) Structures of four carboxylic acids being retested. B) Stacked PrOF NMR spectra with 
5 mM ligands. * denotes a partial degradation peak from KIX. C) Absolute value of 
chemical shift perturbations of all tyrosine residues with 833 μM (left) and 5 mM ligands 
(right). 
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Figure 2.13 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of 5.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. Tyrosine residues shown as sticks experienced statistically significant 
perturbations at low concentrations (833 µM) but failed to approach saturation, were not 
significantly perturbed, or were significantly perturbed and approached saturation. B) 
Absolute value of chemical shift perturbations for all 3FY KIX tyrosine resonances at 5 
mM 5. C) Binding isotherm of Y631 perturbation for the titration of 5. 
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Table 2.5. 3FY-KIX 19F NMR chemical shift perturbations at varying 5 
concentrations 
Table S6: 3FY-KIX 
19
F NMR chemical shift perturbations at varying 5 concentrations.  
[5] (µM) 
Chemical 
shift 
(ppm) 
Y649 Y650 Y658 Y640 Y631 
0 
Chemical 
shift 
(ppm) 
-134.6704 -138.2670 -138.6540 -138.9117 -139.5613 
416.5 Δδ (ppm) -0.0209 0.0068 0.0145 -0.0310 -0.1013 
833 Δδ (ppm) -0.0173 0.0006 0.0153 -0.0296 -0.1396 
1666 Δδ (ppm) 0.0111 -0.0055 0.0155 -0.0198 -0.2215 
3332 Δδ (ppm) -0.0029 -0.0275 0.0138 -0.0374 -0.3259 
5000 Δδ (ppm) 0.0081 -0.0427 -0.0026 0.0116 -0.3211 
 
To expand on the investigation of aryl + acid SAR, nine arylacetic and benzoic 
acid derivatives were tested as analogs of molecule 2 to inform optimization studies, 
based on the affinity of 2 and the readily modifiable structure of phenylacetic acids. Of 
the nine compounds, only the biphenyl (PAA5) yielded a pronounced chemical shift 
perturbation close to one standard deviation above the average at 5 mM,
183
 despite the 
structural similarity of these analogues to 2, e.g., 3-chloro-4-hydroxy phenylacetic acid 
(PAA2), phenylacetic acid (PAA3), and 4-hydroxyphenylacetic acid (PAA4) (Fig. 3).  
Each analog was also analyzed at 2 mM and 833 µM, due to the potential for higher order 
binding at high concentrations (> 2 mM). The trend remained consistent with all 
compounds aside from PAA5 yielding insignificant changes in chemical shift. The Kd for 
PAA5 binding to KIX was 6.9 ± 0.7 mM. These results suggest that hydrophobic groups 
at the para position on the phenylacetic acid play a key role in ligand binding.  
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Figure 2.14. 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of PAA5.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. Tyrosine residues shown as sticks experienced statistically significant 
perturbations at low concentrations (833 µM) but failed to approach saturation, were not 
significantly perturbed, or were significantly perturbed and approached saturation. B) 
Absolute value of chemical shift perturbations for all 3FY KIX tyrosine resonances at 5 
mM PAA5. C) Binding isotherm of Y631 perturbation for the titration of PAA5. 
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Table 2.6. 3FY-KIX 
19
F NMR chemical shift perturbations at varying PAA5 
concentrations 
[PAA5] 
(µM) 
Chemical 
shift 
(ppm) 
Y649 Y650 Y658 Y640 Y631 
0 
Chemical 
shift 
(ppm) 
-134.7310 -138.3225 -138.7184 -138.9099 -139.4771 
500 Δδ (ppm) -0.0137 -0.0097 -0.0057 0.0021 -0.0287 
1000 Δδ (ppm) -0.0183 -0.0084 0.0001 0.0019 -0.0591 
1500 Δδ (ppm) 0.0097 -0.0152 -0.0039 0.0105 -0.0837 
3000 Δδ (ppm) -0.0290 -0.0360 -0.0015 0.0177 -0.1453 
5000 Δδ (ppm) -0.0582 -0.0418 0.0076 0.0042 -0.1890 
7000 Δδ (ppm) -0.0591 -0.0645 -0.0067 -0.0363 -0.2378 
 
Phenylacetic acids are a common scaffold found in several nonsteroidal anti-
inflammatory drugs. As an additional analysis of SAR, naproxen, ibuprofen, and 
flurbiprofen were used to further support the model that para-substituted phenylacetic 
acid derivatives would bind to KIX. All three compounds were analyzed by PrOF NMR. 
The chemical shift perturbations from enantiopure naproxen were under the statistical 
cutoff at low concentrations. Racemic ibuprofen yielded significant chemical shift 
perturbations (Δδ), while racemic flurbiprofen yielded the largest Δδ for Y631 observed 
thus far (0.38 ppm at 5 mM, Kd = 5.9 ± 0.6 mM, Fig. 3). Subsitution at the α-position 
affords an additional site of diversity and both stereochemistry and elaboration of side 
chains can be investigated as starting points for structure activity studies. 
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Figure 2.15. 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of flurbiprofen.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. Tyrosine residues shown as sticks experienced statistically significant 
perturbations at low concentrations (833 µM) but failed to approach saturation, were not 
significantly perturbed, or were significantly perturbed and approached saturation. B) 
Absolute value of chemical shift perturbations for all 3FY KIX tyrosine resonances at 5 
mM flurbiprofen. C) Binding isotherm of Y631 perturbation for the titration of 
flurbiprofen. 
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Table 2.7. 3FY-KIX 
19
F NMR chemical shift perturbations at varying flurbiprofen 
concentrations 
[Flu] (µM) 
Chemical 
shift (ppm) 
Y649 Y650 Y658 Y640 Y631 
0 
Chemical 
shift (ppm) 
-134.6964 -138.3180 -138.7125 -138.9233 -139.4756 
500 Δδ (ppm) 0.0009 0.0062 0.0020 0.0059 -0.0601 
833 Δδ (ppm) 0.0261 -0.0035 -0.0012 -0.0205 -0.1104 
1200 Δδ (ppm) 0.0.0229 0.0049 0.0057 0.0019 -0.1464 
1700 Δδ (ppm) 0.0298 0.0034 0.0023 -0.0045 -0.1918 
2000 Δδ (ppm) 0.0323 0.0093 0.0084 -0.0165 -0.1991 
3000 Δδ (ppm) -0.0154 0.0120 0.0061 -0.0231 -0.2842 
4000 Δδ (ppm) -0.0320 0.0050 0.0146 -0.0478 -0.3427 
5000 Δδ (ppm) 0.0112 0.0156 0.0259 -0.0729 -0.3848 
 
 
Figure 2.16 SAR analysis of phenylacetic/arylacetic acid derivative compounds.  
A) Chemical shift perturbations at three different concentrations of small molecule. B) 
Interpretation table for phenylacetic acid derivatives. Structures of compounds that did 
not match the general template are drawn.  
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As a complementary method to evaluate the ligand binding site on KIX and rule 
out concerns of generating false positives from fluorine incorporation, we studied the 
binding of the original four ligands (1-4) by 
1
H-
15
N HSQC NMR using uniformly 
15
N-
labeled KIX. Experiments were performed at 0, 1, and 5 mM ligand concentration for 1, 
2, and 3 while 4 was characterized at 0, 0.5, and 1 mM due to low solubility above 2 mM. 
Residues whose chemical shifts were perturbed by one and two standard deviations above 
the average perturbation in a residue were mapped onto the protein structure to infer the 
corresponding binding site of each ligand.  
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Figure 2.17 
1
H-
15
N HSQC of 1 binding to KIX.  
A) 
15
N KIX alone, 15N KIX + 1 mM 1, and 15N  KIX + 5 mM 1 are shown in the 
spectrum. The peak arrows refer to KIX without ligand. B) Chemical shift perturbation 
mapping of KIX residues with 1 mM and 5 mM 1. Residues that were not detected or not 
assigned are designated as ND. Dashed lines represent the average chemical shift 
perturbation + one standard deviation at the corresponding concentration. Assignments 
previously obtained by Majmudar et al.
42
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Figure 2.18. 
1
H-
15
N HSQC of 2 binding to KIX. 
A) 
15
N KIX alone, 15N KIX + 1 mM 2, and 15N KIX + 5 mM 2 are shown in the spectrum. 
The peak arrows refer to KIX without ligand. B) Chemical shift perturbation mapping of 
KIX residues with 1 mM and 5 mM 2. Residues that were not detected or not assigned 
are designated as ND. Dashed lines represent the average chemical shift perturbation + 
one standard deviation at the corresponding concentration. Assignments previously 
obtained by Majmudar et al.
42
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Figure 2.19. 
1
H-
15
N HSQC of 3 binding to KIX. 
A) 
15
N KIX alone, 15N KIX + 1 mM 3, and 15N KIX + 5 mM 3 are shown in the spectrum. 
The peak arrows refer to KIX without ligand. B) Chemical shift perturbation mapping of 
KIX residues with 1 mM and 5 mM 3. Residues that were not detected or not assigned 
are designated as ND. Dashed lines represent the average chemical shift perturbation + 
one standard deviation at the corresponding concentration. Assignments previously 
obtained by Majmudar et al.
42
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Figure 2.20. 
1
H-
15
N HSQC of 4 binding to KIX. 
A) 
15
N KIX alone, 15N KIX + 0.5 mM 4, and 15N KIX + 1 mM 4 are shown in the 
spectrum. The peak arrows refer to KIX without ligand. B) Chemical shift perturbation 
mapping of KIX residues with 0.5 mM and 1 mM 4. Residues that were not detected or 
not assigned are designated as ND. Dashed lines represent the average chemical shift 
perturbation + one standard deviation at the corresponding concentration. Assignments 
previously obtained by Majmudar et al.
42
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Consistent with PrOF NMR, perturbed residues in each case showed 
concentration dependent shifts and localized near the MLL binding site.
183
 Additional 
residues were perturbed near an unstructured loop connecting helices α2 and α3 of KIX 
near the N-terminal portion of the protein. These perturbations may result from a 
conformational change induced by ligand in the MLL site rather than direct ligand 
binding near this loop region but will need further investigation.  We conclude from this 
study that PrOF NMR was able to identify a related class of ligands all targetting the 
MLL site.  
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Figure 2.21. Surface map comparison of small molecule ligands from amide based 
HSQC data.  
KIX + MLL is shown in the middle as a reference for binding site location. Each small 
molecule perturbs a slightly different set of residues but localize near the MLL binding 
site. 4 also yields additional resonance shift affects along α3 as well near the MLL site.  
All four experiments also showed perturbations at residues towards the N-terminal 
portion of the protein and the loop between helices α2 and α3 which are thought to be the 
result of slight conformational changes rather than direct ligand binding. Side chains are 
shown for the amino acids whose amide resonance is perturbed. 
 
Despite few hits, the hit rates from the PrOF NMR screen could be used to assess 
the “druggability“ of the MLL and CREB sites on KIX. Consistent with the literature, the 
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CREB interface is a challenging target while the MLL site is more amenable to ligand 
binding. For example, disulfide tethering screens reported fewer and less efficacious 
ligands for the CREB versus the MLL site.
186
 These results support designing larger 
peptidomimetic inhibitors against the CREB site rather than using small molecules.
22
 
Both naturally occurring acidic transcription factors as well as synthetic ligands (Figure 
2.1) have a higher propensity for interacting at or near the MLL region, providing a 
starting point for MLL-site ligand development.  The KIX-interacting peptide of MLL 
contains the sequence DIMDFVL where both aspartic acid residues and phenylalanine 
are important for binding.
178
 The aryl and phenylacetic acid derivatives reported here, 
may be minimal mimics of these motifs.   
Table 2.8. Small Molecule Analysis via NMR and Computation 
Compound 
PrOF 
NMR 
1
H-
15
N 
HSQC 
Kd 
(PrOF) 
(mM) 
Ligand 
Efficiency 
(kcal mol-1NHA-1) 
pKa clogP 
1 
 
 
Yes Yes >10 >0.13 - 3.48 
2 
 
Yes Yes 
1.4 ± 
0.3* 
0.32* 4.00 2.699 
3 
 
Yes Yes 5.3 ± 0.9 0.24 3.77 2.013 
4 
 
Yes Yes 1.7 ± 0.6 0.29 3.67 2.720 
5 
 
Yes - 1.6 ± 0.3 0.27 4.22 2.864 
Ibuprofen 
 
Yes - - - 4.36 3.496 
Naproxen 
 
Yes - - - 4.35 3.180 
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Flurbiprofen 
 
Yes - 5.9 ± 0.3 0.17 4.14 4.154 
PAA1 
 
No - - - 2.20 0.865 
PAA2 
 
No - - - 4.36 1.596 
PAA3 
 
No - - - 4.30 2.159 
PAA4 
 
No - - - 4.54 1.271 
PAA5 
 
Yes - 6.9 ± 0.7 0.19 4.30 3.786 
PAA6 
 
No - - - 3.51 0.768 
PAA7 
 
No - - - 1.99 1.800 
PAA8 
 
No - - - 4.54 0.426 
PAA9 
 
No - - - 2.96 0.784 
6 
 
No - - - 4.37 0.638 
7 
 
No - - - 4.57 2.441 
8 
 
No - - - 3.33 1.565 
KM07508 
 
Yes - - - - 3.589 
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KM09042 
 
No - - - - 3.986 
KM09000 
 
No - - - - 3.762 
9 
 
No - - - - 2.271 
 
2.3 Conclusion 
PrOF NMR has several advantages as a screening method due to its sensitivity to 
detect changes in chemical environment including dynamic structural information of the 
protein, low background signal, and ease of use. Here we demonstrated the first full small 
molecule screen using PrOF NMR, evaluated its efficacy for druggability determination, 
and reported on a class of small molecules (biaryl and phenylacetic acids) as KIX 
ligands. Additional SAR analysis guided our investigation to discover three additional 
KIX-binding small molecules. The biarylacid and phenylacetic acid structural motif is 
corroborated by several of the reported KIX ligands (Fig. 1) providing a starting point for 
small molecule derivitization and development. This study also demonstrates preferential 
targetability for the MLL site over the CREB site. While additional optimization is 
required to develop the discovered ligands into potent inhibitors of KIX interactions, this 
study has demonstrated the applicability of PrOF NMR as a useful tool for library 
screening, ligand discovery, and druggability assessment. This second phase of this 
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project including SAR development of 2 and the installation of additional fluorine probes 
into KIX will be described in the next chapter.  
2.4 Methods       
Materials 
Unless otherwise noted, all reagents were obtained from commercial vendors and 
used without further purification. For expression of proteins in E. coli, Lennox L. (LB) 
broth, unlabeled amino acids, uracil, thiamine-HCl, nicotinic acid, biotin, ampicillin, 
chloramphenicol, IPTG, PMSF, and Triton X-100 were purchased from RPI corp. 
Nucleotide bases and 3-fluorotyrosine (3FY) were purchased from Alfa Aesar. Lysozyme 
was purchased from Gold Biotech, HEPES was purchased from Fischer Scientific, and 
[
15
N] ammonium chloride was obtained from Cambridge Isotope Laboratories.  The small 
molecule library was acquired from Maybridge. 
1
H, 
13
C, and 
19
F spectra were recorded at 
500 MHz, 125 MHz, and 470 MHz respectively. 
WT or 3FY-Labeled Protein Expression and Purification of His6-KIX (586-672)  
Expression  
Protein expression using the same plasmid DNA for KIX was performed as 
previously described
41
 with slight modifications. The protein expression plasmid was 
transformed into either the E. coli BL21(DE3) strain contransformed with pRARE 
(Novagen) (unlabeled) or DL39(DE3) cells with the plasmid pRARE (3FY-labeled) and 
plated on an agar plate containing ampicillin (100 mg/L) and chloramphenicol (35 mg/L).  
5 mL primary cultures of DL39 or BL21 cells transformed with the KIX expression 
plasmid supplemented with ampicillin (100 mg/L) and chloramphenicol (34 mg/L) were 
grown overnight (~12-14 h, 25 °C, 250 rpm) in an incubator shaker (New Brunswick 
Scientific Excella E25). Primary cultures were added to fresh LB Broth (1 mL primary/50 
mL media) to begin secondary culture growth. Secondary cultures were grown at (37 °C, 
250 rpm) until they reached an OD600 of approximately 0.8 as evaluated by a Varian Cary 
50 Bio UV/Vis spectrophotometer. The culture was centrifuged (8000 g, 10 min, 4 °C) to 
form a solid pellet of bacteria. The media was decanted, and 50-100 mL of phosphate 
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buffered saline (PBS) was added to resuspend the pellet. The solution was centrifuged 
under the same conditions and resuspended in defined media
187
 containing 80-150 mg/L 
3FY in the place of regular tyrosine at the original volume of LB media. A recovery time 
of 2-3 hours was allowed prior to the addition of isopropyl-β-D-1-thiogalactopyranoside 
(IPTG) to induce protein overexpression (3 h, 25 °C, 250 rpm). Cultures were spun down 
(6000 g, 20 min, 4 °C). Media was decanted, and the pellet was stored at -20 °C.  
Alternatively, overnight expression could be conducted at lower temperature (18 h, 20 
°C, 250 rpm), which have resulted in the highest protein yield (70 mg/L vs 35 mg/L 
previously). Under these expression conditions, two other modifications to the procedure 
were made. The first modification involved resuspending the bacterial pellet in the 
defined media rather than first washing the cells with the PBS buffer. The second change 
was to lower the temperature in the incubator to 20 °C during the last hour of the 
recovery time.   
Purification via Fast Protein Liquid Chromatography (FPLC) 
Following cell lysis (lysis buffer, lysozyme, β-mercaptoethanol, protease inhibitor 
phenylmethanesulfonylfluoride (PMSF, 2 mM), and sonication), proteins were purified 
on a GE Äktapurifier FPLC equipped with a Superloop for large volume injections. A 
column containing Ni-NTA beads (Qiagen) was used for affinity purification of the His-
tagged protein. An elution gradient (30-400 mM) imidazole was used to initially bind and 
subsequently elute the His-tagged-protein from the Ni beads. Protein was then buffer 
exchanged into 50 mM HEPES and 100 mM NaCl, pH 7.2 using a HiPrep 26/10 
Desalting column (GE Healthcare Life Sciences) and stored at -20 °C or 4°C. During 
protein purification multiple aliquots of the protease inhibitor PMSF were added due to 
the instability of PMSF in aqueous solution.  
Protein characterization  
 Mass spectrometry data was acquired on an Agilent MSD SL Ion Trap equipped 
with a liquid chromatography system (C18 column) to desalt the protein samples prior to 
MS analysis. 
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1D 
19
F NMR.  
Conditions and Parameters Used.  All NMR spectra were obtained on a Bruker 
Avance III 500 MHz instrument. Initial measurements were obtained using a 5 mm 
BBFO “SmartProbe” (19F S/N 550:1). The fragment screen and follow-up experiments 
were performed using a 5 mm Prodigy TCI Cryoprobe (
19
F S/N 2100:1). Samples 
containing 30-50 µM 3FY KIX were prepared in NMR buffer as noted above with 5% 
D2O and 50 µM trifluoroacetic acid (-76.5 ppm) as a reference. T1 relaxation times were 
calculated using an inversion recovery experiment.  Optimized parameters for PrOF 
NMR experiments included a 0.6 s delay time and a 0.1-0.3 s acquisition time (AQ). 
Spectral width and offset were 10 ppm and -136 ppm respectively. A line-broadening of 
15-20 Hz was applied to all protein spectra upon processing. The screening data were 
acquired using 300 scans while the deconvolutions and titrations were performed with 
800 scans. Data from follow-up experiments were acquired using 400-800 scans. Spectra 
were acquired at 294 K) 
Fragment Screening. A rule of 3 (RO3) compliant library from Maybridge was 
obtained for fragment screening. Compounds were stored as 200 mM DMSO stock 
solutions. Mixtures of six compounds, consisting of one acidic, one basic, and four 
neutral compounds, were compiled from the library to make stock mixtures at 33.3 mM 
per compound.  NMR samples were prepared with a total DMSO concentration of 2.5% 
which was shown previously to not significantly perturb the chemical shifts of the NMR 
spectrum. The final concentration of each fragment was 833 µM.  NMR parameters are 
listed above.  
2D 
1
H-
15
N HSQC NMR Experiments 
Uniformly 
15
N labeled KIX protein was expressed and purified using M9 minimal 
media supplemented with [
15
N] ammonium chloride as described previously.
42
 A 30-35 
µM solution of 
15
N-labeled KIX was prepared in a 9:1 H2O:D2O 10 mM phosphate buffer 
with 100 mM NaCl and 2.5% DMSO at pH 7.2. HSQC experiments were recorded at 27 
°C on an Agilent/Varian 600 MHz NMR spectrometer equipped with a 5 mM Cold HCN 
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probe. Spectra were collected in the presence and absence of small molecule ligands 
discovered from the PrOF NMR fragment screen. Data was processed using NMRPipe 
and analyzed using Sparky (UCSF). Chemical shift changes for individual resonances 
were quantified using the equation ((0.2*Δδ15N)2 + (Δδ1H)2)0.5. 
Small Molecule Extraction 
Extraction of Naproxen 
 One CVS Naproxen Sodium liquid-filled gel capsule (220 mg (+)-1S-
naproxen/capsule) was placed in water and heated to aid in dissolution. Remaining 
undissolved material was pelleted by centrifugation (8000 x g, 5 min, 4 °C and filtered 
away from the supernatant. Naproxen was precipitated out of solution using concentrated 
HCl. The sample was centrifuged and vacuum filtered, isolating crude naproxen. Product 
was recrystallized from an ethanol/dilute HCl solution and dried via vacuum filtration. 
Identity was confirmed by 
1
H NMR and mass spectrometry.  
1
H NMR (500 MHz, (CD3)2CO): δ 7.81–7.77 (m, 3 H, CH), 7.47 (dd, J = 8.5, 1.8 Hz, 1 
H; CH), 7.29 ppm (d, 
3
J(H,H) = 2.48 Hz, 1 H; CH), 7.16 ppm (dd, J = 9.0, 2.5 Hz, 1 H), 
3.92 (s, 3 H), 3.90 (q, J = 7.1 Hz, 1 H), 1.53 (d, J = 7.2 Hz, 3 H):  ESI-MS: calcd m/z 
229.1, found 229.1 [M
—
H
+
].  
Extraction of Ibuprofen 
One Advil Migraine liquid-filled gel capsule (200 mg) was placed in 0.5 M NaOH 
and heated to aid in dissolution. Remaining undissolved material was pelleted by 
centrifugation (8000 x g, 5 min, 4 °C and filtered away from the supernatant. Ibuprofen 
was precipitated out of solution using concentrated HCl. The sample was centrifuged and 
vacuum filtered, isolating crude ibuprofen. Final product was recrystallized from an 
ethanol/dilute HCl solution. Product (racemic mixture of the R and S enantiomers) was 
dried via vacuum filtration and stored in a desiccator. Identity was confirmed by 
1
H-
NMR and mass spectrometry. 
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1
H NMR (500 MHz, (CD3)2CO): δ 7.27 (d, J = 8.3 Hz, 2 H) , 7.14 (d, J = 8.3 Hz, 2 H), 
3.73 (q, J = 7.3 Hz, 1 H), 2.47 (d, J = 7.3 Hz, 2 H), 1.86 (sep, J = 6.8 Hz, 1 H), 1.44 (d, J 
= 7.1 Hz, 3 H), 0.90 (d, J = 6.6 Hz, 6 H): ESI-MS: calcd m/z 205.1, found 205.2 [M
—
H
+
] 
Extraction of Flurbiprofen 
 Eight Strepfen lozenges (8.75 mg flurbiprofen/lozenge) were added to 40 mL of 
water and heated to aid in dissolution. Flurbiprofen was precipitated using concentrated 
HCl. The sample was centrifuged and vacuum filtered, isolating crude flurbiprofen. The 
purified product was recrystallized from a methanol/water solution. The remaining 
aqueous solution was extracted with diethyl ether followed by an acid/base extraction to 
obtain a second batch of flurbiprofen. Identity was confirmed by 
1
H NMR, 
19
F NMR, and 
mass spectrometry.  
1
H NMR (500 MHz, (CD3)2CO): δ 7.60–7.57 (m, 2 H), 7.52–7.46 (m, 3 H), 7.4 (app tt, J 
= 7.5, 1.4 Hz, 1 H), 7.26 (dd, J = 11.9, 1.8 Hz, 1H), 3.87 (q, J = 7.1 Hz, 1 H), 1.52 (d, J = 
7.1 Hz, 3 H). 
19
F NMR (470 MHz, (CD3)2CO) : δ -119.576 (m, 1 F), ESI-MS: calcd m/z 
243.1, found 243.1 [M
—
H
+
] 
Computation 
 Access to the Schrodinger Software Suite was provided through the Minnesota 
Supercomputing Institute (MSI). SiteMap, Qikprop, and Epik modules were utilized to 
identify binding sites, calculate the water-partition coefficient (clogP), and pKa values 
respectively.  
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1
H NMR of Naproxen (500 MHz, (CD3)2CO) 
 
1
H NMR of Ibuprofen (500 MHz, (CD3)2CO) 
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1
H NMR of Flurbiprofen (500 MHz, (CD3)2CO) 
 
Stock solution of flurbiprofen (200 mM in DMSO) and analyzed in acetone-D6 giving rise to both a water 
peak (2.8 ppm) and a DMSO peak (2.5 ppm) as indicated by an asterisk in addition to the acetone solvent 
peak. 
 
19
F NMR of Flurbiprofen (470 MHz, (CD3)2CO) 
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Chapter 3. Dual Labeling of the CBP/p300 KIX domain for 19F NMR leads 
to identification of a new small molecule binding site 
 
This paper is manuscript was resubmitted August 7
th
, 2017 as follows: 
 
“Dual labeling of the CBP/p300 KIX domain for 19F NMR Leads to identification of a new small 
molecule binding site,” C. T. Gee*, K. E. Arntson*, E. J. Koleski,  W. C. K. Pomerantz, 
 
Motivation: This manuscript was the follow-up to the previous chapter and the 
combination of two different research directions. The first goal was to take one of the hit 
compounds from the fragment screen (as discussed in Chapter 2) and develop it into a 
more potent small molecule inhibitor. The second goal was to push the limits of fluorine 
labeling in a protein. We already had established the process for labeling a protein with a 
single type of fluorinated amino acid, so we wanted to explore the feasibility of 
incorporating more than one type of amino acid in the same protein. These two projects 
came together when one of the developed ligands demonstrated some unexpected 
behavior by not perturbing the newly incorporated 4-fluoro-phenylalanine, leading to the 
discovery of the new binding site.  
3.1 Introduction 
Small-molecule inhibition of protein-protein interactions (PPIs), while successful in 
several cases,
7-8, 13
 is still a challenging area of research.
169
 Due to their large surface 
areas, multiple low-affinity binding partners in the case of transcription factors, and 
allosteric networks, PPIs are notoriously difficult to target with small molecules.
14
 In 
contrast with enzymes (e.g., kinases)
188
 or epigenetic “reader“ proteins (e.g., 
bromodomains)
189
 that typically have one primary binding site, transcription factors 
involved in PPIs often have multiple native binding partners which in some cases, bind to 
different sites on a protein surface.
15
 These sites may be allosterically coupled. Multiple 
  80 
binding sites can make it difficult to identify exactly where a small molecule is 
interacting with a protein. For example, the KIX domain of the CREB Binding Protein 
(CBP/p300) interacts with over a dozen different transcription factors through two 
allosterically coupled sites.
190
 Here we report on a new small-molecule binding site 
distinct from those used by native transcription factors. (Figure 3.1).  
 
Figure 3.1 New small molecule binding site on KIX discovered through the use of a 
dual-fluorine-labeled protein.  
 
In a recent characterization of KIX, Pomerantz et al. found that 3-fluorotyrosine 
incorporation at all five tyrosine sites for Protein-Observed Fluorine NMR spectroscopy 
(PrOF NMR) was sufficient for distinguishing the binding footprints of three native 
ligands from the transcriptional activation domains of c-Myb, MLL, and CREB.
41
 These 
proteins interact with the KIX domain through two distinct binding sites. Allosteric 
effects on the protein were further shown to be different between c-Myb and CREB 
despite their similar binding surfaces on KIX.
191-192
 Screening of 508 small molecules 
against this fluorinated protein by PrOF NMR revealed several molecules which 
perturbed the resonance for Y631 consistent with binding near the second transcription 
factor site engaged by MLL.
193
   
We and others have shown that fluorine-labeling of aromatic amino acids for PrOF 
NMR spectroscopy provides structural information on the ligand-binding site and can 
quantify interaction affinities.
74, 194-195
  Due to the speed of this method, which can be run 
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in five minutes or fewer at low- to mid- micromolar concentrations, it has been used for 
screening libraries of low molecular weight compounds called fragments in both primary 
and follow-up screens on small- to medium-sized proteins.
75, 99, 193, 196
 Paramagnetic 
additives have further increased the throughput of the method, reducing experiment times 
by 60%.
107
  
     Although enriched at protein-protein interfaces, aromatic amino acids occur at low 
frequency in proteins.
170
 Thus this sparse labeling strategy may not be sufficient to 
elucidate the protein binding site of small molecule ligands in all cases. For example, in 
the MLL binding site, the presence of a single tyrosine residue, Y631, limits the amount 
of structural information that can be inferred and increases the likelihood of false 
negatives in screening. However, there is a phenylalanine present in the MLL binding site 
near Y631, which could also serve as an additional probe for PrOF NMR if 
simultaneously fluorine labeled (Figure 3.2). 
Budisa and co-workers were the first to show the ability to incorporate multiple 
non-natural amino acids into proteins via sequence selective methods using auxotrophic 
bacteria for 4-fluoroproline, 6-fluorotryptophan, and 4-fluorophenylalanine.
197
 
Fluorinated aromatic amino acids are particularly challenging due to their toxicity 
towards bacteria during recombinant protein expression conditions.  In these prior 
studies, labeling was high but still resulted in a heterogeneously labeled sample, which 
may have a significant effect on the resulting NMR spectrum.  
Due to the challenges presented by the bacteriostatic effects of fluorinated amino 
acids on bacterial cell growth,
198
 a fluorine NMR study on a multi-labeled protein has yet 
to be reported. To address this need, we explore a dual-labeling strategy using both 3-
fluorotyrosine (3FY) and 4-fluorophenylalanine (4FF) as a test case for characterizing 
native peptides sequences and newly discovered small molecules for the KIX domain for 
future chemical probe development. We report on a new small molecule and our data 
supports a new binding site, distinct from native transcription factor binding sites for 
regulating KIX PPIs. Results from this study provide insights into new approaches for 
using fluorine-labeled proteins to characterize protein-ligand interactions by PrOF NMR. 
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Figure 3.2 PrOF NMR comparison of 3FY KIX and 3FY/4FF KIX.  
Top Right: PrOF NMR spectrum of 3FY KIX. Bottom: PrOF NMR spectrum of 
3FY/4FF KIX. Inset: Solution structure of KIX with tyrosines and phenylalanine shown 
as sticks. (PDB ID: 1KDX) *This resonance is an artifact that does not originate in the 
sample. 
3.2 Results and Discussion 
 To obtain a protein labeled with two different fluorinated amino acids, 3FY and 
4FF, an auxotrophic cell needed to be selected which suppressed natural production of 
both tyrosine and phenylalanine. While the herbicide glyphosate inhibits the shikimate 
pathway in bacteria and thus suppresses tyrosine and phenylalanine biosynthesis to 
induce auxotrophy, this method results in low protein expression yields and high costs 
due to the amount required in the expression (1 g/L expression).
199-200
 Alternatively, the 
DL39(DE3) cell line is auxotrophic for both tyrosine and phenylalanine.
200
 We have 
obtained yields as high as 70 mg/L  of singly-labeled KIX with 3FY with this cell line, 
and thus chose it for our study.
41, 193
 Previous expressions for 4FF-labeled KIX resulted in 
highly variable yields, possibly due to varying conditions, including expression and 
recovery time (the amount of time after the media change for bacteria to recover). Of 
note, we observed significant bacterial growth inhibition in the case of incorporating 4FF 
where yields were lower than an independent expression of KIX with 3FY.
 
It has 
previously been demonstrated by Bann et al. that DL39(DE3) cells give higher 4FF-
protein yields when supplied with 0.1 mM phenylalanine.
200
 We thus used this approach 
in our first set of optimization conditions. 
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 The optimization of 4FF KIX and by extension 3FY/4FF KIX expression, is 
therefore contingent on two conflicting variables. Higher unlabeled phenylalanine 
concentration added to expression media, increases yield but hinders fluorine-labeling, 
while lower concentration of phenylalanine in the media decreases yield and increases 
fluorine-labeling. Optimization experiments identified ideal conditions for expression: 
media containing 10 μM phenylalanine, 160 μM 4FF, and a 30 min recovery time after 
the defined media change, resulting in 80% fluorine labeling (Table 3.1). Following the 
optimization process, expression yields of 4FF KIX ranged from 15-22 mg/L with 80-
88% fluorine incorporation.    
Table 3.1 Optimization of 4FF KIX Conditions 
4FF KIX 
4FF (μM) F (μM) Recovery Time (min) % Fluorine Labeling 
160 
160 
80 
40 
0 
30 min 
32% 
27% 
28% 
84% 
160 
40 
20 
0 
30 min 
33% 
66% 
75% 
640 
320 
40 30 min 
36% 
27% 
160 
20 
10 
0 
0 min 
21% 
32% 
66% 
160 
20 
10 
0 
30 min 
73% 
80% 
75% 
160 
10 
7.5 
5 
40 min 
73% 
84% 
79% 
160 10 
60 min 
120 min 
68% 
77% 
3FY/4FF KIX 
160 0 40 min 95.5% 
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The first successful expression of a dual-labeled 3FY/4FF KIX was achieved 
using the conditions established for 4FF KIX above, with the addition of 400 μM 3FY 
and removal of tyrosine from the defined media. High fluorine incorporation (85%) was 
achieved, and a 
19
F NMR spectrum of the dual-labeled sample was obtained. Under these 
conditions, yields of 3FY/4FF KIX ranged from 14-22 mg/L, with fluorine incorporation 
ranging from 70-85%. Although this degree of incorporation may be sufficient in some 
cases, we ultimately wanted to obtain higher incorporation levels. By leaving 
phenylalanine out of expressions, fluorine incorporation of 95% can reliably be obtained, 
reducing protein yield to 3-7 mg/L.  All subseqent studies have used this highly-labeled 
protein (Figure 3.2, Figure 3.3). 
 
Figure 3.3 The deconvoluted ESI-mass spectrogram of a 3FY/4FF KIX sample 
demonstrating high fluorine incorporation.  
The peak at 12004.2 is a 67% labeled protein, the peak at 12022.6.6 is an 83% labeled 
protein, the peak at 12040.1 is the 100% labeled protein containing all six fluorinated 
residues, and the peak at 12054.9 is consistent with a small percentage of an oxidized 
product that was presumed to occur from methionine oxidation. Percent labeling is 
calculated with the equation below, using the integration values of the various 
deconvoluted mass peaks as the values for F KIX.  
 
% 𝐼𝑛𝑐𝑜𝑟𝑝𝑜𝑟𝑎𝑡𝑖𝑜𝑛 =
(0𝐹 𝐾𝐼𝑋) ∗ 0 + (1𝐹 𝐾𝐼𝑋) ∗ 1 + (2𝐹 𝐾𝐼𝑋) ∗ 2 … (6𝐹 𝐾𝐼𝑋) ∗ 6
(0𝐹 𝐾𝐼𝑋) ∗ 6 + (1𝐹 𝐾𝐼𝑋) ∗ 1 + (2𝐹 𝐾𝐼𝑋) ∗ 6 … (6𝐹 𝐾𝐼𝑋) ∗ 6
 
 
 
  85 
 
Figure 3.4 Structure and function validation of dual labeled protein.  
A) CD Spectra, B) thermal melt, and C) MLL affinity comparisons of unlabeled (UL), 
3FY-labeled, and 3FY/4FF-labeled KIX. Unlabeled protein is plotted with squares. 3FY 
protein is plotted with circles. 3FY/4FF protein is plotted with triangles. D) Summary 
table of structural and functional data.   
 
Once protein expression conditions were established, we first sought to test the 
possibility of any significant structural or functional perturbation from fluorine 
incorporation. In prior reports, fluorescence polarization (FP) binding studies and circular 
dichroism (CD) investigations of thermal stability and secondary structure revealed minor 
perturbation of structure and binding from 3FY incorporation.  Far-UV CD spectra 
showed all three protein constructs to be highly α-helical based on molar ellipticity at 222 
nm, with the dual-labeled protein with an 11% lower molar ellipticity (Figure 3.4A, D). 
Similar to 3FY-labeling, the dual-labeled protein did show a remarkable thermal 
stabilization of 7 degrees relative to the unlabeled protein.  The origin of this effect is 
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unclear. Wang et al. demonstrated that a covalent ligand was able to stabilize KIX by 15-
18 degrees leading to the first and only x-ray structure of this protein.
47
  We speculate 
that fluorine labeling may serve the same purpose.  Because we labeled F612 which is in 
the MLL binding site, we also compared binding of the unlabeled, 3FY-labeled, and 
3FY/4FF dual-labeled-KIX protein to MLL by FP. We saw approximately a 2-fold 
difference in binding affinity across samples (Figure 3.4C, D, Kd = 3.78 μM, 1.66 μM, 
and 1.82 μM, respectively). Together these results support only a modest perturbation 
from fluorine labeling to global secondary structure and ligand binding.   
The fluorine nucleus is highly sensitive to small changes in chemical environment 
and thus is also a sensitive reporter of subtle conformational effects.
74
 In our first PrOF 
NMR experiment on this new construct, we compared the chemical shift of the 
resonances of our 3FY-labeled KIX protein to the 95% 3FY/4FF- labeled protein (Figure 
3.2). In both cases, the 3FY resonances were very similar (0.04 ppm average difference) 
between the two spectra indicating a minimal change in chemical environment despite the 
slightly lower molar ellipticity from CD. To date, this is the first example of dual-labeled 
protein by 
19
F NMR. The single 4FF resonance found at -117.3 ppm is also in a similar 
region as our previously reported singly-labeled protein.
41
 The large chemical shift 
dispersion between the two sets of resonances (~20 ppm between 3FY and 4FF) indicates 
distinct windows for fluorinated aromatic amino acid resonances. Furthermore, 5-
fluorotryptophan resonances typically originate near -125 ppm, allowing sufficient 
chemical shift space for future triple-labeling experiments.
195
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Figure 3.5 PrOF NMR results with 3FY/4FF KIX and MLL.  
A) Stacked PrOF NMR spectra of 3FY/4FF KIX and increasing concentrations of MLL. 
Y631 and F612 are the only two resonance that are perturbed. MLL also demonstrates 
slow exchange kinetics, as noted by the unbound and bound states being resolved at 0.5 
EQ MLL. * This resonance is an artifact that does not originate in the sample. B) 
Structure of KIX:MLL complex (2AGH) with Y631 and F612 highlighted on the surface. 
Both are in close proximity to the native MLL peptide. C) Chemical shift perturbations of 
3FY/4FF KIX with 2eq MLL. 
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Table 3.2 3FY/4FF KIX 
19
F NMR chemical shift perturbations at varying MLL 
concentrations 
 
With both sets of fluorinated resonances clearly resolved, we sought to 
characterize the binding interactions of native and synthetic ligands. The solution NMR 
structure of MLL binding to KIX (PDB ID: 2AGH) indicates close interactions with the 
MLL transcriptional activation domain and KIX at both F612 and Y631. Our PrOF NMR 
experiment is able to capture these interactions, where both resonances yield large 
perturbations (Δδ = 1.1-1.2 ppm) upon increasing ligand concentration in the slow 
exchange regime (Figure 3.5).  A second transcription factor, CREB, binds a second site 
on the KIX surface but is known to enhance MLL binding through an allosteric 
network.
192
 We previously showed that the 3FY resonances (Y658, Y650, and Y649) 
which mapped to the binding site were affected as well as Y631 in the MLL binding site.  
Independent experiments with 4FF-labeled KIX showed no effects on the F612 
resonance.
41
  Because the singly-labeled KIX and dual-labeled KIX are different and 
could be presenting slightly different binding surfaces, we characterized this binding-
induced allosteric effect again with dual-labeled KIX. (Figure 3.6)  In this experiment, 
Y631 was similarly perturbed and F612 was unaffected, supporting an allosteric network 
that affects Y631, but does not involve F612 within the binding site.  
[MLL] 
Chemical 
shift 
(ppm) 
F612 Y649 Y650 Y658 Y640 Y631 
0 δ (ppm) -117.2887 -134.6191 -138.2642 -138.6706 -138.7750 -139.3630 
2 EQ Δδ (ppm) -1.1385 -0.0680 -0.0250 0.0236 0.0189 -1.1238 
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Figure 3.6 PrOF NMR results with 3FY/4FF KIX and pKID.  
A) Stacked PrOF NMR spectra of 3FY/4FF KIX and increasing concentrations of pKID. 
Y649, Y650, and Y658 are perturbed by direct contact while Y631 is allosterically 
perturbed. * This resonance is an artifact that does not originate in the sample. B) 
Structure of KIX:MLL complex (1KDX) with Y649, Y650, Y658, and Y631 highlighted 
on the surface. C) Chemical shift perturbations of 3FY/4FF KIX with 1.5 eq pKID. 
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Table 3.3 3FY/4FF-KIX 
19
F NMR chemical shift perturbations at varying pKID 
concentrations. 
 
 
Few small molecules have been reported to bind to the KIX domain.  Naphthol 
AS-E phosphate is one of the most well characterized PPI inhibitors of KIX-transcription 
factor interactions between both c-Myb and CREB.
36, 201
  Our studies and those by Best et 
al. using 
1
H-
15
N HSQC, argue against binding at the CREB or c-MYB site, despite the 
similarity of the phosphate group in the inhibitor and  phosphoserine 133 of CREB which 
binds to KIX, in contrast to the binding-site hypothesis proposed by Uttarkar et al.
201
  
Similar to our experiments with CREB, we were concerned that KIX labeled with 4FF 
might be altering the protein structure and masking interactions within the MLL binding 
site. Titrating naphthol-AS-E phosphate against the dual-labeled protein however, 
confirmed that Y631 is the sole residue that exhibits a large dose dependent effect and 
supports the existence of an alternate small molecule binding site distinct from those used 
by the native transcription factors (Figure 3.7). 
[pKID] 
Chemical 
shift 
(ppm) 
F612 Y649 Y650 Y658 Y640 Y631 
0 δ (ppm) -117.3396 -134.7238 -138.3410 -138.7253 -138.9210 -139.4710 
1.5 EQ Δδ (ppm) 0.0136 -0.2809 -0.2155 -0.2253 -0.0061 0.4167 
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Figure 3.7 
19
F NMR spectral analysis of 3FY/4FF KIX in the presence of increasing 
concentrations of naphthol AS-E phosphate.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. * This resonance is an artifact that does not originate in the sample. B) Stacked 
spectra of 3FY/4FF KIX with increasing concentrations of naphthol AS-E phosphate. 
Inset) Resonances from F612. C) Absolute value of chemical shift perturbations for all 
3FY/4FF KIX resonances at 500 μM naphthol AS-E phosphate. D) Binding isotherm of 
Y631 perturbation for the titration of naphthol AS-E phosphate. 
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Table 3.4 3FY/4FF-KIX 
19
F NMR chemical shift perturbations at varying naphthol 
AS-E phosphate concentrations 
 
The above results led us to test small molecule 1, discovered in our fragment 
screen, which affected Y631 and at higher concentrations exhibited a non 1:1 
interaction.
193
 We speculated that this interaction was caused by two molecules fitting 
within the MLL site. However, addition of 1 at increasing concentration did not affect 
F612.  Either 1, due to its small size, was too far away from F612, or it bound near but 
outside the MLL binding site similar to naphthol AS-E-phosphate. To this end, we 
designed several more extended molecules through acylation with amino acids 
tryptophan, phenylalanine, and tyrosine (molecules 2, S3, S4). Structure-activity 
relationships studies showed the carboxylic acid of 1 to be important for binding, as 
noted by the methyl ester of 1 being inactive (Figure 3.8).  
[Nap] 
Chemical 
shift 
(ppm) 
F612 Y649 Y650 Y658 Y640 Y631 
0 δ (ppm) -117.311 -134.6720 -138.2915 -138.6966 -138.8242 -139.3750 
31.25 |Δδ| (ppm) 0.0084 0.0065 0.0022 0.0060 0.0106 0.0386 
62 |Δδ| (ppm) 0.0090 0.0189 0.0114 0.0043 0.0351 0.0714 
125 |Δδ| (ppm) 0.0225 0.0220 0.0101 0.0794 0.0482 0.1076 
250 |Δδ| (ppm) 0.1114 0.0593 0.0119 0.0202 0.0552 0.1796 
500 |Δδ| (ppm) 0.0467 0.0490 0.0045 0.0344 0.0242 0.2138 
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Figure 3.8 PrOF NMR data comparing 1 and 1-OMe.  
Tthe methyl ester eliminates the activity of the parent compound based on the 
observation that Y631 is no longer perturbed. 
 
Therefore, 2, S3, and S4 were synthesized to maintain the carboxylic acid.  
Titration of 2, against 3FY KIX indicated binding near the MLL site, and a saturating 
binding isotherm, consistent with 1:1 binding was observed, yielding a Kd of 740 µM 
(Figure 3.9). S3 and S4 were also titrated against 3FY KIX, but there was little to no 
improvement in affinity relative to the parent compound, 1 (Figure 3.10, Figure 3.11). 
Testing 2 with the 3FY/4FF labeled protein, again perturbed Y631 near the MLL binding 
site but  did not affect F612 (Figure 3.14, Figure 3.12). The profile of 2 binding to both 
3FY KIX and 3FY/4FF KIX indicated similar binding modes though a slightly weaker 
affinity (Figure 3.12, Figure 3.13 A,B). Together these data support 1, 2, and naphthol 
AS-E phosphate interacting at a similar binding site, distinct from native transcription 
factors.  
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Figure 3.9 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of 2.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. B) Stacked spectra of 3FY KIX with increasing concentrations of 2 C) Absolute 
value of chemical shift perturbations for all 3FY KIX resonances at 1500 μM 2. D) 
Binding isotherm of Y631 perturbation for the titration of 2 
Table 3.5 3FY-KIX 
19
F NMR chemical shift perturbations at varying 2 concentrations 
[2] (µM) 
Chemical shift 
(ppm) 
Y649 Y650 Y658 Y640 Y631 
0 δ (ppm) -134.6638 -138.3012 -138.7056 -138.8887 -139.437 
250 |Δδ| (ppm) 0.0451 0.0048 0.0061 0.0099 0.1038 
500 |Δδ| (ppm) 0.0503 0.0019 0.0110 0.0060 0.1974 
800 |Δδ| (ppm) 0.0910 0.0120 0.0181 0.0250 0.2507 
1000 |Δδ| (ppm) 0.0840 0.0014 0.0410 0.0428 0.2641 
1500 |Δδ| (ppm) 0.1034 0.0085 0.0626 0.0301 0.3071 
2000 |Δδ| (ppm) 0.0657 0.0186 0.1008 0.0231 0.3456 
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Figure 3.10 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of S3.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. B) Stacked spectra of 3FY KIX with increasing concentrations of S3 C) Absolute 
value of chemical shift perturbations for all 3FY KIX resonances at 1500 μM S3. D) 
Binding isotherm of Y631 perturbation for the titration of S3 
 
Table 3.6 3FY-KIX 
19
F NMR chemical shift perturbations at varying S3 concentrations 
[S3] (µM) 
Chemical shift 
(ppm) 
Y649 Y650 Y658 Y640 Y631 
0 δ (ppm) -134.6927 -138.2924 -138.6904 -138.9366 -139.4730 
100 |Δδ| (ppm) 0.0111 0.0045 0.0009 0.0132 0.0431 
250 |Δδ| (ppm) 0.0212 0.0114 0.0139 0.0094 0.0757 
500 |Δδ| (ppm) 0.0170 0.0073 0.0138 0.0335 0.1336 
800 |Δδ| (ppm) 0.0357 0.0053 0.0208 0.0270 0.1747 
1000 |Δδ| (ppm) 0.0397 0.0101 0.0335 0.0081 0.2104 
1200 |Δδ| (ppm) 0.0959 0.0180 0.0394 0.0140 0.2269 
1500 |Δδ| (ppm) 0.0936 0.0156 0.0587 0.0269 0.3154 
2000 |Δδ| (ppm) 0.0956 0.0157 0.0719 0.0554 0.3549 
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Figure 3.11 
19
F NMR spectral analysis of 3FY KIX in the presence of increasing 
concentrations of S4.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as 
sticks. B) Stacked spectra of 3FY KIX with increasing concentrations of S4 C) Absolute 
value of chemical shift perturbations for all 3FY KIX resonances at 1500 μM S4. D) 
Binding isotherm of Y631 perturbation for the titration of S4 
 
Table 3.7 3FY KIX 
19
F NMR chemical shift perturbations at varying S4 concentrations 
[S4] 
(µM) 
Chemical 
shift (ppm) 
Y649 Y650 Y658 Y640 Y631 
0 δ (ppm) -134.6927 -138.2924 -138.6904 -138.9366 -139.4730 
100 |Δδ| (ppm) 0.0471 0.0008 0.0098 0.0125 0.0258 
250 |Δδ| (ppm) 0.0167 0.0067 0.0083 0.0026 0.0668 
500 |Δδ| (ppm) 0.0124 0.0128 0.0027 0.0067 0.1082 
800 |Δδ| (ppm) 0.0042 0.0116 0.0146 0.0099 0.1411 
1000 |Δδ| (ppm) 0.0147 0.0267 0.0192 0.0063 0.1458 
1200 |Δδ| (ppm) 0.0325 0.0186 0.0224 0.0307 0.1987 
1500 |Δδ| (ppm) 0.0688 0.0324 0.0292 0.0188 0.1924 
2000 |Δδ| (ppm) 0.0739 0.0198 0.0331 0.0040 0.2669 
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Figure 3.12 
19
F NMR spectral analysis of 3FY/4FF KIX in the presence of increasing 
concentrations of 2.  
A) Ribbon diagram of KIX (PDB Code: 1KDX) with tyrosine side chains indicated as sticks. B) 
Stacked spectra of 3FY/4FF KIX with increasing concentrations of 2 * This resonance is an 
artifact that does not originate in the sample. C) Absolute value of chemical shift perturbations for 
all 3FY/4FF KIX resonances at 1500 μM 2. D) Binding isotherm of Y631 perturbation for the 
titration of 2. 
 
Table 3.8 3FY/4FF-KIX 
19
F NMR chemical shift perturbations at varying 2 concentrations 
[2] 
Chemical 
shift (ppm) 
F612 Y649 Y650 Y658 Y640 Y631 
0 δ (ppm) -117.3300 -134.7212 -138.3184 -138.7131 -138.8843 -139.4560 
250 |Δδ| (ppm) 0.0187 0.0361 0.0030 0.0100 0.0119 0.0892 
500 |Δδ| (ppm) 0.0260 0.0278 0.0180 0.0351 0.0143 0.1586 
800 |Δδ| (ppm) 0.0428 0.0352 0.0177 0.0396 0.0100 0.2218 
1000 |Δδ| (ppm) 0.0362 0.0605 0.0146 0.0568 0.0056 0.2573 
1500 |Δδ| (ppm) 0.0433 0.0643 0.0155 0.0718 0.0063 0.3063 
2000 |Δδ| (ppm) 0.0376 0.0739 0.0153 0.0884  0.3551 
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Figure 3.13 Comparison of binding data with 2.  
A) Chemical shift perturbations of 2 with 3FY KIX and 3FY/4FF KIX demonstrating 
very similar perturbations. B) Binding isotherm of Y631 perturbations for the titrations of 
2 against 3FY KIX and 3FY/4FF KIX. C) Chemical shift perturbations of 1 and 2 against 
3FY/4FF KIX. Y631 is perturbed more significantly by 2 than it is by 1. D) Binding 
isotherm of Y631 perturbations for the titrations of 1 and 2 against 3FY/4FF KIX. 
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Figure 3.14 Small molecule binding to 3FY/4FF KIX.  
Y631 shows significant perturbations while F612 (inset) shows no significant 
perturbations to chemical shift upon small molecule binding.  The concentration 3FY/4FF 
KIX in the samples was 35 μM. Comparable ligand concentrations of 1 and 2 (1.6 mM 
and 1.5 mM, respectively) were used for chemical shift perturbation comparisons while 
0.25 mM naphthol AS-E phosphate was used as a control. 
 
Our PrOF NMR data led us to reevaluate the data that initially pointed towards 
the conclusion that 1 and its related analogs bound to KIX in the MLL site. We turned to 
the FTMap server to investigate possible binding sites in KIX.
202-205
 As expected, the 
software identified the MLL and pKID binding sites with clusters of its probe solvent 
molecules. However, additional clusters were found distal to these binding sites yet still 
near Y631, the residue most perturbed in our PrOF NMR experiments (Figure 3.15B). 
Further, these clusters were situated in close proximity to amino acid residues perturbed 
by naphthol AS-E phosphate in previous 
1
H-
15
N HSQC experiments by Best et al. These 
clusters were also situated close to the residues perturbed by 1 in our previous 
1
H-
15
N 
HSQC validation studies. Clusters were consistently found in similar locations within the 
protein across multiple KIX PDB structures, lending more weight to this potential, 
previously unreported ligand binding site (1KDX, 2AGH, 2LXT, 2LXS, Figure 3.16). 
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Figure 3.15 Structural representations of KIX highlighting binding sites mapped 
onto 1KDX.  
A) Ternary complex of MLL, KIX, and pKID. B) Select FTMap results displaying probe 
molecule clusters in a third site in the protein (PDBID 1KDX). C) Glide docking pose of 
2 using the Schrödinger  Maestro Suite. D, E, F) Chemical shift perturbations from 
1
H-
15
N HSQC or HMQC experiments. Perturbations greater than one standard deviation are 
shown in the backbone.   
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Figure 3.16 FTMap comparison of multiple KIX structures.  
KIX ribbon structures are shown in gray with the native MLL peptide at the top, and the 
pKID peptide around the back. FTMap solvent probe clusters that do not occupy either 
the MLL or pKID site are shown in green, indicating the possibility of a new, previously 
unreported binding site. 
 
As an additional followup, Glide docking studies in Schrödinger were performed 
with naphthol AS-E phosphate and 2 against the four previously listed KIX PDB 
structures. Grids large enough to encompass both the MLL binding site and this 
potentially new binding site were used to provide an unbiased comparative prediction. 
Using extra precision (XP) docking, two poses for each molecule were generated per 
PDB structure. Six out of eight poses for naphthol AS-E phosphate were found to be in 
the new binding site while two were predicted to be in the MLL site. For 2, all eight 
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poses were found in the new binding site consistent with the clusters predicted by FTMap 
(Figure 3.15C, Figure 3.17). 
 
 
Figure 3.17 Glide docking pose comparisons of small molecule ligands against four 
different KIX PDBs (1KDX, 2AGH, 2LXT, 2LXS).  
Two poses per PDB are presented. A) Naphthol AS-E phosphate binding poses predicted 
by Glide docking. Six poses place naphthol AS-E phosphate in the new binding site while 
the remaining two are placed in the MLL site. B) Binding poses of 2 predicted by Glide 
docking. All eight predicted poses are in the new binding site, and no poses are predicted 
for the MLL site. 
 
Reevaluation of the HSQC NMR data from Best et al. (naphthol AS-E 
phosphate)
36
 and Gee et al. (1)
193
 revealed the possibility of a new ligand binding site, 
consistent with the most significant perturbations in the amide backbones being found on 
the α1 helix. 1H-15N HMQC NMR data on 2 resulted in similar perturbations to both 
naphthol AS-E phosphate and 1. (Figure 3.15D, E, F, Figure 3.18) 
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Figure 3.18 
1
H-
15
N HSQC of 2 binding to KIX.  
A) Spectra of 
15
N KIX alone, 
15
N KIX + 0.5 mM 2, 
15
N KIX + 1 mM 2, and 
15
N KIX + 2 mM 2 
B) Chemical shift perturbation mapping of KIX residues with 0.5 mM, 1 mM and 2 mM 2. 
Residues that were not detected or not assigned are designated as ND. Dashed lines represent the 
average chemical shift perturbation + one standard deviation at the corresponding concentration. 
Assignments previously obtained by Majmudar et al.
42
 In the secondary structure box schematic, 
G1 and G2 refer to the two 310-helices, while α1, α2, and α3, refer to the three alpha helices 
comprising the structure 
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Notably, in contrast to 1, vectors for the chemical shift perturbations in the 
presence of increasing concentrations of 2 were consistently linear, indicative of 1:1 
binding (Figure S15). Surprisingly, one of the most significantly perturbed amide 
backbones was that of F612. This apparent contradiction could be the result of a number 
of different factors. The 4FF may be sensitive enough to detect stronger binders like the 
native MLL peptide but not sensitive enough to detect weaker binders that are farther 
away. As an additional distinction HMQC experiments reports on changes in the 
chemical environment of the amide backbone while PrOF NMR reports on changes in the 
chemical environment of the fluorine on the side chain, which may be less sensitive to 
local secondary structure effects.  It is also possible that the chemical environment of this 
solvent-exposed 4FF has not changed sufficiently, relative to the change in chemical 
environment near the backbone amide, due to either direct or distant binding effects. 
Additional experiments are ongoing to test the sensitivity of other fluorinated 
phenylalanine variants. 
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Figure 3.19 Comparison of 
1
H-
15
N HSQC/HMQC data from KIX.  
A) Select region of 
1
H-
15
N HSQC NMR spectrum with 1. Native protein, 2 mM 1 and 5 
mM 2 are shown. B) Select region of 
1
H-
15
N HMQC NMR spectrum with 2. Distinctly, 
the chemical shift perturbations in the presence of 2 consistently exhibit a linear change 
in chemical shift relative to the parent compound 1. Native protein, 0.5 mM 2, 1 mM 2, 
and 2 mM 2 are shown. Assignments previously obtained by Majmudar et al.
42
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3.3 Conclusion 
This dual-labeling strategy augments previously reported PrOF NMR methods for 
studying ligand-protein interactions. Dual-labeling provides the ability to insert additional 
probes into the protein of interest and report on potentially new ligand binding modes. 
Using this novel dual-labeling strategy in conjunction with computational predictions and 
HSQC NMR data, our data supports a new small-molecule binding site in KIX, distal to 
the two native transcription factor binding sites. Such a new binding site provides an 
opportunity to positively or negatively allosterically regulate KIX PPIs, such as with 
naphthol AS-E phosphate, without competing with endogenous transcription factors. 
Identifying ligand binding modes in this site will be the subject of future studies. 
Although this method produces lower protein expression yields making it less ideal for 
full screens, dual-labeling a protein can serve as a useful tool and extension of PrOF 
NMR for further studying ligand binding and characterizing their binding modes.  
3.4 Future Directions 
There are still a number of directions that these projects could go. The most 
immediate follow-up would be to further study the discrepancy between the results from 
2 binding to KIX via HSQC and PrOF NMR. The sensitivity of different fluorinated 
phenylalanines could be assessed to see if alternate substitutions would provide more 
insight into the ligand binding. Another round of experiments related to further studying 
the binding site would be to utilize fluorescence polarization. While 2 is not a potent 
enough ligand to compete with the native peptide sequences, it is possible that its binding 
could still allosterically regulate the binding of MLL, pKID, or both. One could first 
saturate the protein with 2, then assess the affinity of either native peptide individually 
and together to see if their relative affinities are affected by the presence of 2. One might 
expect that if 2 is stabilizing the fold of the protein through binding that the peptides may 
actually bind with a tighter affinity.  
Additionally, more direct approaches could also be taken. With the appropriate 
mutations in the protein sequence, one could perform a disulfide tethering experiments or 
a photocrosslinking experiment to form a covalent bond between the protein and the 
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ligand.
8
 Once bound, the protein could be digested, and analyzed to identify where the 
crosslink was formed. An alternative strategy would be to use a transfer-nuclear 
overhauser effect NMR experiment in which the ligand is irradiated and the protein 
signals are observed to identify which residues receive a transfer of energy. This type of 
experiment would help to identify which amino acids are in close proximity to the bound 
small molecule as a complementary approach to the HSQC experiments.  
The clearest method to identify exactly where the molecules are binding in the 
protein would be to obtain x-ray crystal structures. However, KIX has been notoriously 
difficult to crystallize and has only been crystallized with a covalent ligand attached. In 
conjunction with the crosslinking idea, one could attempt crystallization experiments 
once the molecule is crosslinked to see if the covalent attachment is enough to help 
stabilize the protein. Crosslinking to 3FY KIX instead of unlabeled KIX would also 
provide additional stabilization as demonstrated by the increased Tm of 3FY KIX.  
On the protein labeling side, it would still be interesting to work on other dual-
labeling strategies with other combinations of amino acids. It could also be interesting to 
apply a dual labeling strategy to the bromodomains that are already being expressed in 
the lab. The bromodomains tend to express more efficiently. One of the main drawbacks 
to the current dual-labeling process is the need to use DL39 cells. We can already express 
5-fluoro-tryptophan labeled proteins in regular BL21 cells, so if it were possible to 
express proteins with other fluorinated amino acids in a non-auxotrophic cell line, it 
might make the process significantly more efficient.  
3.5 Materials and Methods 
Materials 
Unless otherwise noted, all reagents were obtained from commercial vendors and 
used without further purification. For expression of proteins in E. coli, Lennox L. (LB) 
broth, unlabeled amino acids, uracil, thiamine-HCl, nicotinic acid, biotin, ampicillin, 
chloramphenicol, IPTG, PMSF, and Triton X-100 were purchased from RPI corp. 
Nucleotide bases and 3-fluorotyrosine (3FY) were purchased from Alfa Aesar. Lysozyme 
was purchased from Gold Biotech, HEPES was purchased from Fischer Scientific, and 
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[
15
N] ammonium chloride was obtained from Cambridge Isotope Laboratories.  
1
H, 
13
C, 
and 
19
F spectra were recorded at 500 MHz, 125 MHz, and 470 MHz respectively. MLL 
and pKID peptide sequences, synthesis, and characterization were reported by Pomerantz 
et al.
41
  
Methods: 
Unlabeled (UL), 3FY, 4FF, and 3FY/4FF-Labeled Protein Expression and Purification 
of His6-KIX (586-672)  
Expression  
Protein expression using the same plasmid DNA for KIX was performed as 
previously described
41
 with slight modifications. The protein expression plasmid was 
transformed into either the E. coli BL21(DE3) strain co-transformed with pRARE 
(Novagen) (unlabeled protein) or DL39(DE3) cells with the plasmid pRARE (3FY-, 4FF-
, or 3FY/4FF-labeled proteins) and plated on an agar plate containing ampicillin (100 
mg/L) and chloramphenicol (35 mg/L).  5 mL primary cultures of DL39 or BL21 cells 
transformed with the KIX expression plasmid supplemented with ampicillin (100 mg/L) 
and chloramphenicol (34 mg/L) were grown overnight (~12-14 h, 25 °C, 250 rpm) in an 
incubator shaker (New Brunswick Scientific Excella E25). Primary cultures were added 
to fresh LB media (1 mL primary/50 mL media) to begin secondary culture growth. 
Secondary cultures were grown at (37 °C, 250 rpm) until they reached an OD600 of 
approximately 0.8 as evaluated by a Varian Cary 50 Bio UV/Vis spectrophotometer. The 
culture was centrifuged (8000 g, 10 min, 4 °C) to form a solid pellet of bacteria. The LB 
media was decanted, and the pellet was resuspended in defined media
187
 containing the 
designated amount of aromatic or fluorinated aromatic amino acids (Table S1)  at the 
original volume of LB media.. A recovery time of 30-120 min at 20 °C, 250 rpm was 
allowed prior to the addition of isopropyl-β-D-1-thiogalactopyranoside (IPTG) to induce 
protein overexpression overnight (15-20 h) Cultures were spun down (6000 g, 20 min, 4 
°C). Media was decanted, and the pellet was stored at -20 °C.   
Optimization of 4FF and 3FY/4FF KIX Expression Conditions 
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 A range of conditions were varied to determine optimal expression conditions, 
including amount of 4FF, phenylalanine, and recovery time. Results are summarized in 
the table below. Yields were not recorded for many early experiments since the first goal 
was to optimize label incorporation conditions. Initial results indicated that additional 
phenylalanine should be kept under 40 μM. Follow-up studies showed little to no 
improvement in label incorporation with higher amounts of 4FF. The next round of 
experiments determined that a 30 minute recovery time and 10 μM provided improved 
label incorporation. Longer recovery times were also explored and slightly lower 
amounts of phenylalanine were explored, determining that between 7.5 and 10 μM F and 
a 30 – 40 min. recovery time yielded the best results. High labeling of the dual-labeled 
protein is also achievable by leaving out phenylalanine.  
Purification via Fast Protein Liquid Chromatography (FPLC) 
Following cell lysis (lysis buffer, lysozyme, β-mercaptoethanol, protease inhibitor 
phenylmethanesulfonylfluoride (PMSF, 2 mM), and sonication), proteins were purified 
on a GE Äktapurifier FPLC equipped with a Superloop for large volume injections. A 
column containing Ni-NTA beads (Qiagen) was used for affinity purification of the His-
tagged protein. An elution gradient (30-400 mM) imidazole was used to initially bind and 
subsequently elute the His-tagged-protein from the Ni beads. Protein was then buffer 
exchanged into 50 mM HEPES and 100 mM NaCl, pH 7.2 using a HiPrep 26/10 
Desalting column (GE Healthcare, Life Sciences) and stored at -20 °C or 4°C. During 
protein purification multiple aliquots of the protease inhibitor PMSF were added due to 
the instability of PMSF in aqueous solution.  
UPLC/MS
 
Conditions for Protein Characterization 
     For UPLC/MS analysis of proteins, a Waters Acquity UPLC coupled to a Waters 
Synapt G2 HDMS quadrupole orthogonal acceleration time of flight mass spectrometer 
was used (Waters Corp., Milford, MA USA). A Waters Acquity UPLC Protein BEH C4 
2.1 mm x 100 mm column (1.7 m diameter particles) at 35C was used for the following 
15 min linear gradient separation at a flow rate of 0.400 mL/min using A: water 
containing 0.1% formic acid and B: acetonitrile containing 0.1% formic acid: 3% B, 0 
min to 3 min; 3% B to 97% B, 3 min to 9 min; 97% B, 9 min to 11 min; 97% B to 3% B, 
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11 min to 13 min; 3% B 13 min to 15 min. Mass spectra were collected in profile mode 
over the range m/z 300-2500 every 0.1 s during the chromatographic separation. MS 
parameters in positive electrospray ionization mode were as follows: capillary, 0.3 kV; 
sampling cone, 35.0 V; extraction cone, 4.0 V; desolvation gas flow, 800 L/h; source 
temperature, 100 C; desolvation temperature, 350 C; cone gas flow, 20 L/h; trap CE, 
off. Lockspray (on-the-fly mass calibration) configuration consisted of infusion of a 5 
g/mL solution of leucine-enkephalin and acquisition of one mass spectrum (0.2s scan, 
m/z 50-1200) every 10s. Three lockspray m/z measurements of protonated (positive 
ionization mode) leucine-enkephalin were averaged and used to apply a mass correction 
to measured m/z values during the course of the analysis.  
Circular Dichroism 
 CD spectra were acquired using a peltier equipped temperature controlled Jasco J-
815 spectropolarimeter. Protein samples were prepared in a 10 mM sodium phosphate, 
100 mM sodium chloride buffer at pH 7.2. Unlabeled KIX was prepared at 10.5 μM 
while 3FY and 3FY/4FF KIX were prepared at 11.5 μM. Molar ellipticity was monitored 
from 200-260 nm. Samples were collected at 25 °C using a 1 mm cuvette path-length. 
Reported data is the average of 5 acquired spectra. Thermal stability of unlabeled and 
fluorine-labeled KIX was measured by following the change in ellipticity at 222 nm from 
20 °C to 95 °C. For the thermal melt experiments, the concentration of 3FY/4FF KIX was 
increased to 35 μM.  The Tm was calculated using a sigmoidal fit. Data analysis was 
performed using Origin 2016. Molar ellipticity was calculated using the following 
equation.  
Θ222 =  𝛹/(1000𝑛𝑙𝑐)                                                       (1) 
In equation 1, Ψ is the CD signal in degrees, n is the number of amides in the protein 
construct, l is the path lenth in centimeters, and c is the concentration of the protein 
sample in decimoles per cubic centimeter.  
Fluorescence Polarization 
 Fluorescence polarization experiments were performed on a Tecan Infinte F500. 
A FITC-MLL peptide
41
 was used to compare the binding activity of the three different 
protein constructs. UL and 3FY/4FF KIX were prepared at a starting concentration of 40 
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μM while 3FY KIX was prepared at a starting concentration of 35 μM. Samples also 
contained 85 nM tracer (FITC-MLL), 0.01% Triton X-100, with a total DMSO 
concentration of 0.5%. Excitation and emission wavelengths were 485 nm and 535 nm 
respectively. Samples were incubated for 30 min at room temperature prior to scanning. 
Each data point in Figure S2 C is the average of three independent experiments with the 
standard deviations listed as the error. Data analysis was performed with GraphPad 
Prism. Kd values were determined as follows 
                                          𝑦 = 𝑐 + (𝑏 − 𝑐) ∗  
√(𝐾𝑑+𝑎+𝑥)2−4𝑎𝑥
2𝑎
                                              (2) 
In the above equation, y corresponds to the observed anisotropy, c and b and the 
minimum and maximum observed entropies, respectively, Kd is the dissociation constant, 
and a and x are the concentrations of fluorescent peptide and KIX, respectively,  
1D 
19
F NMR.  
Conditions and Parameters Used.  All NMR spectra were obtained on a Bruker 
Avance III 500 MHz instrument equipped with a 5 mm Prodigy TCI Cryoprobe (
19
F S/N 
2100:1). Samples containing 30-50 µM 3FY, 4FF, or 3FY/4FF KIX were prepared in 
NMR buffer as noted above with 5% D2O and 50 µM trifluoroacetic acid (-76.5 ppm) as 
a reference. T1 relaxation times were calculated using an inversion recovery experiment.  
Optimized parameters for PrOF NMR experiments included a 0.6 s delay time, a 0.1-0.3 s 
acquisition time (AQ), and 400-800 scans. Spectral width and offset were 10 ppm and -
136 ppm respectively for 3FY KIX. Spectral width and offset were 10 ppm and -115 ppm 
respectively for 4FF KIX. Both of the aforementioned parameter sets were used when 
analyzing the 3FY/4FF KIX in addition to an experiment with a spectral width of 26 ppm 
and offset of -128 ppm for a full spectrum containing the 3FY and 4FF resonances. A 
line-broadening of 15-20 Hz was applied to all protein spectra upon processing. Spectra 
were acquired at 294 K) 
PrOF NMR Kd values are determined using the following equation: 
𝑆 = 𝐷 ∗ 
(𝐾𝑑+𝐿+𝑃)−√(𝐾𝑑+𝐿+𝑃)2−4𝑃𝐿
2𝑃
                                            (3)  
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In equation 2, S corresponds to the observed change in chemical shift, D is the maximum 
change in chemical shift, Kd is the dissociation constant of the ligand, L is the ligand 
concentration, and P is the protein concentration.  
2D 
1
H-
15
N HSQC NMR Experiments 
Uniformly 
15
N labeled KIX protein was expressed and purified using M9 minimal 
media supplemented with [
15
N] ammonium chloride as described previously.
42
 A 30-35 
µM solution of 
15
N-labeled KIX was prepared in a 9:1 H2O:D2O 10 mM phosphate buffer 
with 100 mM NaCl and 2.5% DMSO at pH 7.2. HSQC experiments were recorded at 27 
°C on a Bruker Ascend 850 MHz NMR spectrometer equipped with a 5 mM TCI Cryo 
probe. Spectra were collected with 0, 0.5, 1, and 2 mM 2. Data was processed using 
NMRPipe and analyzed using Sparky (UCSF). Chemical shift changes for individual 
resonances were quantified using the equation ((0.2*Δδ15N)2 + (Δδ1H)2)0.5. 
Small Molecule Synthesis 
 
Scheme 3.1 Methyl esterification of carboxylic acids 
 
General Procedure A: Methyl esterification of carboxylic acids: One of the compounds 
1 or amino acids tryptophan, tyrosine, or phenylalanine, was dissolved in 5-10 mL 
MeOH.  TMSCl (5 eq) was added, and the reaction was stirred at room temperature 
overnight. TLC indicated the reaction was complete. The solvent was evaporated in 
vacuo, and material was collected to carry on to the next step without further purification.   
methyl 2-(3,4-dichlorophenyl)acetate (1-OMe)  
3,4-Dichlorophenylacetic acid (1) was converted to its methyl ester according to general 
procedure A on a 0.512 mmol scale. The purification of this compound deviated from the 
general procedure since it was the final compound. After removing the MeOH solvent, 
the material was dissolved in EtOAc, and the organic phase was washed three times with 
a NaHCO3 solution, and then washed with brine. The organic layer was removed, dried 
over MgSO4, filtered to remove the drying agent, and concentrated in vacuo, providing 1-
OMe as a white solid (80 mg/0.365 mmol, 71%): 
1
H NMR (500 MHz, CDCl3): δ 7.39 (d, 
J = 8.1 Hz, 1 H), 7.38 (d, J =  2.0 Hz, 1 H), 7.11 (dd, J = 8.1, 2.0 Hz, 1 H), 3.70 (s, 3 H), 
3.57 (s, 2 H); 
13
C NMR (125 MHz, CDCl3): δ 171.14, 134.10, 132.64, 131.51, 131.41, 
130.58, 128.88, 52.40, 40.21;  
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Scheme 3.2 Analog synthesis for ligand development 
 
General Procedure B: Amide bond formation Compound 1 and S2a, S3a, or S4a (1 eq) 
were dissolved in DMF with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) 
(1.2 eq) and N,N-diisopropylethylamine (DIEA) (2 eq). Reactions were stirred at room 
temperature overnight. TLC indicated the completion of the reaction. The reaction 
mixture was then diluted with EtOAc and washed with water and brine. The organic layer 
was collected, dried over MgSO4, and the solvent was evaporated in vacuo. The product 
was then purified by column chromatography and isolated as a solid.  
General Procedure C: Hydrolysis of methyl ester to carboxylic acid. Compound S2b, 
S3b, or S4b (1 eq) were dissolved in a 1:1 THF:H2O solution with LiOH (2 eq) and 
stirred for approximately 6 hours. TLC indicated the completion of the reaction. The final 
product was isolated using an acid/base extraction to separate starting materials and 
unreacted methyl esters from the free carboxylic acid. The final organic layer was dried 
over MgSO4, filtered, and concentrated in vacuo to isolate a solid. It is important to note 
that the stereochemistry of the final product (2, S3, S4) is not indicated in the reaction 
scheme because it is believed that racemization may occur during hydrolysis.  
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Tryptophan Analogs 
Methyl Tryptophanate (S2a)  
Tryptophan (Trp) was converted to its methyl ester according to general procedure A on 
a 1.47 mmol scale in 10 mL of MeOH. Removal of solvent yielded S2a as a red-purple 
solid and was used without further purification. 
1
H NMR (500 MHz, MeOD): δ 7.54 (d, J 
= 7.9 Hz, 1 H), 7.39 (d, J = 8.1 Hz, 1 H), 7.19 (s, 1 H), 7.15 (t, J = 7.6 Hz, 1 H), 7.07 (t, 
7.6 Hz, 1 H), 4.32 (dd, J = 7.6, 5.5 Hz, 1 H), 3.80 (s, 3 H), 3.46 (dd, J = 15.1, 5.4, 1 H), 
3.35 (dd, J = 15.1, 7.6 Hz, 1 H); 
13
C NMR (125 MHz, MeOD): δ 170.86, 138.36 (low 
intensity), 128.17, 125.53, 123.00, 120.36, 118.79, 112.70, 107.49, 54.64, 53 65, 27.62; 
Hi-Res MS calc’d m/z, 218.10553, found M+H [219.11366] 
 
Methyl (2-(3,4-Dichlorophenyl)acetyl)tryptophanate (S2b)  
Compound S2a was coupled to 1 according to general procedure B on a 1.18 mmol scale. 
Following the removal of solvent in vacuo, the material was purified by column 
chromatography using a 3:2 EtOAc:Hexanes mobile phase. The final product (S2b) was 
isolated as a yellow solid (199 mg/0.491 mmol, 41.5% yield). 
1
H NMR (500 MHz, 
MeOD): δ 7.47 (d, J = 7.9 Hz, 1 H), 7.30-7.34 (m, 3 H), 7.09 (t, J = 7.6 Hz, 1 H), 6.95-
7.01 (m, 3H), 4.76 (dd, j = 8.3, 5.3 Hz 1 H), 3.68 (s, 3 H), 3.45 (s, 2 H), 3.3 (m, 1 H)*, 
3.16 (dd, J = 14.7, 8.3 Hz, 1 H)  *Signal obscured due to solvent overlap; 
13
C NMR (125 
MHz, MeOD): δ 173.82, 172.70, 138.02, 137.35, 133.08, 132.21, 131.69, 131.38, 129.98, 
128.69, 124.36, 122.47, 119.87, 119.08, 112.36, 110.62, 54.98, 52.73, 42.16, 28.35; Hi-
Res MS calc’d m/z, 404.06945 found M+Na [427.06065] 
 
(2-(3,4-Dichlorophenyl)acetyl)tryptophan (2)  
Compound S2b was hydrolyzed according to general procedure C on a 0.10 mmol scale. 
The final compound 2 was isolated as a yellow oil (26 mg/, 66.5% yield). 
1
H NMR (500 
MHz, MeOD): δ 7.51 (d, J = 8.0 Hz, 1 H), 7.33 (d, J = 8.1 Hz, 1 H), 7.29 (s, 1 H), 7.28 
(d, J = 8.1 Hz, 1 H), 7.09 (ddd, J = 7.9, 7.2, 1.0 Hz, 1 H), 7.03 (s, 1 H), 6.98 (ddd, J = 7.9, 
7.2, 1.0 Hz, 1 H), 6.92 (dd, J = 8.2, 1.9 Hz, 1 H), 4.75 (dd, J = 8.3, 4.8 Hz, 1 H), 3.43 (s, 
2 H), 3.37 (dd, J = 14.8, 4.7 Hz, 1 H), 3.17 (dd, J = 14.7, 8.3 Hz, 1 H); 
13
C NMR (125 
MHz, MeOD): δ 175.64, 172.54, 137.97, 137.36, 133.05, 132.27, 131.64, 131.37, 130.01, 
128.93, 124.33, 122.36, 119.81, 119.23, 112.29, 111.04, 55.15, 42.35, 28.42; Hi-Res MS 
calc’d m/z, 390.05380 found M-H [389.04570] 
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Phenylalanine Analogs 
Methyl Phenylalaninate (S3a)  
Phenylalanine (Phe) was converted to its methyl ester according to general procedure A 
on a 1.82 mmol scale in 10 mL of MeOH. Removal of solvent yielded S3a as a white 
solid and used without further purification. 
1H NMR (500 MHz, MeOD): δ 7.38 (t, J = 
7.3 Hz, 2 H),  7.33 (t, J = 7.3 Hz, 1 H), 7.26 (d, J = 7.3 Hz, 1 H), 4.32 (dd, J = 6.2, 7.3 
Hz, 1 H), 3.80 (s, 3 H), 3.27 (dd, J = 14.4, 6.2 Hz, 1 H), 3.17 (dd, J = 14.4, 6.2 Hz, 1H); 
13C NMR (125 MHz, MeOD): δ 170.47, 135-27, 130.40, 130.20, 129.01, 55.20, 53.60, 
37.42; Hi-Res MS calc’d m/z, 179.19463 found M+H [180.10942] 
 
Methyl (2-(3,4-Dichlorophenyl)acetyl)phenylalaninate (S3b)  
Compound S3a was coupled to 1 according to general procedure B on a 0.858 mmol 
scale. Following the removal of solvent in vacuo, the material was purified by column 
chromatography using a 2:1 EtOAc:Hexanes mobile phase. The final product (S3b) was 
isolated as a white solid (116 mg/0.317 mmol, 37.0 % yield). 
1
H NMR (500 MHz, 
MeOD): δ 7.48 (d, J = 8.3 Hz, 1 H), 7.35 (d, J = 2.0 Hz, 1 H), 7.19-7.24 (m, 3 H), 7.13 
(dd, J = 8.0, 1.7 Hz, 2 H), 7.06 (dd, J = 8.4, 2.0 Hz, 1 H), 4.68 (dd, J = 9.4, 5.3 Hz, 1 H), 
3.71 (s, 3 H), 3.45 (s, 2 H), 3.17 (dd, J = 13.9, 5.2 Hz, 1 H), 2.94 (dd, J = 13.9, 9.6 Hz, 1 
H); 
13C NMR (125 MHz, MeOD): δ 173.35, 172.69, 138.02, 137.44, 133.12, 132.16, 
131.76, 131.45, 130.15, 130.05, 129.48, 127.89, 55.18, 42.77, 42.24, 38.23; Hi-Res MS 
calc’d m/z, 365.05855 found M+Na [388.05118] 
 
(2-(3,4-Dichlorophenyl)acetyl)phenylalanine (S3)  
Compound S3b was hydrolyzed according to general procedure C on a 0.082 mmol scale. 
The final compound S3 was isolated as a white solid, though a small contamination does 
not allow for accurate yield calculations.  1H NMR (500 MHz, MeOD): δ 7.37 (d, J = 8.3 
Hz, 1 H), 7.34 (d, J = 2.0 Hz, 1 H), 7.18-7.24 (m, 3 H), 7.13 (dd, J = 8.0, 1.1 Hz, 2 H), 
7.04 (dd, J = 8.4, 2.0 Hz, 1 H), 4.66 (dd, J = 9.4, 5.0 Hz, 1 H), 3.45 (d, J = 2.0 Hz, 2 H), 
3.22 (dd, J = 14.0, 4.9 Hz, 1 H), 2.93 (dd, J = 14.0, 9.4 Hz, 1 H); 
13
C NMR (125 MHz, 
MeOD): δ 174.80 (low intensity), 172.55, 138.37, 137.53, 133.11, 132.21, 131.73 (low 
intensity), 131.42, 130.22, 130.07, 129.39, 127.74, 55.14, 42.38, 38.35; Hi-Res MS 
calc’d m/z, 351.04290, found M-H [350.02350] 
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Tyrosine Analogs 
Methyl Tyrosinate (S4a)   
Tyrosine (Tyr) was converted to its methyl ester according to general procedure A on a 
1.66 mmol scale in 10 mL of MeOH. Removal of solvent yielded S4a as a white solid 
(126.4 mg/0.648 mmol, 39% yield). 
1
H NMR (500 MHz, CDCl3/MeOD): δ 6.96 (d, J = 
8.3 Hz, 2 H), 6.73 (d, J = 8.3 Hz, 2 H), 3.69 (s, 3 H), 3.65 (dd, J = 7.6, 5.4 Hz, 1 H), 2.97 
(dd, J = 13.7, 5.2 Hz, 1 H), 2.78 (dd, J = 13.7, 7.6 Hz, 1 H); 
13
C NMR (125 MHz, 
CDCl3/MeOD): δ 175.28, 155.79, 130.37, 127.61, 115.65, 55.56, 52.18, 39.78; Hi-Res 
MS calc’d m/z, 195.08954 found M+H [196.09711] 
 
Methyl (2-(3,4-Dichlorophenyl)acetyl)tyrosinate (S4b)  
Compound S4a was coupled to 1 according to general procedure B on a 0.647 mmol 
scale. Following the removal of solvent in vacuo, the material was purified by column 
chromatography using a 79:1 DCM:MeOH mobile phase. The final product (S4b) was 
isolated as a white solid (44.9 mg/0.117 mmol, 18.0 % yield). 
1
H NMR (500 MHz, 
MeOD): δ 7.39 (d, J = 8.3, 1 H), 7.37 (d, J = 2.0 Hz, 1 H), 7.03 (dd, J =  8.2, 2.0 Hz, 1 
H), 6.95 (d, J = 8.5 Hz, 2 H), 6.67 (d, J = 8.6 Hz, 2 H), 4.62 (dd, J = 9.2, 5.4 Hz, 1 H), 
3.70 (s, 3 H), 3.47 (s, 2 H), 3.07 (dd, J = 14.1, 5.4 Hz, 1 H), 2.85 (dd, J = 14.1, 9.2 Hz, 1 
H) 
13C NMR (125 MHz, MeOD): δ 173.50, 172.69, 157.47, 137.47, 133.14, 132.21, 
131.75, 131.45, 131.16, 130.01, 128.59, 116.27, 55.48, 52.70, 42.22, 37.50; Hi-Res MS 
calc’d m/z, 381.05346 found M-H [380.04781] 
 
(2-(3,4-Dichlorophenyl)acetyl)tyrosine (S4)  
Compound S4b was hydrolyzed according to general procedure C on a 0.045 mmol scale. 
An excess of LiOH was used in this reaction (~400 eq). The final compound S4 was 
isolated as a white solid, though a small contamination does not allow for accurate yield 
calculations. 1H NMR (500 MHz, MeOD): δ 7.40 (d, J = 8.3 Hz, 1 H), 7.38 (d, J = 2.0 
Hz, 1 H), 7.02 (dd, J = 8.3, 2.0 Hz, 1 H), 6.97 (d, J = 8.5 Hz, 2 H), 6.66 (d, J = 8.5 Hz, 2 
H), 4.60 (dd, J = 9.27, 4.82 Hz, 1 H), 3.47 (d, J = 5.61 Hz, 2 H), 3.12 (dd, J = 14.0, 4.9 
Hz, 1 H), 2.85 (dd, J = 14.1, 9.2 Hz, 1 H) 13C NMR (125 MHz, MeOD): δ 175.06 (low 
intensity), 172.53, 157.33, 137.55, 133.13, 132.26, 131.71, 131.43, 131.23, 130.04, 
129.02, 116.19, 55.47, 42.38, 37.60; Hi-Res MS calc’d m/z, 367.03781 found M-H 
[366.03161] 
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Computation 
 Access to the Schrodinger Software Suite was provided through the Minnesota 
Supercomputing Institute (MSI).  The four following KIX PDB structures were used for 
docking studies: 1KDX, 2AGH, 2LXT, and 2LXS. The generated grid that was used was 
25 Å x 25 Å x 25 Å. Docking studies were performed with extra precision (XP). Two 
poses for each molecule were generated per PDB structure resulting in eight poses for 
naphthol AS-E phosphate and eight poses for 2.  
FTMap Computational Solvent Mapping was provided by Boston University at 
ftmap.bu.edu. 
202-205
 Experiments were performed on the main KIX chain from each of 
the four following PDB structures : 1KDX, 2AGH, 2LXT, and 2LXS.  
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1
H NMR of 1-OMe (500 MHz, CDCl3) 
 
13
C NMR of 1-OMe (125 MHz, CDCl3) 
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1
H NMR of S2a (500 MHz, MeOD) 
 
13
C NMR of S2a (125 MHz, MeOD) 
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1
H NMR of S2b (500 MHz, MeOD) 
 
13
C NMR of S2b (125 MHz, MeOD) 
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1
H NMR of 2 (500 MHz, MeOD) 
 
13
C NMR of 2 (125 MHz, MeOD) 
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1
H NMR of S3a (500 MHz, MeOD) 
 
13
C NMR of S3a (125 MHz, MeOD) 
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1
H NMR of S3b (500 MHz, MeOD) 
 
13
C NMR of S3b (125 MHz, MeOD) 
 
 
 
 
 
  124 
 
1
H NMR of S3 (500 MHz, MeOD) 
 
13
C NMR of S3 (125 MHz, MeOD) 
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1
H NMR of S4a (500 MHz, CDCl3/MeOD) 
 
13
C NMR of S4a (125 MHz, CDCl3/MeOD) 
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1
H NMR of S4b (500 MHz, MeOD) 
 
13
C NMR of S4b (125 MHz, MeOD) 
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1
H NMR of S4 (500 MHz, MeOD) 
 
13
C NMR of S4 (125 MHz, MeOD) 
 
 
 
 
  128 
Chapter 4. Protein-observed 19F-NMR for fragment screening, affinity 
quantification and druggability assessment 
 
Reproduced with permission from “Protein-observed 19F-NMR for fragment screening, 
affinity quantification and druggability assessment,” C. T. Gee, K. E. Arntson, A. K. 
Urick, N. K. Mishra, L. M. L. Hawk, A. J. Wisniewski, W. C. K. Pomerantz, Nature 
Protocols 2016, 1414-1427. Copyright 2016 Nature Publishing Group. 
Reproduced in part with permission from “Paramagnetic relaxation enhancement for 
protein-observed 19F NMR as an enabling approach for efficient fragment screening,” L. 
M. L. Hawk, C. T. Gee, A. K. Urick, H. Hu, W. C. K. Pomerantz, RSC Advances 2016, 
95715-95721. Copyright 2016 Royal Society of Chemistry. 
 
Note: A version of the following was also previously reproduced in the dissertation of 
Andrew Urick, Ph.D.  
 
Motivation: This manuscript sought to disseminate our procedure for our PrOF NMR 
method, from protein expression to ligand-binding experiments. The goal of this 
manuscript was to make it as easy as possible for others to adopt and utilize our 
techniques for incorporating fluorinated amino acids into proteins of interest for NMR 
characterization and screening. As such, a paper focused on the details of the 
methodology was a good fit in order to share both our protocols as well as pitfalls that 
may be encountered throughout the process.  
 
4.1 Introduction 
NMR spectroscopy, using either labeled proteins or labeled small molecules is 
emerging as a preferred method for screening low-complexity molecules (typically < 
300 Da with a minimal number of functional groups) termed fragments in early-stage 
ligand discovery campaigns.
172, 206
 Fragments typically bind to their protein target with 
low affinity (mid micromolar to millimolar dissociation constants). These low affinity 
interactions are readily detected using NMR methods.
207-208
 Fragment molecules can be 
compared to higher molecular weight counterparts found in traditional high throughput 
screening libraries, via evaluation of their ligand efficiency, which compares binding 
affinity or activity relative to the number of atoms in the molecules.
150, 209
 Highly ligand 
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efficient compounds can be developed in an atom-economical manner into more potent 
compounds by fragment linking or growing approaches.
61, 210
 Enthusiasm for this 
approach remains high with the approval of Vemurefanib
211
 in 2011 and Venetoclax
167
 in 
2016,
212
 discovered through an initial fragment screening campaign and several more 
lead molecules which emerged from fragment screens are in late-stage clinical trials.
147, 
211
 
Fluorine NMR is an attractive approach for fragment screening because the spin-½ 
nucleus 
19
F, is stable, has a natural abundance of 100%, and is nearly absent in biological 
systems. Many fluorinated amino acids and building blocks are commercially available 
including aromatic amino acids 3-fluorotyrosine, 4-fluorophenylalanine, and 5-
fluoroindole described herein. In many cases, minimal structural and functional 
perturbation has been observed.
74, 194, 213
 
19
F chemical shifts are also sensitive to changes 
in the molecular environment, and therefore 
19
F is an ideal background-free NMR-active 
nucleus for studying challenging problems of molecular recognition by biopolymers.
74
 
131
 
In the case of fluorine-labeled proteins, the environmental sensitivity of fluorine nuclei 
typically results in well-resolved 1D 
19
F NMR spectra of proteins whose fluorine-labeled 
side-chains are observed at low-to-mid micromolar concentrations (e.g., 25–100 μM).74 
Fragment screening  using low molecular weight, low complexity molecules has 
attracted considerable attention due to the reduction of chemical space compared to that 
of higher molecular weight, functional group-rich small molecules used in high 
throughput screening. As a result, fragment libraries are typically smaller than high 
throughput screening libraries
147, 172, 206, 214
 An analysis by Scanlon and coworkers
215
 of 
20 different fragment libraries developed in the context of academic or industrial research 
yielded an average library member size of 4,543 fragment library members with a median 
size of 1280. The use of smaller library sizes is further supported by the hit rates from 
these fragment screens where the researchers detected a binding event averaging 8.2% as 
reported by 11 different screening centers. The high hit rates suggest adequate chemical 
space is being covered. Fragments identified as hits have been have been used to develop 
efficient ligands with favorable physicochemical properties.
176
  
One of the challenges when screening fragment molecules for binding to a 
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specific protein target is the detection and quantification of low-affinity interactions. 
Achieving this important research goal often forces researchers to use high ligand 
concentrations. NMR is a technique well-suited for working at these high concentrations. 
With NMR, mixtures of fragment molecules can also be tested simultaneously. In 
experiments using proteins labeled with NMR-active nuclei, the NMR spectrum of a 
mixture that results in a large change in chemical shift of the NMR-active nucleus is 
deconvoluted by obtaining NMR spectra of the protein with individual molecules to find 
the small molecule that actively binds the protein (thus causing the observed change in 
chemical shift). One advantage of this fragment mixture approach is that it enables 
researchers to test a large number of compounds in a shorter period of time than testing 
individual compounds one at a time. A second advantage when using a labeled protein 
(i.e., protein-observed NMR methods) is the added structural information the protein 
resonances provide. These specific resonance perturbations can be used to guide 
molecular designs aimed at increasing fragment affinity.  
Ligand-observed NMR methods, such as saturation transfer difference (STD) or 
transverse relaxation-Carr-Purcell-Meiboom-Gill-based experiments
216-217
, provide 
complementary information which can be used in parallel with protein-observed methods. 
Ligand-observed and protein-observed 
19
F NMR-based methods are tolerant to a variety 
of experimental conditions. For example, contrary to many 
1
H NMR-based experiments, 
NMR spectra of fluorine-labeled small molecules or fluorine-labeled proteins are not 
affected by the presence of detergents and buffers that are traditionally used.
174
 
Advantages associated with the implementation of ligand-observed experiments with 
respect to protein-observed experiments are the lower protein concentration needed (0.1–
10 μM) in many cases — although increasing protein concentration can lead to better 
signal
218
 — and lack of an upper limit in protein size. Additionally, with respect to 
protein-observed experiments, the active ligand can be readily identified from the 
fragment mixture without deconvolution.  However, in STD NMR, false positive hit rates 
can be as high as 50%,
215
 although the occurrence of such false positives can be partly 
mitigated by repeating the experiment in the presence of a competitor ligand (if one is 
known).  
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We have proposed a protein-observed 
19
F NMR screening method abbreviated as 
PrOF NMR, in which we rapidly monitor changes in the chemical shifts of fluorine 
resonances in 
19
F-labeled protein side chains induced by the presence of small molecules 
Figure 4.1). An approach that is analogous to that adopted in structure–activity 
relationship (SAR) by NMR using labeled amides in 
1
H-
15
N heteronuclear single 
quantum coherence spectroscopy (HSQC) experiments.
61
 The increasing availability of 
improved instrumentation using 
19
F-tuned cryoprobes, (e.g., the QCI-F cryoprobe from 
Bruker), speed of PrOF NMR experiments, and ease of spectral interpretation, have 
increased the accessibility of these experiments in academic and industrial settings. We 
recently applied PrOF NMR for fragment screening with the transcription factor–binding 
domain KIX.
41, 193
 In this study, we analyzed in 85 mixtures (comprising a total of 508 
small molecules) in 10 hours of experiment time using a total of 20 mg of protein. PrOF 
NMR has been employed by others, including follow-up screens against the SPRY 
domain-containing SOCS box protein 2
219
 and AMA1
220
, and shown to be more than 
twice as fast as 
1
H-
15
N HSQC NMR for small proteins.
193, 221
 We have also used the 
bromodomain BrdT, described below.
98
 G-protein coupled receptor (GPCR) agonists and 
antagonists can also be identified by this method.
79
 2D PrOF NMR methods have 
validated binding modes of fluorinated ligands via 
19
F–19F homonuclear nuclear 
Overhauser effect (NOE) experiments with BcL-xL.
222
 As the incorporation of fluorine in 
drug molecules increases, NOE experiments provide an additional structural biology tool 
for characterizing ligand-binding modes. Our lab recently demonstrated a simultaneous 
analysis (i.e., multiplexed) of small-molecule binding using two 15-kDa bromodomains 
Brd4 and BPTF
98
 In this study, 229 small molecules were screened using this approach.
99
 
Because a protein and potential off-target are screened together, this multiplexed 
experiment is similar to the RAMPED-UP 2D NMR experiments with differently labeled 
proteins.
223
 These approaches are advantageous for studies where protein selectivity is 
important.  
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Figure 4.1 General workflow for using PrOF NMR for fragment screening and 
ligand characterization. 
 
In 1974, Sykes et al. first reported the 
19
F NMR analysis of an 86-kDa protein, 
alkaline phosphatase, using 3-fluorotyrosine (3FY) to label the protein.
137
 Sequence-
selective labeling of recombinant proteins with fluorinated amino acids is now a well-
documented methodology that facilitates the general use of the present screening method 
based on PrOF NMR.
200, 224
 In this protocol, using sequence-selective labeling with 
fluorinated aromatic amino acids, we describe the application of PrOF NMR to the 
screening of small-molecule libraries as potential protein ligands and the quantification of 
the micromolar to millimolar dissociation constants from chemical shift perturbation 
analysis. We demonstrate our ligand-binding screening method on two proteins, the 
transcription factor–binding domain of the CREB-binding protein, KIX, and the 
bromodomain Brd4 (Figure 4.2). Application of PrOF NMR with a third protein, the first 
bromdomain of BrdT, will be subsequently described to highlight several additional 
important aspects of the PrOF NMR protocol. The sequence-selective incorporation of 
the three fluorinated aromatic amino acids, 3FY, 4-fluorophenylalanine (4FF), and 5-
fluorotryptophan (5FW) into recombinant proteins in E. coli using either the auxotrophic 
bacterial cell lines [e.g., DL39(DE3)] or standard bacterial strains [e.g., BL21(DE3)] will 
first be detailed, as previously described.
41, 200, 224
 This section of the Procedure will then 
be followed by our ligand-discovery procedures.   
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Figure 4.2 PrOF NMR examples.  
(a) Crystal structure of Brd4 (PDB 3MXF) with its three tryptophan residues shown in 
red. (b) Solution structure of KIX (PDB 1KDX). (c) PrOF NMR spectra for each of these 
variants, in which the residues highlighted in a and b were replaced by 5FW (Brd4), 3FY 
(KIX) or 4FF (KIX). In these spectra, the wide chemical shift dispersion of the signals 
due to the fluorine-labeled, aromatic amino acid analogs are highlighted. The structures 
of the mentioned fluorinated amino acids are shown next to their corresponding spectra. 
4.2 Experimental Design 
4.2.1 Fluorinated Protein Expression and Characterization.  
All expressed proteins in the Procedure are characterized for purity and fluorine 
incorporation via SDS-PAGE and protein mass spectrometry via electrospray ionization. 
Protein yields vary based on the protein system, fluorinated amino acid, and cell line 
used. We have achieved yields as high as 70 mg/l for 3FY-labeled KIX and 65 mg/L for 
4FF-labeled KIX using auxotrophic DL39(DE3) cells, while obtaining up to 62 mg/L of 
5FW-labeled KIX
23
 using non-auxotrophic BL21(DE3) cells with 5-fluoroindole added 
to the cell culture medium. All expressions led to high labeling efficiency. We observed 
even higher yields with our fluorinated bromodomains (84 mg/L for 5FW BPTF and 
88 mg/L for 5FW Brd4).
99
 The SDS-PAGE gel in Figure 3A shows four KIX protein 
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samples that are either unlabeled, 3FY-labeled, 4FF-labeled, or 5FW-labeled.  
 
Figure 4.3 Characterization of fluorinated proteins expressed according to present 
protocol.  
(a) SDS-PAGE gel stained with Coomassie blue showing wild-type and three fluorinated 
variants of KIX. (b) Deconvoluted electrospray ionization mass spectrometry (ESI-MS) 
spectrum (left) and 
19
F NMR spectrum (right) of 3FY-labeled KIX with 98% fluorine 
incorporation. The dominant population present is the fully fluorinated variant. (c) 
Deconvoluted ESI-MS spectrum (left) and 
19
F NMR spectrum (right) of 3FY-labeled 
KIX with 64% fluorine incorporation.
193
  
 
Mass spectrometry is used to assess fluorine incorporation into the protein. For 
the mass spectrogram of 3FY-labeled KIX, the dominant mass of 12,021.8 Da 
corresponds to the incorporation of a fully labeled protein (five 3FY residues). The minor 
mass of 12,004.6 Da corresponds to four of the five tyrosine residues being replaced with 
3FY. These major and minor populations lead to a 98% labeled protein Figure 4.3 b). 
Low levels of incorporation can result in a heterogeneous protein sample, which can 
complicate the analysis of 
19
F NMR spectra (see troubleshooting sections). A 
19
F NMR 
spectrum of 3FY-labeled protein that is only 64% labeled is reported for comparison 
(Figure 4.3 c). The resulting spectrum is a statistical mixture of multiply labeled proteins 
and can result in additional (e.g. Y650) or broadened resonances.  In some instances, and 
if needed, the concentration of fluorinated amino acids can be increased in the culture 
media with respect to those recommended in the Procedure, to increase the extent of 
protein labeling. Low levels of labeling can also be attributed to residual unlabeled amino 
acid from the initial expression conditions, an inconvenience that can be reduced with 
careful washings of bacterial pellets and preincubations with fluorinated amino acids.  
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Figure 4.4 Direct binding experiment of BODIPY-BI, a Brd4 bromodomain ligand 
to unlabeled Brd4 and 5FW-labeled Brd4 by fluorescence polarization. 
 
Fluorine is not an element naturally found in proteins. Therefore, prior to the 
implementation of the screening protocol, the structural and functional perturbations 
caused by the introduction of the fluorine label in the protein must be carried out. We 
have characterized our proteins by a variety of methods, using x-ray crystallography, 
circular dichroism and thermal stability measurements to assess structure.
41, 98
 When a 
ligand was known beforehand, we have also employed isothermal titration calorimetry or 
fluorescence anisotropy ligand-binding experiments to compare the affinity of the known 
ligand with the fluorinated and non-fluorinated protein.  Figure 4.4 shows an example of 
a direct binding experiment with a fluorescently-labeled bromodomain ligand, BI-
BODIPY with 5FW-labeled Brd4 and unlabeled Brd4 yielding dissociation constants of 
110 nM and 55 nM, respectively. In our experience, we have considered a two-to-three-
fold change in binding affinity between fluorine-labeled and unlabeled protein acceptable 
for continuing on with the labeled protein with a ligand screen. We recommend 
alternative labeling approaches or amino acids (e.g., 6-fluoro versus 5-fluorotryptophan) 
to be tested if larger perturbations are observed.  
4.2.2 Protein-observed fluorine NMR.  
PrOF NMR spectra of small to medium-sized fluorinated proteins typically reveal 
well-resolved resonances for each labeled aromatic amino acid, but not in all cases. The 
different aromatic residues are seen in close but distinct chemical shift regions (Figure 
4.2).  A well-dispersed NMR spectrum is an additional confirmation of a well-folded 
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protein.  Protein resonances tend to be broad. Fluorine resonances from small-molecule 
impurities or peptides resulting from proteolytic degradation appear as sharp signals in 
19
F NMR spectra, and their presence can help assess the stability and purity of the 
protein. A resonance due to a small-molecule impurity can be seen in Figure 4.2 at –
120 ppm. In some cases, protein precipitation or aggregation leads to loss of signal for all 
of the protein resonances, which can be useful for identifying false positives in a ligand 
screen.  
 
Figure 4.5 Using site-directed mutagenesis to assign PrOF NMR resonances. 
Asterisks denote the resonance that has disappeared after mutation of the relevant 
(fluorine-labeled) tryptophan into a phenylalanine, which allows assignment of that 
resonance to the specific mutated amino acid residue.
98
 
Resonances can be assigned by recording the spectrum of a fluorinated protein, 
where one residue has been mutated to an amino acid that can no longer be fluorine-
labeled in the expression conditions, because the corresponding fluorinated analog is not 
present in the culture medium (e.g., Trp to Phe).  As an example, three relevant spectra 
are reported in Figure 4.5.  In this case, the bromodomain Brd4 is labeled with three 5FW 
residues, which results in three well-resolved resonances. The disappearance of the 
resonances at –124.9 ppm and –126.2 ppm upon directed mutation of specific tryptophan 
residues leads to the assignment of these resonances to fluorine-labeled W75 and 
fluorine-labeled W81, (Figure 4.5, middle and top spectra).  However, due to the 
sensitivity of fluorine to subtle changes in environment, additional chemical shift changes 
can occur, which, in some cases, preclude assignment.  In this case, addition of a known 
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ligand can help identify side-chain resonances in the ligand-binding site. For example, the 
first bromodomain of BrdT has two tryptophan resonances, and W50 is known to be 
located in the WPF shelf at the histone-binding site.  Addition of the known BrdT ligand 
dinaciclib (IC50 = 61 μM) was used to help assign the resonance due to the fluorine-
labeled W50. The broadening and the 0.25-ppm chemical shift perturbation of the upfield 
resonance is consistent with x-ray crystallography data on the co-crystal structures, which 
show a significant conformational change of W50 upon binding
225
 (Figure 4.6 and Figure 
4.7). This assignment was also confirmed by site-directed mutagenesis.
166
 Chemical shift 
perturbation upon addition of a known ligand can also serve as a useful confirmation of 
the functional integrity of a fluorine-labeled protein.
41, 98
 Alternative strategies for 
assignments are described in the troubleshooting section. Fragment screening can be 
carried out once a well-folded highly labeled protein has been obtained, although the 
protein NMR spectrum does not necessarily need to be assigned first.  
 
Figure 4.6 Results from experiments involving small-molecule ligands for BrdT.  
(a) Crystal structure of BrdT (PDB 4FLP) showing the two tryptophans. Please note that 
W50 is located in the protein's WPF shelf. (b) PrOF NMR spectra of 5FW-BrdT by itself 
(bottom spectrum) and in the presence of two different small molecules, fragment A, 
middle spectrum (see also the structure of the compound above the spectrum, to the right-
hand side), and dinaciclib, top spectrum (see also the structure of the compound above 
the spectrum, to the right-hand side). (c) Binding isotherms for fragment A generated by 
plotting the change in chemical shift for both 5FW resonances as a function of ligand 
concentration, which yield comparable Kd values.  
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Figure 4.7 Titration of Dinaciclib with BrdT. 
(a) Left: Ribbon diagram of BrdT (PDB Code: 4FLP) with tryptophan side chains 
indicated as sticks shown in red. Right: Stacked PrOF NMR spectra with increasing 
concentration of dinaciclib. (b) Absolute value of chemical shift perturbations for all 
5FW BrdT tyrosine resonances at 400 μM Dinaciclib. (c) Binding isotherm of both W44 
and W50 perturbations for the titration with Dinaciclib.  
 
4.2.3 Dissociation constant and ligand efficiency determination.  
The affinity of fragment hits from the screen can be readily assessed for protein 
ligands with up to millimolar dissociation constants via ligand titration and subsequent 
non-linear regression of the binding isotherm produced by monitoring changes in 
chemical shift. This chemical shift perturbation experiment is valid when the molecules 
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are in fast exchange, as indicated by the presence of a single resonance signal, whose 
chemical shift is the weighted average of the bound and unbound states. The speed of the 
experiment, the low concentration of proteins needed for it, and the possible automation 
of the procedure enable the rapid testing of multiple small molecules.  
In the present approach, separate samples are set up with varying concentrations 
of the small molecule. The dissociation constant (Kd) is obtained by fitting the obtained 
data to a non-linear regression curve using equation 1, accounting for receptor 
depletion.
221
 Analysis of the affinity of the small molecule and location of perturbed 
resonances can then be used to assess valuable structure–activity relationships between 
molecules and differential binding to alternate surfaces on a protein. 
 
                𝑆 = 𝐷 ∗ 
(𝐾𝑑+𝐿+𝑃)−√(𝐾𝑑+𝐿+𝑃)2−4𝑃𝐿
2𝑃
                                            (1)  
In equation 1, S is the observed change in chemical shift, D is the maximum change in 
chemical shift, Kd is the dissociation constant of the ligand, L is ligand concentration, and 
P is protein concentration. The maximal shift, D, can be obtained through non-linear 
regression, or experimentally, when further addition of a small molecule no longer 
perturbs the resonance. Additionally, as a means of prioritizing ligands for future 
development, these affinity data can be used to calculate the ligand efficiency (LE) using 
eq. 2, which enables this efficiency to be calculated on the basis of the binding affinity of 
the ligand and the contribution of each non-hydrogen atom to the free energy of the 
interaction.  
                                      𝐿𝐸 =  
−𝑅𝑇 ln(𝐾𝑑)
# 𝑁𝑜𝑛−ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛 𝑎𝑡𝑜𝑚𝑠
                                                         (2) 
Although this scenario is not as commonly encountered in fragment screens, 
ligands with high affinity may have a sufficiently long residence time on the protein that 
the bound and unbound states are partially resolved (intermediate exchange) or fully 
resolved (slow exchange) in the 
19
F NMR experiment. In these instances, titration will 
not result in a binding isotherm. Intermediated exchange kinetics result when 
interchanging species at equal populations (e.g., bound and unbound states) lead to 
coalescence into a single resonance.
226-227
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                                               𝜏𝑐𝑜𝑎𝑙𝑒𝑠𝑐𝑒𝑛𝑠𝑒 = (√2𝜋∆𝜐)
−1 = 𝑘−1                                                  (3) 
In equation 3, the frequency difference in Hertz between the two resonances (Δν) — 
bound versus unbound state — establishes a relationship that enables researchers to 
estimate the residence time of the ligand on the protein based on the rate of dissociation 
(k-1). In the case in which the rate of exchange approaches the coalescence point (τ ≈ Δν), 
during a protein–ligand titration, the resonances will coalesce, so that the signal will 
initially broaden, but it will become sharp again, in a dose-dependent manner, as the 
chemical shift is perturbed by the titration process. With slow exchange kinetics (likely to 
be associated with a low dissociation constant), both resonances can be well resolved, 
and, during a protein–ligand titration, one resonance will gradually disappear while 
another will grow from the baseline in a dose-dependent manner.  
4.2.4 Experimental considerations and assay limitations  
Although the additional rotational freedom in protein-side chains versus the amide 
backbone can lead to smaller linewidths relative to amide resonances. One consideration that 
should be made before using 
19
F-labeled proteins for NMR is the sensitivity of the 
fluorine nucleus to substantial chemical shift anisotropy (CSA) relaxation effects. CSA 
relaxation leads to resonance broadening, which is enhanced by protein dynamics, 
including long rotational correlation times of amino acids found in large proteins.
125
 CSA 
relaxation is proportional to the square of the magnetic field strength. From a practical 
standpoint, we carry out NMR experiments at 471–564 MHz using fluorinated aromatic 
amino acids. 5FW experiences a lower degree of CSA relative to other fluorinated 
tryptophan analogs, and in some cases it has been used with proteins as large as 
65 kDa.
228
 As an alternative to 5FW, fluorine-labeled cysteine or methionine derivatives 
with substantially reduced CSA effects are recommended for proteins larger than 40 kDa, 
as has been demonstrated in experiments with GPCRs and amyloid-β aggregates.78-80, 229 
Site-selective fluorine labeling with trifluoromethylphenylalanine has also been 
employed for large proteins.
230-231
 For small-to-medium-sized proteins, PrOF NMR is 
applicable using a variety of fluorine-labeled amino acids, including singly fluorinated 
(tyrosine, phenylalanine, and tryptophan, Fig. 2) as well as more heavily fluorinated 
amino acids, such as di- and trifluoromethylmethionine
140, 232
 and tri- and 
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hexafluoroleucine
233-235
.  We propose using singly fluorinated aromatic amino acids, as 
this approach reduces spectral complexity with respect to using amino acids with multiple 
non-equivalent fluorines. Furthermore, it allows high levels of enrichment in labeled 
amino acids at protein–protein interaction interfaces,170 while minimizing the perturbing 
effect of fluorine substitution. Nevertheless, we reiterate that protein structural and 
functional perturbation caused by fluorine substitution should always be assessed 
conducting preliminary complementary structural and functional biophysical 
experiments.  
 
4.3 MATERIALS 
4.3.1 Reagents:  
Unless noted, reagents of comparable quality from alternative suppliers can be 
substituted. 
Protein Expression Components 
 Fragment mixtures. <CRITICAL> These are prepared according to guidelines 
outlined in Box 1. Sources of fragment libraries include Maybridge and 
Chembridge 
 Plasmid encoding your protein of choice that also encodes for the resistance to an 
antibiotic of choice  
Critical: For nickel affinity purification, ensure that the plasmid includes a His tag 
described in step 9 and in the supporting information.  
 Plasmid vectors pRARE (Novagen), pRSETB-HIS6KIX (Invitrogen), pNIC28-
BSA4 (Addgene) 
 Competent DL39(DE3)* (DL39, CGSC) or BL21(DE3) (Novagen) Escherichia 
coli cell lines 
Note: We thank I. Ropson for providing the DL39(DE3) cell line.   
 
Critical: Choice of cell lines must be made carefully. Auxotrophic cell lines (e.g., 
DL39(DE3)) are necessary for labeling with 3-fluorotyrosine or 4-fluorophenylalanine. 
For tryptophan labeling, 5-fluoroindole with non-auxotrophic cell lines (e.g., 
BL21(DE3)) is recommended for higher protein yields.  
 QiAprep Spin Miniprep Kit (250) (Qiagen, Cat. No. 27106) 
 Lennox L. Broth (LB) (RPI, powdered or granulated, L24066)Lennox L  Agar 
(RPI, powdered or granulated, L24030) 
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 Super Optimal Broth with Catabolite Repression (SOC) (SOB with added 
glucose) (RPI, S25000)  
 Antibiotics:  Ampicillin (RPI, A40040), Kanamycin (RPI, K22000), 
Chloramphenicol (RPI, C61000) 
 Natural amino acids (see Table 1) (RPI)  
 Isopropyl β–d-1-thiogalactopyranoside (IPTG)(RPI, I56000)  
 Imidazole (RPI, I52000) 
 Sodium Phosphate Monobasic, monohydrate (RPI, S23120) 
 Sodium Phosphate Dibasic, heptahydrate (Sigma, S9390)  
 Sodium chloride(Fisher, S2713). 
 HEPES (Fisher, BP310) 
 Tris (Acros, 167620010) 
 3-fluoro-DL-tyrosine (Alfa Aesar, L01479) 
 4-fluoro-DL-phenylalanine (Sigma Aldrich, F5251) 
 5-fluoro-indole (Sigma Aldrich, F9108) 
 Ultrapure water 18.2 ΜΩ x cm 
Protein Purification Components 
 Lysozyme (Gold Biotech, L040) 
 β-mercaptoethanol (Sigma Aldrich, M6250) 
 Phenylmethanesulfonylfluoride (PMSF), (RPI, P20270)  
NMR Components 
 Dimethylsulfoxide (Fisher, D128) 
 Ethylene Glycol (Sigma Aldrich, 102466) 
 Trifluoroacetic acid (TFA, Sigma Aldrich, T6508) 
 Deuterium oxide (Cambridge Isotope Labs, DLM-6) 
Prepared Buffer Solutions (Filtered and stored at room temperature) 
 Lysis Buffer: 50 mM Phosphate, 300 mM NaCl, pH = 7.4 
 Wash Buffer: 50 mM Phosphate, 100 mM NaCl, 30 mM Imidazole, pH = 7.2 
 Elution Buffer: 50 mM Phosphate, 100 mM NaCl, 400 mM Imidazole, pH = 7.2 
 NMR Buffer for Brd4: 50 mM Tris, 100 mM NaCl, pH = 7.4 
 NMR Buffer for KIX: 50 mM HEPES, 100 mM NaCl, pH = 7.2 
Protein Characeterization/SDS-PAGE Components:  
 Formic Acid (Sigma, 56302) 
 Acetonitrile (J.T. Baker, 9853) 
 40% Acrylamide/Bis solution (Bio-Rad, 1610148)  
 Ammonium persulfate (Sigma Aldrich, 248614)  
 Bis-Tris (RPI, B75000) 
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 Tetramethylethylenediamine, (TEMED) (RPI, T18000) 
 Coomassie Brilliant Blue R-250 (Bio-Rad, 161-0400) 
Equipment 
 Refrigerated Incubator Shaker  
 UV/Vis spectrophotometer  (e.g., Varian Cary 50 Bio UV/Vis spectrophotometer) 
 High speed centrifuge  
 Sonicator (Fisher FB505) with 1/8” microtip (FB 4418) 
 FPLC (GE Äktapurifier) 
 HiPrep 26/10 Desalting Column (GE Healthcare 17-5087-01) 
 50 mL Superloop (GE Healthcare 18-1113-82) 
 Ni-NTA Agarose Beads (Life Technologies R901-01) 
 NMR spectrometer (Recommended 19F S/N ≥ 550:1) 
Critical: NMR probe must be able to tune to the 
19
F nucleus (e.g. Bruker BBO probe), 
For optimal PrOF NMR experiments, a cryoprobe (e.g. Bruker TCI-Prodigy) should be 
used for increased S/N.)  
 19F tuned NMR probe, e.g. (TCI-Prodigy cryoprobe, Bruker)   
 Electrospray Ionization Mass Spectrometer 
Critical: Mass spectrometer must be capable of resolving proteins to 2-3 amu for 
accurate protein characterization as fluorinated proteins will differ by 18 amu per 
incorporated fluorine. 
 SDS PAGE gel apparatus and power supply (for use in protein characterization 
 NMR tubes 
 Microcentrifuge tube 
 15-ml Falcon Tubes 
 50-ml Falcon Tubes 
 Protein concentrators (Millipore Centricon UFC900324, UFC800324) 
Software 
 NMR processing software (e.g. TopSpin, MNova, etc…) 
 Non-linear regression software (e.g. OriginPro, GraphPad, etc…) 
4.3.2 Reagent Setup 
LB Media/Agar: Autoclave media prior to using.  
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Defined Media 
To simplify the preparation if it is going to be done multiple times, a sterile-filtered stock 
solution consisting of the reagents listed in Step 3 (CaCl2 through biotin) may be 
prepared and stored at 4°C for several months; an appropriate volume of stock solution 
would then be added to the defined media instead of adding the components individually. 
1. Combine the amino acids, salts, and nucleotide bases listed below (Table 4.1) in 
a total volume of 1 L of deionized water, omitting the amino acid that will be 
labeled, and autoclave the solution. Natural amino acids were all purchased from 
RPI. 
Pause Point: If the defined media is not going to be used right away, do not 
continue media preparation beyond this step. Media with just the amino acids and 
salts with no carbon source (glucose) or vitamins can be stored covered at room 
temperature for several months.  
Table 4.1 Amino Acids, Nucleotide Bases, and Salts 
Component Supplier (Cat. #) Amount for 1L expression  
Alanine  RPI (A20060) 500 mg 
Arginine  (A50010) 400 mg 
Asparagine  (A50030) 400 mg 
Aspartic Acid  (A50060) 400 mg 
Cystine HCl  (C81020) 50 mg 
Glutamine  (G36040) 400 mg 
Glutamic Acid  (G36020) 650 mg 
Glycine  (G36050) 550 mg 
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Histidine  (H75040) 100 mg 
Isoleucine  (I54020) 230 mg 
Leucine  (L22000) 230 mg 
Lysine HCl  (L37040) 420 mg 
Methionine  (M22060) 250 mg 
Phenylalanine  (P20260) 130 mg 
Proline  (P50200) 100 mg 
Serine  (S22020) 2.1 g 
Threonine  (T21060) 230 mg 
Tyrosine  (T68500) 170 mg 
Valine (V42020) 230 mg 
Sodium acetate  Macron (7372) 1.5 g 
Succinic acid  Sigma Aldrich (S3674) 1.5 g 
Ammonium chloride  Fisher (A661) 500 mg 
Sodium hydroxide  Alfa Aesar (A16037) 850 mg 
Potassium phosphate (dibasic)  RPI (P41300) 10.5 g 
Adenine RPI (A11500) 500 mg 
Guanosine Alfa Aesar (A11328) 650 mg 
Thymine TCI (T0234) 200 mg 
Uracil RPI (U32000) 500 mg 
Cytosine Alfa Aesar (A14731) 200 mg 
40% (wt/vol) glucose solution RPI (G32030)  50 ml 
0.01M FeCl3 Sigma Aldrich (157740) 1 ml 
1M MgSO4 Sigma Aldrich (M7506) 4 ml 
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2. Once the solution is sterilized, add the components sequentially, adding MgSO4 
last.   
Table 4.2 Vitamin Solution 
Vitamin Solution   
Component  Amount for 1-l expression 
Tryptophan  RPI (T60080) 50 mg 
CaCl2 dihydrate  Sigma Aldrich (C3306) 2 mg 
ZnSO4 heptahydrate Sigma Aldrich (Z4750) 2 mg 
MnSO4 monohydrate Sigma Aldrich (M7634) 2 mg 
Thiamine RPI (T21020) 50 mg 
Niacin Sigma Aldrich (72340) 50 mg 
Biotin RPI (B40040) 1 mg 
 
3. Adjust the pH to 7.2 using HCl or NaOH. Media can be stored at room 
temperature for a few weeks, though it is recommended that the glucose and 
vitamin solutions not be added until immediately prior to use (Table 4.2). 
4. Add the necessary fluorinated amino acid(s) or amino acid precursor for 
appropriate fluorine labeling (Table 4.3). 
Table 4.3 Fluorinated amino acids or precursor for defined media 
Fluorine Label Fluorinated Substitution  
Amount for 1-L 
expression 
Final concentration in 
media 
3FY 3-fluoro-DL-tyrosine 80 mg 400 μM 
4FF 4-fluoro-DL-phenylalanine
 a 
29 mg 160 μM 
5FW 5-fluoroindole 60 mg 444 μM 
a
Addition of 5 μM of phenylalanine to the defined media when using 4-fluoro-DL-phenylalanine 
has led to increased protein yield but minimal effects on fluorinated amino acid incorporation. 
4.3.3 Equipment Setup 
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Sonicator Program. Sonication time = 4 minutes at 30% amplitude (this entails eight x 
30 second pulses with 60 second rest times between pulses.) Total elapsed time: 12 
minutes 
Ni Affinity Gradient Elution Method. Set up the FPLC method that will be used in Step 
9. In our laboratory we use a GE Äktapurifier with a column packed with Ni-NTA 
Agarose for affinity purification . The four steps are as follows: Wash the nickel column 
with 15 column volumes of wash buffer. Perform a gradient elution across 20 column 
volumes ramping from 0 to 100% elution buffer. Wash with 5 column volumes of 100% 
elution buffer. Return to 0% elution buffer by applying the reverse gradient in 5 column 
volumes. UV absorbance is monitored at 280 nm. Total time (at 1 mL/min flow rate): 4 
hours 
Buffer Exchange Method. Set up the FPLC method that will be used in step 10. In our 
laboratory, we use a GE Äktapurifier with a GE HiPrep 26/10 Desalting column (17-
5087-01). Equilibrate the column with 0.5-1 column volume of buffer prior to loading the 
sample. Elute the column with 1 column volume of buffer and monitor the UV 
absorbance at 280 nm. Total time (at 2 mL/min flow rate): 40 minutes.  
4.4 PROCEDURE 
4.4.1 Bacterial Transformation (Timing: 1 day) 
1. Prepare bacterial colonies transformed with the plasmid for the protein of interest . 
using standard transformation and inoculation methods. A detailed sample protocol is 
provided in Supplementary Method.  
Critical As noted in the materials section, choice of cell lines must be made carefully. 
Auxotrophic cell lines (e.g., DL39(DE3)) are necessary for labeling with 3-fluorotyrosine 
or 4-fluorophenylalanine. For tryptophan labeling, 5-fluoroindole with non-auxotrophic 
cell lines (e.g., BL21(DE3)) is recommended for higher protein yields. 
Pause Point Culture plates with transformed bacteria may be stored at 4 °C for up to a 
month.  
  148 
4.4.2 Fluorinated protein expression Timing: 2 days 
Critical: Maintain sterile conditions while working with media. Standard protein 
expression methods can be used; these steps are those that are used routinely in our 
laboratory and provide information about when in the process, the fluorinated amino 
acids should be added. 
2. Inoculate primary and secondary cultures using standard E. coli  expression methods. 
Detailed steps of a sample protocol are provided in the supporting information.  
3. Using a spectrophotometer, determine the optical dispersion at 600 nm (OD600). 
Remove the culture from the shaker when the OD600 is between 0.6 and 0.8. Please note 
that this value may vary based on the cuvette distance to the detector in the 
spectrophotometer. 
4. Centrifuge the culture for 20 min at 6000 g at 4 °C.  
5. Decant the LB media and resuspend the pellet in an equivalent amount of the defined 
media containing the desired fluorinated amino acid or amino acid precursor [see Reagent 
setup] and appropriate antibiotic.  
6. Shake the solution prepared in the previous step at 37 °C and 250 RPM for  90 min as 
a recovery time for the bacteria then decrease the temperature to 20 °C to cool down the 
media. Continue to shake for an additional 30 min to allow the solution to equilibrate. 
Please note that the most suitable temperature and recovery time will vary for each 
protein. Our lab has generally found the above conditions to work well, though there are 
cases when a shorter recovery time has produced better results.  
7. Induce protein expression by adding IPTG to the solution to a final 1-mM 
concentration. Continue to shake at 20 °C and 250 RPM for 16–20 h. Please note that the 
most suitable IPTG concentration and induction time will vary for each protein.  
8. Centrifuge the cell culture at 6000 g at 4 °C for 20 min. For ease of purification, we 
recommend centrifuging cultures in 500-ml aliquots or smaller. Decant the supernatant 
medium and store the cell pellet at –20 °C or –80 °C.  
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Pause Point The cell pellet may be stored at –20 °C or –80 °C for months. 
9. Purify and characterize overexpressed protein. Sample purification methods are 
described in the supporting information and mass spectrometry characterization is 
described in Box 1. SDS PAGE characterization can be performed at this step to evaluate 
the presence of the desired protein. However, due to the low resolution nature of SDS 
PAGE characterization, it will not be able to quantify fluorine incorporation or 
distinguish between fluorinated variants. (Figure 4.3) 
10. Buffer exchange the protein into the desired buffer. In our lab we use a HiPrep 
desalting column, but other methods work as well (Nap-5 columns, PD-10 columns, and 
dialysis are all viable options). For PrOF NMR, it is best to avoid buffers with high 
concentrations of high mobility salts due to their impact on NMR signal sensitivity. 
When possible, the lower mobility salts (e.g. Tris, HEPES, etc…) are preferred.  
Pause Point: The purified protein can be stored at 4 °C or flash-frozen and stored at –
20 °C for several months. For long-term storage, we recommend flash-freezing and 
storing at –20 °C. Exact storage conditions may vary from one protein to another. 
Box 1 – Fluorine Incorporation Characterization Timing 0.5-1 h 
1. Concentrate protein to at least a low μM concentration. In our lab we utilize centrifugal 
protein concentrators with either a 3k or 5k MW cutoff. The exact membrane cutoff 
needed will depend on the size of the protein of interest 
2. On an ESI mass spectrometer equipped with a liquid chromatography system, use 
0.1% formic acid in water (v/v) and acetonitrile as solvents and a C18 column for 
separation. Run a gradient elution ramping from 8% acetonitrile to 80% acetonitrile.  
3. Select the protein peak on the chromatogram and deconvolute the corresponding mass 
spectrum.  
4. Integrate the peaks corresponding to the protein of interest and its fluorinated variants.  
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5. Use the following formula to calculate the percent of fluorine incorporation.  
% 𝐼𝑛𝑐𝑜𝑟𝑝𝑜𝑟𝑎𝑡𝑖𝑜𝑛
=  
(0 𝐹 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 0) + (1𝐹 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 1) + ⋯ (𝑛𝐹 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 𝑛)
(0𝐹 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 𝑛) + (1𝐹 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 𝑛) + ⋯ (𝑛𝐹 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 𝑛)
∗ 100 
Where n corresponds to the number of incorporated fluorinated residues.  
 
 
 
4.4.3 Protein-Observed Fluorine (PrOF) NMR Timing 5 min–1 h 
11. Concentrate the protein solution to 40–50 μM as done in Box 1  
12. To a microcentrifuge tube, add 2 μl of 0.1% (v/v) TFA, 25 μl of D2O, and 473 μl of 
protein solution just prepared. Mix well and transfer solution to a 5-mm NMR tube.  
13. Acquire two fluorine NMR spectra. Focus the first experiment on the TFA reference 
peak, which can be obtained within several scans, and focus the second experiment on the 
protein. We find that a spectral width (sw) of 10–20 ppm is sufficient with an offset 
(O1P/tof) of –76.5 ppm for the TFA, –136 ppm for 3FY-labeled proteins, –125 ppm for 
5FW-labeled proteins, or –117 ppm for 4FF-labeled proteins. Experiment time and 
number of scans required will be dependent on availability of a cryoprobe versus a room-
temperature probe as well as protein On a 500 MHz NMR with a Prodigy inverse 
cryoprobe (
19
F S:N 2100:1) 400 scans are sufficient for proteins KIX and bromodomain 
Brd4, which would lead to a 4–5-min experiment. 
14. Process the data setting the TFA reference peak to –76.5 ppm and applying the same 
correction factor to the second experiment. Resonance assignments can be performed as 
described in section Box 2  
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Box 2: (Optional) Assigning PrOF Resonances Timing ~3 weeks 
 
Note: PrOF NMR screening and binding experiments can still be performed without 
resonances assigned. The assignments can provide additional structural information but 
are not necessary to evaluate small molecule binding. 
 
1. Perform site-directed mutagenesis to mutate each amino acid of interest to an 
alternate amino acid chosen such that it will have very little effect on the protein 
structure (e.g., Y->F) 
2. Obtain PrOF NMR spectra of each mutant (see Steps 11-14 of the Procedure). The 
resonance that has disappeared corresponds to the mutated amino acid residue.  
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Box 3: Fragment Mixture Preparation Timing Variable  
1. Obtain or prepare concentrated ligand stock solutions (200 mM) in a given solvent 
(e.g., DMSO or ethylene glycol) for the fragments of interest. Please note that solvent 
choice will depend on ligand solubility and solvent effects on the protein of interest. 
Critical Step The maximum volume of solvent that will be tolerated without 
significantly perturbing the chemical shifts or the shapes of the 19F NMR resonances must 
be determined in order to accurately assess ligand binding. We recommend that the final 
solution is composed of 1–5% organic solvent.  
2. Determine the desired number of fragments for each screening mixture. Commonly 
screening mixtures include 5–10 fragment compounds.  Fragment mixtures of five of six 
compounds will reduce the number of compounds needed in the deconvolution step, if a 
high hit rate is anticipated. 
3. Decide the concentration at which each fragment will be screened. Fragment mixture 
concentrations will depend on the expected Kd’s for ligands in the mixture. Due to the 
low affinity nature of fragment compounds, mid-μM to low-mM Kds for individual 
fragments are common. For example, using six fragments per mixture starting from 
200 mM DMSO stock solutions yields mixtures containing ligands at 33.3 mM and a 
final ligand concentration of 833 μM at 2.5% (v/v) DMSO in the NMR sample. 
Screening ligands at lower concentrations will yield smaller changes in chemical shift, 
potentially resulting in more false negatives. If the ligandability and/or druggability of the 
protein is unknown, a pilot screen with ligands at various concentrations can be 
performed.  
4. Compile the fragment mixtures, taking into account the number of acidic, basic, and 
neutral compounds present to avoid significant pH dependent effects.  
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4.4.4 Fragment screening via PrOF NMR Timing Variable 
 
15. Prepare a blank sample (See step 10) with the addition of the selected amount of the 
organic solvent for the fragment mixtures (no ligand or ligand mixtures), maintaining a 
total sample volume of 500 μL. (e.g. 2  μL 0.1% (v/v) TFA, 25 μL D2O, 468 μL protein 
solution, and 5 μL DMSO) 
Critical Step This blank sample must be identical to the screening samples in regards to 
the protein concentration and amount of solvents used. The only difference should be that 
the blank contains organic solvent (with no ligands) while the screening samples will 
contain the same amount of organic solvent (with the ligand mixtures).   
16. Prepare the fragment mixture NMR samples in a similar manner to Step 15 with the 
ligand mixture in place of just the organic solvent.  
17. Acquire and process PrOF NMR spectra for each mixture (see Steps 13 and 14) 
18. Record the chemical shift of each fluorine resonance and calculate the change in 
chemical shift for each resonance relative to the ‘blank’ spectrum.  
19. Using the results obtained in the library screen, identify promising mixtures by 
statistically analyzing the changes in chemical shifts for each resonance from each 
mixture, and select the mixtures that yield a change in chemical shift between one and 
two standard deviations above the average change in chemical shifts from all experiments 
obtained from the library screen. 
4.4.5 Deconvolution of fragment mixtures Timing Variable 
 
20. Identify the compounds comprising the mixtures that yielded significant changes in 
chemical shift.  
21. Prepare NMR samples with each of these compounds separately maintaining 
equivalent ligand concentrations.  
22. Collect the PrOF NMR spectra for each new sample (see Step 13) 
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23. Process and analyze the data as before calculating the changes in chemical shift to 
identify the ligand or ligands that bind to the protein target. (see Steps 14 and 19)  
4.4.6 Kd determination of fragment compounds Timing Variable 
24. Select a range of ligand concentrations for the binding isotherm being sure to include 
points below and above the anticipated Kd.  
25. Prepare NMR samples with varying concentrations of ligands, making sure to add 
solvent until the final volume of ligand solution is equal to the total amount of solvent 
that was added to the blank prepared in step 15. (1 μL ligand/4 μL DMSO, 2 μL ligand/3 
μL DMSO, etc…) 
26. Mix the solutions well and transfer them to NMR tubes.  
27. Collect PrOF NMR spectra for each sample and analyze data (see Steps 13, 14 and 
18). 
28. Plot the change in chemical shift (Δδ) as a function of ligand concentration.  
29. Fit the data using non-linear regression software (e.g. Originpro or Graph Pad Prism) 
the following equation to solve for Kd using equation 1 reported above.  
              𝑆 = 𝐷 ∗ 
(𝐾𝑑+𝐿+𝑃)−√(𝐾𝑑+𝐿+𝑃)2−4𝑃𝐿
2𝑃
                                              (1) 
4.4.7 Timing  
Steps 1, Bacterial Transformation: 1 d 
Steps 2-10, Fluorinated Protein Expression and Purification: 2 d (plus characterization 
time; see Box 1) 
Steps 11-14, Protein Observed Fluorine (PrOF) NMR: 5 min-1 h (plus resonance 
assignments; see Box 2) 
Steps 15-19, Fragment Screening via PrOF NMR: Variable (plus fragment mixture 
preparation time; see Box 3) 
Steps 20-23, Deconvolution of Fragment Mixtures: Variable  
Steps 24-27, Kd determination of Fragment Compounds: Variable 
Box 1, Fluorine Incorporation Characterization: 0.5-1 h 
Box 2, Assigning PrOF Resonances: ~3 weeks  
Box 3, Fragment Mixture Preparation: Variable  
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4.5 ANTICIPATED RESULTS 
During fragment screening, resonance assignments facilitate the characterization of 
the binding site of small molecules and of the environmental changes experienced by the 
labeled protein side-chain.  Fragment mixture hits can result in a large change in 
chemical shift (e.g., 0.1–1 ppm) due to the responsiveness of fluorine to changes in its 
chemical environment. The 19F NMR spectra shown in Figure 4.8 show that a peak at 
134.5 ppm observed in the spectrum of the fluorinated protein 3FY-KIX undergoes a 
change in chemical shift of 0.32 ppm in the spectrum of the same protein in the presence 
of a mixture of different potential ligands.  
 
Figure 4.8 Deconvolution of fragment mixture. 
The bottom spectrum corresponds to the fluorinated protein with no ligands added. 
Asterisks denote resonances that have been significantly perturbed. In this particular 
mixture, compound 3 is responsible for the chemical shift perturbation seen in the 
mixture. The top spectrum represents a global reduction in signal due to nonspecific 
effects. 
 
Protein aggregators and denaturants, whose presence is common in many screens, 
can be detected by global analysis of all of the resonances present in the protein. Global 
coalescence, broadening, or a decrease in intensity are all indications of non-specific 
effects induced by the small molecule on the protein, which may lead to false positives in 
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ligand-observed experiments (e.g., top spectrum in Figure 4.8). Active molecules within a 
mixture are then identified by testing the molecules from the fragment mixture hit one at 
a time.  Figure 4.8 shows the example of such a ‘deconvolution’, which helps identifying 
compound 3 as the active compound, i.e., the compound that caused the change in 
chemical environment sensed by the fluorine labels in the protein.  
Table 4.4 Reproducibility of chemical shifts 
Protein/Resonance 
Average 
Chemical Shift 
(ppm) 
Standard 
Deviation 
5FW Brd4 (8 exp) 
W75 -124.813 0.009 
W120 -125.464 0.012 
W81 -126.358 0.026 
3FY KIX (23 exp) 
Y649 -134.668 0.037 
Y650 -138.283 0.024 
Y658 -138.676 0.025 
Y640 -138.894 0.016 
Y631 -139.490 0.011 
 
Chemical shifts are easily measured and highly reproducible.  In Table 4.4 are 
reported data from two screens with 3FY-KIX and 5FW-Brd4, showing high 
reproducibility and low variability of chemical shifts for the protein resonances. In 
particular, 3FY-KIX, across 23 replicate experiments had a standard deviation in 
chemical shift over five resonances from 0.011 to 0.037 ppm. The latter measurement 
was from the broadest resonance, the one assigned to fluorine-labeled Y649. Although 
only one resonance is observed for fluorine-labeled Y649, the potential for rotamers of 
the ortho-substituted phenol, from restricted motion in this environment leads to a 
broadened resonance. In the case of 5FW-labeled Brd4, where the resonances are sharper, 
the standard deviation range for the fluorine resonances was narrower, from 0.009 to 
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0.026 ppm.  Additionally, although aromatic amino acids are commonly found at protein 
binding sites,
170
 labeled amino acids that are far away from the binding site, serve as 
important internal control resonances for non-specific binding and other factors that may 
globally affect the chemical shift. In the 229 compound screen with 5FW-labeled Brd4 
the average change in chemical shift (Δδ) of fluorine-labeled W120, which is located 
outside the ligand binding site, was 0.001 ± 0.014 ppm. However, in the case of W81, 
which is located at the ligand binding site, the average Δδ of W81’s fluorine-labeled 
analog was 0.033 ± 0.026  ppm (Table 4.5).  
Table 4.5 Ligand-induced changes in chemical shift 
Protein/Resonance 
Average 
Chemical Shift 
(ppm) 
Standard 
Deviation 
5FW Brd4 
(229 exp, 100 μM ligand) 
W120 -125.463 0.014 
W81 -126.325 0.069 
3FY KIX 
(111 exp, 833 μM ligand) 
Y640 -138.888 0.011 
Y631 -139.485 0.026 
 
Compound affinity is determined for each fragment-hit molecule. Figure 4.9 
shows three binding isotherms.  The first binding isotherm was used to identify molecule 
9B11, a ligand that binds to the protein KIX in the presumed MLL binding site near 
Y631 (Kd = 1.6 mM, LE = 0.27). The six experiments can be completed in 30 minutes. In 
the following two binding isotherms, the protein Brd4 was separately labeled with 5FW 
and 3FY. Titration with Brd4 ligand, acetaminophen, yielded a similar Kd for both 
proteins (LE =0.44). Titration of two alternately labeled proteins is a useful control to 
assess any perturbing effects of fluorine on ligand–protein binding.  Additionally the 
magnitude of chemical shift change was substantially larger for the protein labeled with 
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3FY than for that labeled with 5FW (0.61 ppm vs. 0.14 ppm). These data are consistent 
with acetaminophen binding farther away from W81 than the affected tyrosine side 
chains. In some cases, more than one resonance in the NMR spectrum is affected by 
ligand binding.  In these instances, binding isotherms can be obtained based on 
perturbation of each resonance, thus providing multiple dissociation constant 
determinations from the same experiment.  An example of two affected resonance 
perturbations for the 5FW-labled bromomdomain, BrdT, in the presence of a new 
fragment is shown in Figure 4.6 and Figure 4.10, yielding comparable dissociation 
constants of 250 μM and 210 μM. The larger magnitude of the change in chemical shift is 
consistent with ligand binding near the presumed WPF resonance W50.  
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Figure 4.9 Binding isotherms from PrOF NMR titrations. 
(a) Stacked spectra for the titration of 3FY KIX with molecule 9B11 (see structure at the top of 
the panel). A dashed line is added for reference. The asterisk denotes a partial degradation 
resonance. (b) Binding isotherm generated by monitoring the change in chemical shift of fluorine-
labeled Y631 as a function of small-molecule concentration. (c) Stacked spectra for the titration 
of 3FY Brd4 with acetaminophen (see structure at the top of the panel). A dashed line is added 
for reference. (d) Binding isotherm generated by monitoring the change in chemical shift of 
fluorine-labeled Y139 as a function of small-molecule concentration. (e) Stacked spectra for the 
titration of 5FW Brd4 with acetaminophen (see structure at the top of the panel). A dashed line is 
added for reference. (f) Binding isotherm generated by monitoring the change in chemical shift of 
fluorine-labeled W81 as a function of small-molecule concentration. 
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Figure 4.10 Titration of A with BrdT. 
(a) Left: Ribbon diagram of BrdT (PDB Code: 4FLP) with tryptophan side chains 
indicated as sticks. Right: Stacked PrOF NMR spectra with increasing concentration 
of A. (b) Absolute value of chemical shift perturbations for all 5FW BrdT tyrosine 
resonances at 2 mM A. (c) Binding isotherm of both W44 and W50 perturbations for the 
titration with A.  
 
Hajduk et al. have demonstrated the efficacy of NMR-based screening methods to 
assess the druggability of a protein target.
175
 Proteins with screening hit rates that are 
lower than 0.1% using fragment libraries are characterized to have low druggability. 
Upon completion of the fragment screen, PrOF NMR can also provide druggability 
information based on the screening hit rate, both for different proteins or different 
binding sites within a single protein. As an example, of the 508 compounds screened 
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against KIX, the MLL site was preferential for ligand binding (0.8% hit rate) over the 
CREB site (0% hit rate),
193
 consistent with previously reported work.
186
  
 While we have demonstrated the high speed of PrOF NMR experiments for 
screening,
193
  it is dependent on the available equipment. Without a cryoprobe, the same 
experiment will take 16-20 times longer, even on a magnet of the same field strength. To 
mitigate this time challenge in the absence of higher end equipment, as may be the case at 
a primarily undergraduate institution (PUI), we sought to develop solution additives that 
could shorten experiment time.  
 As discussed in Chapter 1, paramagnetic metals have been well established in the 
literature as relaxation agents in the magnetic resonance field.
123
 We sought to take 
advantage of this property of paramagnetic metals with the goal of being able to apply it 
to PrOF NMR.
107
 In the presence of paramagnetic metals, the relaxation times of the 
fluorine nuclei on the side chains of proteins would be shorten, thereby allowing us to 
shorten the overall recycle delay for the NMR experiment, leading to an ultimately 
shorter experiment (Figure 4.11).  
 
Figure 4.11 Overall schematic for PRE additives for PrOF NMR.  
A) Brd4 with sites of fluorine-labelled tryptophans shown as sticks. B) Standard 1D 
19
F 
NMR pulse sequence with a 90° pulse. C) Structures of EDTA and DTPA chelates used 
in these experiments.   
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To find a metal that would shorten T1 while minimally affecting T2, the effects of 
several metals on 
19
F T1 and T2 times were compared. To minimize interactions between 
the metal and protein or small molecule, the metals were chelated, initially with the 
common chelator EDTA. For subsequent work we moved to DTPA, which forms a more 
stable metal chelate (Figure 4.11C).
236-237
 We initially tested nickel, dysprosium, 
holmium, and thulium chelates to determine their effect on the relaxation properties of 
small molecule 4-fluorophenylalanine (4FF).
171, 194
 
In addition to changing the sample's relaxation properties, the three lanthanides 
tested also cause lanthanide-induced shifts in the NMR spectrum, which have been 
utilized in 2D 
1
H–1H and 1H–15N systems to resolve resonance overlap.237 Because of the 
environmental sensitivity of the 
19
F nucleus, most PrOF NMR spectra of folded proteins 
show strong resonance dispersion and would not significantly benefit from lanthanide-
induced shift reagents. Chelated Ni(II) showed the strongest effect on T1 of the metals 
tested (Figure 4.12A), was the most economical, and did not introduce the additional 
complications of a shift reagent. Therefore, it was selected for further study. 
To determine the optimal chelated Ni(II) concentration for protein studies, we 
explored the effect of a range of concentrations of chelated Ni(II) on the relaxation 
properties of 4FF (Figure 4.12A) as well as 5-fluoroindole (Figure 4.12B), the side chain 
present in proteins that have been 
19
F-labelled at their tryptophan residues. The T1 values 
of both of these molecules at Ni(II) concentrations up to 320 mM for 4FF and 200 mM 
for 5-fluoroindole were determined by inversion recovery experiments. T2*  values were 
determined from the peakwidth at half height. Because of the importance of peakwidth 
for resolving spectral resonances, T2* was used rather than T2. For both 4FF and 5- 
fluoroindole, the highest Ni(II) concentration tested led to a more than a 100-fold 
decrease in T1 values (Table 4.6). T2* also decreased with increasing chelated Ni(II) 
concentration, leading to approximately a 5-fold increase in peak width at 200 mM 
chelated Ni(II). Concentrations of 20–50 mM provide an optimal balance between T1 
reduction and T2* reduction and agree well with the 50 mM Ni(II) used by Cai et al. in 
1
H, 
15
N, and 
13
C experiments.
70 
  163 
 
Figure 4.12 Optimization of paramagnetic metal additives.  
A) T1 and T2* measurements on 4-fluorophenylalanine upon the addition of Dy(III), 
Ho(III), Ni(II), and Tm(III) as EDTA chelates. All metals cause decreases in T1 but Ni(II) 
causes the largest and most rapid decreases for increasing Ni(II) concentrations. B) T1 
and T2* measurements on 5-fluoroindole with increasing concentrations of Ni-DTPA 
 
 
Table 4.6 T1 and T2* values for fluorine resonances of small molecules 
Compound 
Ni-DTPA (mM) T1 (ms) T2* (ms) 
5-fluoroindole 0 4890 208 
 20 528 107 
 50 202 80 
4FF 0 1870 77 
 20 216 97 
 40 113 80 
 
We then moved to testing the effects of Ni-DTPA on the model protein Brd4. We 
were able to demonstrate that under optimized conditions (20 mM-Ni-DTPA, 0.24 sec 
recycle delay), we could obtain spectra of comparable quality in 2 minutes compared to 
our standard 5 minute experiment (Figure 4.13). Protein stability and protein-ligand 
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interactions are unaffected by paramagnetic additives, making this addition useful for 
increasing throughput. Additional work is ongoing for applying this technique at a PUI 
where they are more limited on instrumentation and can therefore benefit significantly 
from reduced experimental time.  
 
Figure 4.13 Comparison of 
19
 NMR spectra of 50 μM 5FW Brd4 in the presence and 
absence of paramagnetic additive.  
The addition of 20 mM Ni-DTPA allows a 60% reduction in experiment time while 
preserving the signal-t0-noise ratio of W81, perturbations of which report on ligand 
binding. The signal-to-noise ratio of W80 without Ni-DTPA was 11.8 and with Ni-DTPA 
was 10.9 
 
In conclusion, PrOF NMR offers the medicinal chemist a useful screening 
platform for small molecule fragments in early stage ligand discovery campaigns either 
as a primary or secondary screen informing future ligand optimization efforts.  Since the 
seminal studies by Sykes et al. on alkaline phosphatase,
137
 
19
F probe developments and 
improvements in fluorinated amino acid incorporation have led to ligand identification 
and affinity quantification with small-to-medium-sized proteins in a time-efficient 
fashion.
194
 However, in all cases, fluorine perturbation to protein function should be 
assessed. While current limitations to PrOF NMR exist, including mixture deconvolution 
steps and CSA relaxation effects on fluorine nuclei located on protein side chains with 
limited mobility or in large proteins. These challenges are beginning to be addressed by 
complementary ligand-observed NMR methods as well as new fluorinated amino acid 
labeling strategies.
74
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4.6 TROUBLESHOOTING 
Table 4.7 Troubleshooting Table 
Step Problem Possible Reason Solution 
9 
Low protein yield 
relative to protein 
expression yields 
using natural amino 
acids 
Cell line may not be 
robust for protein 
expression 
 
 
 
 
 
 
Poor compatibility with 
tRNA synthetase 
 
 
 
 
Toxic levels of 
fluorinated amino acids 
 
Change cell lines. Auxotrophic 
cell lines tend to provide lower 
yields than non-auxotrophic cell 
lines 
 
Use glyphosate to induce 
auxotrophy in a standard cell line 
[e.g. BL21(DE3)]
199, 238
 
 
Cotransform with a plasmid to 
increase tRNA synthetase 
levels
233
 
 
Utilize cell-free methods
239
  
 
Reduce the concentration of 
fluorinated amino acids 
Box 1 
Poor label 
incorporation (< 
90%) 
Non-optimized recovery 
time 
 
Not enough fluorinated 
amino acid or amino acid 
precursor 
Experiment with longer recovery 
times following the media swap 
 
Increase the amount of the 
fluorinated amino acid 
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13 
 
Extremely broad 
NMR resonances 
Magnetic field strength is 
too high or side chain 
dynamics are too slow, 
which can cause 
significant broadening of 
resonances due to 
chemical shift anisotropy  
 
Protein is too large 
We find ideal field strengths to be 
500 MHz – 600 MHz. The signal 
sensitivity and resolution benefits 
of higher field strength magnets 
can be cancelled out by CSA and 
shortened T2 relaxation. 
  
 
Use alternate labeling strategies 
that utilize fluorinated amino 
acids with more rapidly rotating 
fluorine groups (e.g., 
trifluoromethyl)
230, 232
  
 
 
Unknown fluorine 
resonances in the 
NMR spectrum 
A fluorinated impurity is 
present 
Fluorinated impurities in your 
sample may be removed by a 
buffer exchange 
 
Alter spectral window. Polymer 
background is most pronounced 
beyond -140  
  167 
14 
Fluorine referencing 
problems 
Fluorine reference is 
sensitive to solution 
conditions or the 
presence of small 
molecule ligands 
Alternative fluorine references 
(e.g. trifluoroethanol) can be used 
 
Alternative NMR pulses (e.g. 
ERETIC) can be utilized.
240-241
  
Box 2, 
Step 2 
Site directed 
mutagenesis failure 
The specific amino acid 
may be necessary for the 
protein to adopt its proper 
secondary structure or 
affects more than one 
resonance 
Site-selective labeling of 4FF and 
3FY can be used to label 
individual residue positions rather 
than globally changing all of a 
given amino acid
100, 242
 
 
Kitevski-LeBlanc et al. describe a 
multidimensional NMR method to 
assign resonances
101
 
 
Paramagnetic metals (e.g., Gd
3+
) 
can be used to broaden surface 
exposed residues 
19 
Protein signal 
overwhelmed by 
additional fluorine 
resonances 
A fluorine-containing 
molecule is present in the 
mixture 
Deconvolute the mixture to 
ascertain if other ligands are 
binding 
 
Test fluorinated molecules 
separately and at lower 
concentrations  
 
Use a different fluorinated amino 
acid labeled protein 
23 
No deconvoluted 
compounds exhibit 
the same change in 
chemical shift as the 
mixture 
Small molecules may 
have additive effects on 
the protein signals 
Select the compound that 
contributes the most towards the 
change 
 
Prioritize other mixtures with 
more distinct effects from the 
compounds 
29 
Data do not fit well 
for Kd determination 
(Poor R
2
 value) 
Saturation point not yet 
reached, making it 
difficult to accurately 
determine a Kd using the 
equation 
 
Nonspecific or multi-site 
binding 
Increase the concentration of the 
ligand to approach saturation 
 
Deprioritize this compound 
 
 
Change non-linear regression 
analysis to include multiple 
binding sites 
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Chapter 5. Development of selective small-molecule inhibitors for the 
bromodomain BrdT for male contraception.  
 
A portion of this chapter was reproduced with permission from “BET Bromodomain 
Inhibitors with One-Step Synthesis Discovered from Virtual Screen,” A.M. Ayoub, 
L.M.L. Hawk, R.J. Herzig, J. Jiang, A.J. Wisniewski, C.T. Gee, P. Zhao, J. Zhu, N. 
Berndt, N.K. Offei-Addo, T.G. Scott, J. Qi, J.E. Bradner, T.R. Ward, E. Schonbrunn, G.I. 
Georg, and W.C.K. Pomerantz. Journal of Medicinal Chemistry, 2017, 60 (12), 4805-
4817.  
Note that this work was highly collaborative with several members of the Georg lab. In 
particular some of this work will also be published in the dissertation of Andrea 
Wisniewski. All fluorescence polarization experiments performed here were done by 
Alex Ayoub from the Pomerantz lab. Alpha-screen competition data was provided by our 
collaborators at the Broad Institute.  
 
Motivation: This project was a collaborative effort between the Pomerantz lab in 
Department of Chemistry and the Georg lab in the Department of Medicinal Chemistry. 
As part of the cross-disciplinary training under the NIH-funded Chemical Biology 
Interface Training Grant, the idea was to gain experience in synthetic medicinal 
chemistry to complement the expertise that had been developed in biophysical assays. 
This chapter will encompass my contribution to three different projects, all related to the 
development of BrdT inhibitors. In the first project, we pursued a ligand deconstruction 
project with the goal of developing a selective BrdT ligand. In the second and third 
projects, we sought to use PrOF NMR as a secondary screen and to help guide the SAR 
and ligand development process.  
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5.1 Introduction 
5.1.1 An overview of epigenetics 
The field of epigenetics has gained a significant amount of traction in recent years 
for its biological relevance in a cancers,
243
 cardiovascular diseases,
244
 inflammation
245
 
and other diseases.
246
 While the field of genetics addresses questions about genomic 
DNA, the field of epigenetics and the “histone code hypothesis” address questions about 
chromatin accessibility and the process by which certain portions of DNA are transcribed 
and others are not. Epigenetics, as noted by Feinberg and others in the field, is “the 
information heritable during cell division other than the DNA sequence itself.”246 Even 
though every cell in the human body contains the same nuclear DNA sequence, other 
factors, such as environmental stimuli and nutrition, can contribute to epigenetic 
modifications leading to different cellular outcomes and gene expression.
245
 
The accessibility or inaccessibility of DNA for transcription, therefore, is an 
important and necessary factor to consider. In the nucleus of a cell, DNA is tightly 
packed and organized in nucleosome subunits around octamers of histone proteins. This 
octamer is formed from four different histone partners: H2A, H2B, H3, and H4. H3 and 
H4 form a tetramer while H2A and H2B form two dimers. Together, they form an 
octamer which serves as a scaffold around which two superhelical turns of DNA can 
wrap. Strands of nucleosomes, then, form chromatin, which exists in two forms, 
euchromatin which is accessible for transcription, and heterochromatin, which is tightly 
packed and inaccessible. The histone code hypothesis posits the idea that the control of 
whether DNA is in a euchromatic or heterochromatic state is dependent on 
posttranslational modifications on the amino acid side chains  or “tails” of histone 
proteins.
247
     
Histones can be post translationally modified to effect various biological 
functions.
248-249
 The proteins that install, recognize, and remove these modifications are 
colloquially referred to as “writers”, “readers” and “erasers.” The “writer” proteins (e.g., 
acetylases, methylases, and phosphorylases) will add a given post-translational 
modification (PTM) to a histone, thereby marking it for a particular biological effect. The 
“reader” proteins (e.g., bromodomains and chromodomains) recognize the PTMs 
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installed by the “writers” to carry out a given biological function. Once the task has been 
completed, the “eraser” proteins (e.g., deacetylases, demethylases, and phosphatases,) 
will remove the PTM. Because these proteins possess such a vital role in biological 
activity, they are often found to be dysregulated in disease states, making them attractive 
therapeutic targets.
246
  
5.1.2 BET Bromodomains as therapeutic targets 
Bromodomains are a class of epigenetic “reader” proteins that recognize 
acetylated lysine residues on histone tails. There are 61 known human bromodomains 
that are broken up into eight different families based on structural similarity.
250
 The 
second class of bromodomains are known as the Bromodomain and Extra-Terminal 
(BET) family. The BET family consists of four different bromodomain-containing 
proteins, Brd2, Brd3, Brd4, and BrdT, with each having a set of tandem N-terminal 
bromodomains, commonly referred to as domain 1 and domain 2 (Figure 5.1).  
 
Figure 5.1 Phylogenetic tree of the human bromodomains.  
The BET family (Class II) is shown at the top. Adapted from Filippakopoulous et al.
251
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BET bromodomains received tremendous attention in 2010 when Bradner and 
coworkers reported on the small-molecule JQ1 as a selective BET bromodomain 
inhibitor.
189
 In their seminal paper, Filippakopoulos et al. reported a 50 nM and 90 nM 
affinity of JQ1 for Brd4 (D1) and (D2) respectively. They were also able to demonstrate 
the ability of JQ1 to modify cancerous cells to differentiate into normal non-cancerous 
cells (Figure 5.2). At the same time, researchers from GlaxoSmithKline also reported a 
selective BET bromodomain inhibitor, I-BET.
252
 Since then, many BET bromodomain 
inhibitors have been discovered and reported ( 
Table 5.1). 
 
Figure 5.2 Differentiation of cancerous cells into normal cells after treatment with 
(+)-JQ1.  
Reprinted by permission from Macmillan Publishers Ltd: Nature, Filippakopoulous et 
al
189
 2010.  
 
Table 5.1 Select examples of BET bromodomain inhibitors 
Compound Citation 
I-BET151 
 
Seal et al.
253
 
I-BET762 
 
Mirguet et al.
168
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PFI-1 
 
Picaud et al
254
 
RVX-208 
 
Picaud et al
255
 
OTX015 
 
Coudé et al.
256
 
A list of the 18 BET bromodomain inhibitors currently in clinical trials has also been 
compiled by von Schaper.
257
 
5.1.3 BrdT as a target for male contraception 
BrdT, or the Bromodomain Testis-Specific, as its name suggests, is localized to 
the testes and is known to be involved in spermatogenesis.
258
 It has been shown that BrdT 
knockout mice are sterile but still viable.
259-260
 Additionally, male mice that were treated 
with the pan-BET inhibitor JQ1 exhibited sterility while being dosed with the compound 
but regained normal biological function once treatment with JQ1 was stopped (Figure 
5.3).
261
 This discovery validated BrdT as a viable target for male contraception.  
 
Figure 5.3 Dose-responsive effect of (+)-JQ1.  
A) Testis mass, B) Sperm Count, and C) Sperm motility. Adapted from Matzuk et al.
261
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5.1.4 Selectivity challenges for bromodomain inhibitors 
Because bromodomains recognize acetylated lysine residues on histone tails, they 
are often very similar in structure.
189
 Conserved regions, like the WPF shelf, are present 
in a large percentage of bromodomains, making it difficult to develop selective inhibitors. 
Selectivity among bromodomains that are in the same class is an even harder challenge. 
Inhibitors like (+)-JQ1 and I-BET762 are referred to as pan-BET inhibitors because they 
selectively target the BET family but are not selective for specific proteins within the 
BET family.
168, 189
 Therefore, developing ligands that are selective not only for a single 
class of bromodomains but also for a specific bromodomain within a given class is still a 
difficult challenge.  
Given the amount of research that has now gone into the BET family, the most well 
studied of the eight bromodomain families, it is difficult to find unique chemical space, 
making alternative screening techniques, ligand deconstruction, and additional fragment 
screening campaigns all important areas of research to explore further. New techniques 
for small-molecule screening can help identify new scaffolds to explore, especially if that 
technique has some way to also identify selective ligands from the outset. Ligand 
deconstruction studies can provide insight into specific binding modes of ligands. By 
deconstructing a compound, it is possible to identify key moieties for binding and 
potentially aid in determining how the ligand can be made selective for one 
bromodomain over another. Additional fragment screening, allows for the discovery and 
exploration of new core scaffolds that may differ from existing core scaffolds (e.g., 
benzodiazepines,
262
 tri-substituted imidazoles,
99
 and pyridones
263
)  
Recently, Urick et al. reported on the first ligand selective for BPTF, a non-BET 
bromodomain through a dual-protein PrOF NMR screen.
99
 By combining both fluorine-
labeled Brd4 and fluorine-labeled BPTF in the same NMR tube, they were able to 
identify ligands from the published kinase set (PKIS I and II) that selectively perturbed 
Brd4 resonances, ligands that selectively perturbed BPTF resonances, and ligands that 
bound to both proteins. This dual-screening approach led to the discovery of an aryl-urea-
containing compound AU1, the first selective BPTF ligand, as well as additional Brd4-
selective ligands with a tri-substituted imidazole core (Figure 5.4). AU1 was also shown 
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to inhibit BPTF transcription in cells. This study serves as just one example of how novel 
screening techniques can help to address this selectivity challenge in bromodomains.  
 
Figure 5.4 Ligands identified from a dual screen of Brd4 and BPTF.  
AU1 is selective for BPTF while SB-284851-BT is selective for Brd4.  
5.2 Fluorine-Labeling of BrdT for PrOF NMR 
As established by Mishra and Urick et al., fluorine-labeling of bromodomains 
allows for the use of protein-observed fluorine NMR spectroscopy (PrOF NMR) which is 
a useful technique for studying ligand binding in bromodomains.
98
 In particular, labeling 
a bromodomain with a 5-fluorotryptophan (5FW) is particularly efficacious due to the 
conserved tryptophan in the WPF shelf adjacent to the acetylated lysine binding pocket 
(Figure 5.5A). This tryptophan is well positioned to report on ligand binding occurring 
within the pocket. BrdT contains two tryptophans (W44 and W50) which have been 
previously fluorine-labeled for PrOF NMR.
98
 W50 is found in the WPF shelf and is the 
more upfield resonance while W44 is found close to but outside of the binding site and is 
the more downfield resonance (Figure 5.5B).
166
 BrdT also has seven tyrosine residues 
that could be fluorine labeled for PrOF NMR. For our studies, we chose to label BrdT 
with 5FW (5FW BrdT) due to ease of expression, high yields, and high purity.  
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Figure 5.5 BrdT for PrOF NMR.  
A) Crystal structure of BrdT with (+)-JQ1. Tryptophans are shown as sticks and 
designated with arrows. W50 is noted to be in the WPF shelf. Tyrosines are also shown 
as sticks and highlighted for reference. (PDB ID: 4FLP) B) Sample PrOF NMR spectrum 
of 5FW BrdT.  
5.3 Ligand Deconstruction of BI-2536 for BrdT 
5.3.1 BI-2536 bromodomain activity 
In the process of discovering new bromodomain inhibitors, it was reported that a 
number of kinase inhibitors inhibited bromodomains. One of these compounds, as 
reported independently by both the Knapp and Schonbrunn labs, was the compound BI-
2536, a PLK1 inhibitor with a pteridinone scaffold at the core (Figure 5.6).
264-265
 . BI-
2536 has a 25 nM IC50 for Brd4 by an Alpha Screen competition assay
264
 and a 37 nM Kd 
by ITC.
265
 It also possesses about a ten-fold preference for Brd4 over BrdT with its IC50 
for BrdT being determined to be 260 nM by Alpha Screen.
264
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Figure 5.6 Crystal structure of Brd4 crystallized with BI-2536.  
A surface representation of the protein is shown with the small molecule represented as 
sticks. Tryptophans are highlighted to show proximity to binding site. (PDB ID: 4OGI) 
 
A structure activity relationship (SAR) study of BI-2536 against Brd4 was 
recently reported by Chen et al.
266
 In their manuscript, they analyzed a wide range of 
substitutions and compared the affinity of their new analogs for Brd4 and PLK1 with the 
affinity of BI-2536. In most cases, there was either a decrease or a modest change in 
affinity. They were able to identify one change (a replacement of the cyclopentyl group at 
the N-8 with a 3-bromobenzyl group) that resulted in a seven-fold improvement in 
affinity. Their other key discovery in the manuscript was their ability to reverse the 
selectivity and generate compounds that had a better affinity for Brd4 than for PLK1. 
This study demonstrated that it is possible to take a drug compound with 
polypharmacological activity and modify it to make it more selective for a desired target 
(Figure 5.7).  
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Figure 5.7 Summary of results from Chen et al. SAR Study with BI-2536. 
5.3.2 Initial deconstruction efforts 
To date, there has not been a ligand deconstruction study performed for BI-2536 
against BrdT. We sought to fill this gap in knowledge through synthesizing a range of 
deconstructed analogs of BI-2536 with the goal of developing a compound that would be 
selective for BrdT over Brd4. Other Georg lab members synthesized the original set of 
deconstructed analogs. In all cases, the 7-ethyl-pteridin-6-one was maintained with R1 at 
the N5 position, R2 at the N8 position, and R3 at the 2 position (Figure 5.8). One series of 
compounds explored different ring substitutions at the R2 with a hydrogen in the R1 and a 
chloro group at R3. Another series explored substitutions at both the R1 and R2 positions 
while maintaining a chloro substitution at R3. A third series then primarily explored the 
R3 substitutions with the R1 remaining as a methyl group and the R2 either substituted as 
a cyclopentyl or a cyclohexyl substitution. These compounds were all analyzed by 
differential scanning fluorimetry (DSF), and those results will be reported in the 
dissertation of Andrea Wisniewski.  
 
Figure 5.8 Core scaffold of BI-2536 deconstructed analogs. 
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My initial contribution to this project was to analyze a subset of these compounds 
that were synthesized by Georg lab members (G1-G10) by PrOF NMR (Table 5.2). With 
the compounds that were tested, one of the interesting trends that was observed was as 
the R1 alkyl substitution grew larger (G2, G3, G4), the affinity decreased, identifying the 
methyl group as the substitution that provided the highest affinity (Figure 5.9, Figure 
5.10, Figure 5.11, Figure 5.12). This observation is consistent if one extrapolates a 
similar binding pose of BI-2536 with BrdT as with Brd4 (Figure 5.6). The R1 substitution 
is positioned into the binding pocket, so as larger substitutions are placed at this position, 
they may experience greater effects from steric hindrance. Three of the compounds that 
were tested demonstrated low solubility and were therefore removed from further 
consideration. Another appeared to be a weakly-binding ligand and was also removed 
from further consideration. However, G6 demonstrated slow-exchange kinetics upon 
binding, making it our lead compound from the initial set of deconstructed analogs 
(Figure 5.13).  
Table 5.2 Summary of BrdT data from initial set of deconstructed analogs 
Compound 
Kd by PrOF 
NMR (μM) 
LE LLE 
IC50 
(FP) 
(μM) 
Ki (FP) 
(μM) 
G1 
 
ND     
G2 
 
12.6 ± 3.1 
29.5 ± 4.4 
0.332 
0.307 
2.28 
1.91 
13 1.2 
G3 
 
23.4 ± 7.1 
111.0 ± 63.9 
0.299 
0.255 
1.67 
0.995 
92 17 
G4 
 
37.9 ± 3.0 
90.5 ± 17.0 
0.272 
0.249 
1.14 
0.763 
190 38 
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G5 
 
48.5 ± 8.3  
117.2 ± 44.8 
0.278 
0.253 
1.27 
0.891 
52 9.2 
G6 
 
***   0.4305 < 0.330 
G7 
 
ND     
G8 
 
ND     
G9 
 
ND     
G10 
 
ND     
Kd values were measured using both W44 (top) and W50 (bottom) and 44 μM 5FW BrdT 
ND - indicates compounds that did not bind, were insoluble, or bound very weakly 
*** indicates compounds that bound with slow exchange kinetics 
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Figure 5.9 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of G2.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of G2. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM G2. D) Binding 
isotherm of W44 and W50 perturbations for the titration of G2 
 
Table 5.3 5FW BrdT 
19
F chemical shift perturbations at varying G2 concentrations 
[G2] Chemical shift (ppm) W44 W50 
0 δ -124.4795 -126.0442 
25 Δδ 0.0804 0.2530 
45 Δδ 0.1122 0.5525 
100 Δδ 0.1489 0.7572 
250 Δδ 0.1849 0.9429 
500 Δδ 0.1805 1.0309 
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Figure 5.10 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of G3.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of G3. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM G3. D) Binding 
isotherm of W44 and W50 perturbations for the titration of G3 
 
Table 5.4 5FW BrdT 
19
F chemical shift perturbations at varying G3 concentrations 
[G3] Chemical shift (ppm) W44 W50 
0 δ -124.4795 -126.0442 
25 Δδ 0.0478 0.0240 
45 Δδ 0.0832 0.2441 
100 Δδ 0.1442 0.7457 
250 Δδ 0.1663 1.0147 
500 Δδ 0.1624 1.1158 
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Figure 5.11 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of G4.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of G4. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM G4. D) Binding 
isotherm of W44 and W50 perturbations for the titration of G4 
 
Table 5.5 5FW BrdT 
19
F chemical shift perturbations at varying G4 concentrations 
[G4] Chemical shift (ppm) W44 W50 
0 δ -124.4795 -126.0442 
25 Δδ 0.0207 0.0740 
45 Δδ 0.0331 0.1188 
100 Δδ 0.0517 0.2541 
250 Δδ 0.0697 0.3808 
500 Δδ 0.0727 0.4213 
  183 
 
Figure 5.12 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of G5.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of G5. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM G5. D) Binding 
isotherm of W44 and W50 perturbations for the titration of G5 
 
Table 5.6 5FW BrdT 
19
F chemical shift perturbations at varying G5 concentrations 
[G5] Chemical shift (ppm) W44 W50 
0 δ -124.4795 -126.0442 
25 Δδ 0.0367 0.0940 
45 Δδ 0.0610 0.1774 
100 Δδ 0.0940 0.5399 
250 Δδ 0.1399 0.7290 
500 Δδ 0.1419 0.8705 
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Figure 5.13 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of G6.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of G6.  
 
 
Scheme 5.1 Synthesis of G6 analogs. 
5.3.3 Synthesis of G6 analogs 
To further explore the SAR of G6, I synthesized a new series of analogs (1, 2, and 
3). These three compounds removed the methoxy group on the ring, removed the 
carboxylic acid completely, and methyl ester-protected the acid, respectively. These 
compounds were synthesized through a nucleophilic aromatic substitution (SNAr) 
reaction between the chloropteridinone and the differently-substituted anilines (Scheme 
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5.1). Because the affinity of the parent compound G6 was too tight to be quantified by 
NMR, their activity was evaluated by other assays. First they were evaluated by DSF. As 
detailed in Chapter 1, DSF is a thermal shift assay in which the melting temperature (Tm) 
of a protein is monitored as a function of ligand. Ligands that bind to the protein and 
stabilize its fold will increase the Tm of the protein. A large positive shift in Tm is 
indicative of a highly stabilizing ligand. Data is summarized in Table 5.7.This SAR study 
revealed the importance of the acid functionality on the parent compound G6. In 
removing the methoxy group (1), DSF still showed a 6.45 °C stabilization (compared to 
8.27 °C for BI-2536). Removing the carboxylic acid group completely (2) reduces the 
change in stabilization to 3.15 °C while methyl esterifying the acid (3) lowers it even 
further to 0.85 °C. 
 The activity of these ligands was also analyzed by FP and alpha screen with data 
summarized in Table 5.7. Similar to DSF, FP demonstrated the significance of the 
carboxylic acid functionality and the lower significance of the methoxy substitution on 
the ring. By FP, the parent compound G6 was determined to have a 400 nM IC50. 1 and 3 
were measured to have comparable affinities (1.2 and 1.1 μM respectively. By removing 
the carboxylic acid, 2 exhibited a reduction in affinity by almost an order of magnitude to 
5.006 μM. Similarly, Alpha screen data reports almost comparable IC50 values for G6 
and 1 while reporting a six-fold worse IC50 2 and only a four-fold worse affinity for 3. 
Our studies demonstrated that the parent compound G6 retained the highest affinity with 
the removal of either functionality, but especially the carboxylic acid, having negative 
effects on its affinity for BrdT. Compound G6 also retains the highest ligand efficiency 
(LE) and lipophilic ligand efficiency (LLE), which indicate that further optimization 
should continue from G6 rather than one of the other analogs 
 
 
 
 
.  
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Table 5.7 Summary of data from G6 analogs 
Compound ΔTm 
FP 
LE LLE 
α 
screen 
IC50 
(μM) 
IC50 
(μM) 
Ki (FP) 
(μM) 
G6 
 
8.27 0.43 < 0.33 0.28 1.7 0.55 
1 
 
6.45 1.2 < 0.33 0.28 1.2 0.64 
2 
 
3.15 5.0 0.76 0.26 0.43 3.5 
3 
 
0.85 1.1 < 0.33 0.25 0.98 2.0 
ND - indicates compounds that did not bind, were insoluble, or bound very weakly 
 
5.3.4  N5-alkyl hypothesis for selectivity 
With the goal of developing a selective ligand for BrdT, we developed the 
hypothesis that one way we may be able to generate selectivity for BrdT over Brd4 using 
a BI-2536 scaffold would be to take advantage of the N5-alkyl substitution (R1). We had 
observed modest reductions in affinity of the 2-chloro-pteridinone analogs containing 
larger alkyl substitutions at the R1 position (Table 5.2). However, in comparison to the 
reductions in affinity that were reported by Chen et al. for their BI-2536 analogs against 
Brd4, the reductions that we saw were relatively small.
266
 Consequently, we tested G2, 
G3, and G4 against 5FW-labeled Brd4 to compare the affinities of the three compounds 
for both proteins (Figure 5.14, Figure 5.15, Figure 5.16). We also synthesized a fourth 
compound, 4, which had an N5-isobutyl substitution (Scheme 5.2). Consistent with what 
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we expected based on the previous report, the change from methyl to ethyl to isopropyl 
led to a greater change in magnitude of affinity for Brd4 than it did for BrdT (Table 5.8). 
While the affinity for BrdT was reduced two- and three-fold for G3 and G4, respectively, 
the affinity for Brd4 was reduced by nearly an order of magnitude with each additional 
carbon in G3 and G4. The isobutyl-substituted compound, 4, had no affinity for either 
BrdT or Brd4. It is likely that this alkyl substitution is too large and precludes the 
compound from fitting into the binding pocket.  
 
Scheme 5.2 General alkylation of N5 position on the chloropteridinone scaffold 
 
Table 5.8 Comparison of N5-alkyl analogs for BrdT and Brd4 
Compound 
BrdT Brd4 
Kd LE LLE Kd LE LLE 
G2 
 
12.6 ± 3.1 
29.5 ± 4.4 
0.332 
0.307 
2.28 
1.91 
< 3 ND ND 
G3 
 
23.4 ± 7.1 
111.0 ± 63.9 
0.299 
0.255 
1.67 
0.995 
2.9 ± 0.9 *  0.357 2.57 
G4 
 
37.9 ± 3.0 
90.5 ± 17.0 
0.272 
0.249 
1.14 
0.763 
220 ± 40 
55 ± 28 
0.225 
0.262 
-0.212 
0.387 
4 
 
ND ND ND ND ND ND 
IC50 and Ki values are reported in μM. Kd values from both W44 (top) and W50 (bottom) are noted for 
BrdT. Kd values for Brd4 were measured using W75 and W81 (bottom) when possible. 
* This value is an estimate due to it being over an order of magnitude below the protein concentration.  
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Figure 5.14 
19
F NMR spectral analysis of 5FW Brd4 in the presence of increasing 
concentrations of G2.  
A) Ribbon diagram of Brd4 (PDB ID: 3MXF) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW Brd4 with increasing concentrations of G2.  
 
Table 5.9 5FW Brd4 
19
F chemical shift perturbations at varying G2 concentrations 
 
[G] 
Chemical shift 
(ppm) 
W75 W120 W81 
0 δ -124.7678 -125.4327 -126.3300 
25 Δδ 0.0054 0.0157 0.0207 
45 Δδ 0.0083 0.0107 0.0728 
100 Δδ 0.0015 0.0111 0.0544 
250 Δδ 0.0011 0.0310  
500 Δδ 0.0189 0.0287  
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Figure 5.15 
19
F NMR spectral analysis of 5FW Brd4 in the presence of increasing 
concentrations of G3.  
A) Ribbon diagram of Brd4 (PDB ID: 3MXF) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW Brd4 with increasing concentrations of G3. C) 
Chemical shift perturbations for all 5FW Brd4 resonances at 500 μM G3. D) Binding 
isotherm of W75 perturbations for the titration of G3 
 
Table 5.10 5FW Brd4 
19
F chemical shift perturbations at varying G3 concentrations 
[G] 
Chemical shift 
(ppm) 
W75 W120 W81 
0 δ -124.7678 -125.4327 -126.3300 
25 Δδ 0.0101 0.0174 0.0630 
45 Δδ 0.0155 0.0095 0.0313 
100 Δδ 0.0167 0.0164 0.0449 
250 Δδ 0.0182 0.0124 0.0117 
500 Δδ 0.0456 0.0171 0.0546 
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Figure 5.16 
19
F NMR spectral analysis of 5FW Brd4 in the presence of increasing 
concentrations of G4.  
A) Ribbon diagram of Brd4 (PDB ID: 3MXF) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW Brd4 with increasing concentrations of G4. C) 
Chemical shift perturbations for all 5FW Brd4 resonances at 500 μM G4. D) Binding 
isotherm of W75 and W81 perturbations for the titration of G4 
 
Table 5.11 5FW Brd4 
19
F chemical shift perturbations at varying G4 concentrations 
[G] 
Chemical shift 
(ppm) 
W75 W120 W81 
0 δ -124.7678 -125.4327 -126.3300 
25 Δδ 0.0176 0.0084 0.1113 
45 Δδ 0.0347 0.0057 0.3137 
100 Δδ 0.0563 0.0040 0.5432 
250 Δδ 0.0885 0.0077 0.5373 
500 Δδ 0.1306 0.0092 0.7554 
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 To follow this observation, we synthesized two additional G6 analogs (5 and 6) 
using an SNAr reaction to further test this N5-alkyl hypothesis for selectivity (Scheme 
5.3Table 5.12). Using FP, we compared the affinities of 5 and 6 for both BrdT and Brd4. 
The methyl-(G6) and ethyl-substituted (5) still retained a higher affinity for Brd4 than for 
BrdT (Table 5.12). However, in the change from the ethyl to the isopropyl (6), the 
affinity for Brd4 was reduced by almost an order of magnitude (0.792 μM to 6.624 μM) 
while the affinity for BrdT was reduced by about a factor of three (1.052 μM to 3.332 
μM). These results were encouraging in that it was our first compound with decent 
potency that had actually changed selectivity to modestly favor BrdT over Brd4.  
 
Scheme 5.3 Synthesis of G6 analogs with different N5 alkylations 
 
Table 5.12 Summary of G6 analogs with N5-alkyl substitutions 
Compound 
BrdT Brd4 
FP α FP α 
IC50  Ki IC50 IC50 Ki IC50 
G6 
 
0.40 < 0.33 0.55 0.77 < 0.33 0.19 
5 
 
1.1 < 0.33 0.72 0.79 < 0.33 0.27 
6 
 
3.3 0.51 ND 6.6 1.2 ND 
 IC50 and Ki values are reported in μM  
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 Given these results, we then expanded to the fully elaborated BI-2536 compound 
with the ethyl and isopropyl substitutions (Scheme 5.4). Surprisingly, FP reported a lower 
affinity for BrdT than Brd4 for both the ethyl and isopropyl substitution (Table 5.13). 
These results were unexpected given the change in selectivity that we had seen with the 
G6 analogs. This change in affinity could be due to a range of different factors. It has 
been well documented that in ligand deconstruction studies, smaller fragments or core 
scaffolds of compounds may bind to the protein target in a different manner than the fully 
elaborated compound, thereby leading to unexpected results.
267
 It is also possible that as 
the compound is elaborated, the various additions may be inducing small conformational 
changes in the protein such that the protein is no longer in the same conformation as 
before.  
 
Scheme 5.4 Synthesis of BI-2536 analogs with different N5 alkylations 
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Table 5.13 Summary of BI-2536 N5 analogs 
Compound 
BrdT Brd4 
IC50 Ki IC50 Ki 
BI-2536 
 
0.26*  0.025*  
BI-2536-Et 
 
0.55 < 0.33 0.41 < 0.33 
BI-2536-iPr 
 
9.4 1.7 7.7 1.4 
IC50 and Ki values are reported in μM, *Ember et al.
264 
5.3.5 Future Directions for BI-2536 Ligand Deconstruction  
While these results were not ideal, they did provide some new insight into the 
binding properties of BI-2536 for BrdT that had previously not been reported. Further 
investigation into what may be causing the discrepancy between the G6 analogs and BI-
2536 analogs are still needed. From the fragment side, it could be interesting to examine 
the effects starting from the other end of the compound from the piperidyl ring. It is 
possible that a fragment from this side of the compound may reveal insight into how that 
addition affects the overall binding of the elaborated compound. It would also be useful 
to get crystal structures for all of the 2-chloropteridinone fragments and G6 analogs 
binding to BrdT and Brd4 to determine if they in fact adopt a different binding 
conformation than the fully elaborated BI-2536.   
5.4 Fragment Screening for BrdT 
In addition to ligand deconstruction, we took a fragment screening approach to 
discover and develop BrdT inhibitors. The goal was to discover new chemical scaffolds 
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that could then be expanded through SAR studies. PrOF NMR was used as a secondary 
screen to follow up the initial screening hits and to guide the SAR process as new analogs 
were synthesized and characterized. While many compounds were analyzed in this part 
of the project, not all of them will be presented here. Rather, the focus of this section is 
how PrOF NMR was used to help guide the selection and development process. The 
primary researcher on this screening project was Andrea Wisniewski, and as such, this 
work in full detail will be published in her dissertation.   
5.4.1 DSF for a primary screen 
A full fragment screen was performed in the Georg lab using Differential 
Scanning Fluorimetry (DSF) as the primary screening technique. DSF is a thermal shift 
assay which reports on changes in protein stability as a function of ligand binding. When 
a ligand binds to a protein target, the protein is either stabilized or destabilized, thereby 
increasing or decreasing its melting temperature, Tm. By monitoring the change in Tm by 
an environmentally sensitive fluorescent dye, ligand binding can be observed. DSF is a 
rapid technique and requires little material, making it an effective and commonly used 
screening technique.  
Two Rule of 3 (RO3) fragment libraries were obtained from Maybridge, 
consisting of 2,846 fragment molecules. These compounds were all tested by DSF at a 
single concentration. Of all 2,846 fragments, 49 met the criteria of a  ΔTm greater than or 
equal to 0.5 °C. These 49 compounds were then tested in an 8-point dose response 
experiment. Of these 49 fragments, 24 were confirmed as BrdT hits. The other 25 
fragments were removed from further consideration due to poor dose-response or 
abnormal behavior in the assay.  
  195 
 
Figure 5.17 Subset of hits from DSF screen that were tested via PrOF NMR. 
5.4.2 Validation of hits by PrOF NMR 
One of the initial questions immediately following the DSF screen was whether or 
not stabilizers and destabilizers should both be considered as hits. There is a general 
consensus that stabilizing compounds are better ligands, but that is not always the case. 
To address this question, the top ten stabilizing compounds and the top ten destabilizing 
compounds from the DSF screen were analyzed using PrOF NMR as a validation of 
binding activity (Figure 5.17). The twenty compounds were tested at 2 mM. Of those 
compounds, eight of the ten stabilizers and none of the destabilizers yielded a significant 
change in chemical shift. While it is possible that destabilizing compounds can still be 
useful, these compounds that were analyzed had demonstrated fairly large negative 
changes in Tm, which may be indicative more drastic protein unfolding. In answer to the 
original question, it was decided that compounds with positive ΔTm values would be 
favored over compounds with negative ΔTm values. A negative ΔTm does not preclude a 
compound from binding, but specific binding is just one of multiple reasons a compound 
may generate a negative ΔTm.  
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The eight stabilizing compounds that were confirmed as hits by DSF and PrOF 
NMR were then titrated to determine their Kd, LE, and LLE (Figure 5.18, Figure 5.19, 
Figure 5.20, Figure 5.21, Figure 5.22, Figure 5.23, Figure 5.24, Figure 5.25), which are 
all different metrics for prioritizing compounds to explore further (Table 5.14). Given 
these criteria and the unique indanone scaffold, compound J was selected as the lead 
compound for optimization. Compounds with LE values greater than 0.3 kcal mol
-1
 HA
-1
 
and an LLE value greater than 2 are indicative of good compounds to pursue for further 
studies.  
Table 5.14 Summary of PrOF NMR data from DSF hits 
Compound Kd (μM) LE LLE Compound Kd (μM) LE LLE 
A 
 
83 ± 20 0.40 2.4 E 
 
260 ± 18 0.38 1.8 
B 
 
550 ± 55 0.32 0.60 F 
 
91 ± 14 0.37 2.0 
C 
 
200 ± 38 0.50 2.5 G 
 
31 ± 4.7 0.41 2.4 
D 
 
740 ± 92 0.31 1.8 J 
 
94 ± 7.5 0.39 2.9 
Kd values displayed in this table were calculated using either W44 or W50, depending on which yielded a 
higher R
2
 value. Kd values from each both resonances are shown in the titration figures below.  
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Figure 5.18 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of A. 
 A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of A. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 2000 μM A. D) Binding 
isotherms for the titration of A. 
 
Table 5.15 5FW BrdT 
19
F chemical shift perturbations at varying A concentrations 
[A] Chemical shift (ppm) W44 W50 
0 δ -124.4821 -126.0447 
50 Δδ -0.1062 0.0255 
100 Δδ -0.1280 0.0490 
250 Δδ -0.2218 0.0540 
500 Δδ -0.2713 0.0765 
1000 Δδ -0.2520 0.1952 
2000 Δδ -0.3013 0.1293 
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Figure 5.19 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of B.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of B. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 2000 μM B. D) Binding 
isotherms for the titration of B. 
 
Table 5.16 5FW BrdT 
19
F chemical shift perturbations at varying B concentrations 
[B] Chemical shift (ppm) W44 W50 
0 δ -124.4821 -126.0447 
50 Δδ -0.0049 -0.0837 
100 Δδ -0.0099 -0.1876 
250 Δδ -0.0470 -0.3907 
500 Δδ -0.0719 -0.5597 
1000 Δδ -0.1019 -0.8426 
2000 Δδ -0.1037 -0.9756 
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Figure 5.20 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of C.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of C. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 2000 μM C D) Binding 
isotherms for the titration of C. 
 
Table 5.17 5FW BrdT 
19
F chemical shift perturbations at varying C concentrations 
[C] Chemical shift (ppm) W44 W50 
0 δ -124.4729 -126.0409 
50 Δδ -0.0479 -0.0143 
100 Δδ -0.0505 -0.0240 
250 Δδ -0.1180 -0.0595 
500 Δδ -0.1406 -0.0609 
1000 Δδ -0.1807 -0.0873 
2000 Δδ -0.1886 -0.0716 
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Figure 5.21 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of D.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of D. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 2000 μM D. D) Binding 
isotherms for the titration of D. 
 
Table 5.18 5FW BrdT 
19
F chemical shift perturbations at varying D concentrations 
[D] Chemical shift (ppm) W44 W50 
0 δ -124.4729 -126.0409 
50 Δδ 0.0005 -0.0299 
100 Δδ 0.0045 -0.0492 
250 Δδ -0.0429 -0.1454 
500 Δδ -0.0627 -0.2205 
1000 Δδ -0.0867 -0.2967 
2000 Δδ -0.1273 -0.4017 
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Figure 5.22 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of E.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of E. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 2000 μM E. D) Binding 
isotherms for the titration of E. 
 
Table 5.19 5FW BrdT 
19
F chemical shift perturbations at varying E concentrations 
[E] Chemical shift (ppm) W44 W50 
0 δ -124.4729 -126.0409 
50 Δδ -0.0133 -0.0797 
100 Δδ -0.0112 -0.1388 
250 Δδ -0.0330 -0.2944 
500 Δδ -0.0483 -0.3890 
1000 Δδ -0.0592 -0.4713 
2000 Δδ -0.0785 -0.5278 
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Figure 5.23 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of F.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of F. C) Chemical 
shift perturbations for all 5FW BrdT resonances at 2000 μM F. D) Binding isotherms for 
the titration of F. 
 
Table 5.20 5FW BrdT 
19
F chemical shift perturbations at varying F concentrations 
[F] Chemical shift (ppm) W44 W50 
0 δ -124.4729 -126.0409 
50 Δδ -0.0387 0.0504 
100 Δδ -0.0812 0.0737 
250 Δδ -0.1249 0.0741 
500 Δδ -0.1359 0.1007 
1000 Δδ -0.1585 0.1088 
2000 Δδ -0.1575 0.1209 
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Figure 5.24 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of G.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of G. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 2000 μM G. D) Binding 
isotherms for the titration of G. 
 
Table 5.21 5FW BrdT 
19
F chemical shift perturbations at varying G concentrations 
[G] Chemical shift (ppm) W44 W50 
0 δ -124.4888 -126.0330 
50 Δδ -0.1348 0.1885 
100 Δδ -0.1708 0.2808 
250 Δδ -0.2172 0.4905 
500 Δδ -0.2443 0.5272 
1000 Δδ -0.2591 0.5097 
2000 Δδ -0.2560 0.5282 
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Figure 5.25 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of J. 
 A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of J. C) Chemical 
shift perturbations for all 5FW BrdT resonances at 2000 μM J. D) Binding for the 
titration of J. 
 
Table 5.22 5FW BrdT 
19
F chemical shift perturbations at varying J concentrations 
[J] Chemical shift (ppm) W44 W50 
0 δ -124.4888 -126.0330 
50 Δδ -0.0214 -0.2457 
100 Δδ -0.0272 -0.3440 
250 Δδ -0.0372 -0.5755 
500 Δδ -0.0469 -0.6690 
1000 Δδ -0.0391 -0.7513 
2000 Δδ -0.0352 -0.7808 
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5.4.3 SAR development of lead compound 
The lead compound, J, was derivatized, primarily near the amide, though some 
changes were also made to the indanone five-membered ring as well. Eight of the J 
analogs (J1-J8) are shown below in Table 5.23 and in the titration figures (Figure 5.26, 
Figure 5.27, Figure 5.28, Figure 5.29, Figure 5.30, Figure 5.31, Figure 5.32) Titration 
results showed the indanone in J to be important as a naphthalenone (J1) and an 
isoindolinone (J2) demonstrated poor binding (Table 5.23). The largest improvement in 
affinity came from a replacement of the amide with a sulfonamide as noted with J3 and 
J7 with a Kd values of 4.9 and 3.6 μM, respectively. Closely related compounds that lack 
the sulfonamide (J4, J5, and J8) or contain the unfavorable isoindolinone core (J5 and 
J6) have weaker affinities and lower LE and LLE values. Similar results were obtained 
using both FP and an alpha-screen competition assay where J3 and J7 both have single 
digit micromolar IC50 values.  Additional synthesis to further develop these ligands is 
ongoing.  
Table 5.23 Summary of compound J analogs 
Compound 
DSF PrOF NMR FP α-screen 
ΔTm (°C) Kd (μM) LE LLE IC50 (μM) IC50 (μM) 
J 
 
3.8 95 ± 8 0.39 2.31 240 > 50 
J1 
 
ND 460 ± 50 0.30 1.9 ND ND 
J2 
 
0.4 ND ND ND NB > 50 
J3 
 
4.28 4.9 ± 0.5 0.36 3.76 3.3 6.28 
J4 
 
1.96 50 ± 7 0.31 1.80 190 44 
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J5 
 
1.66 117 ± 28 0.28 2.13 41 > 50 
J6 
 
2.28 24 ± 0.3 0.31 3.66 19 33 
J7 
 
3.36 3.6 ± 0.6 0.33 3.56 8.2 6.1 
J8 
 
ND 52 ± 13 0.29 1.56 86 > 50 
ND denotes measurements that were not determined due to assay conditions, solubility, or lack of activity 
NB denotes samples that exhibited no binding behavior 
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Figure 5.26 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of J1.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of J1. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 1700 μM J1. D) Binding 
isotherm of W50 and W44 perturbations for the titration of J1 
 
Table 5.24 5FW BrdT 
19
F chemical shift perturbations at varying J1 concentrations 
 
[J1] Chemical shift (ppm) W44 W50 
0 δ -124.5218 -126.0854 
42.5 Δδ -0.0181 -0.0166 
85 Δδ -0.0181 -0.0393 
212 Δδ -0.0373 -0.0648 
425 Δδ -0.0526 -0.1001 
850 Δδ -0.0687 -0.1323 
1700 Δδ -0.0794 -0.1716 
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Figure 5.27 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of J3. 
 A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of J3. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM J3. D) Binding 
isotherm of W50 perturbations for the titration of J3 
 
Table 5.25 5FW BrdT 
19
F chemical shift perturbations at varying J3 concentrations 
 
[J3] Chemical shift (ppm) W44 W50 
0 δ -124.5098 -126.0815 
25 Δδ 0.0257  
50 Δδ 0.0398 -0.8625 
100 Δδ 0.0440 -0.9508 
250 Δδ 0.0395 -1.0157 
500 Δδ 0.0477 -1.0137 
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Figure 5.28 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of J4.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of J4. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM J4. D) Binding 
isotherm of W50 perturbations for the titration of J4 
 
Table 5.26 5FW BrdT 
19
F chemical shift perturbations at varying J4 concentrations 
 
[J4] Chemical shift (ppm) W44 W50 
0 δ -124.5098 -126.0815 
25 Δδ -0.0105 -0.2208 
50 Δδ -0.0072 -0.2953 
100 Δδ 0.0017 -0.4900 
250 Δδ -0.0189 -0.6271 
500 Δδ -0.0069 -0.6965 
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Figure 5.29 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of J5.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of J5. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM J5. D) Binding 
isotherm of W50 perturbations for the titration of J5 
 
Table 5.27 5FW BrdT 
19
F chemical shift perturbations at varying J5 concentrations 
 
[J5] Chemical shift (ppm) W44 W50 
0 δ -124.5157 -126.0800 
25 Δδ -0.0055 -0.0787 
50 Δδ -0.0399 -0.1339 
100 Δδ -0.0283 -0.2133 
250 Δδ -0.0462 -0.3894 
500 Δδ -0.0439 -0.4107 
  211 
 
Figure 5.30 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of J6.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of J6. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM J6. D) Binding 
isotherm of W50 perturbations for the titration of J6 
 
Table 5.28 5FW BrdT 
19
F chemical shift perturbations at varying J6 concentrations 
 
[J6] Chemical shift (ppm) W44 W50 
0 δ -124.5034 -126.0800 
25 Δδ -0.0178  
50 Δδ -0.0336  
100 Δδ -0.0326 -0.9400 
250 Δδ -0.0459 -1.1170 
500 Δδ -0.0439 -1.1746 
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Figure 5.31 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of J7.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of J7. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM J7. D) Binding 
isotherm of W50 perturbations for the titration of J7 
 
Table 5.29 5FW BrdT 
19
F chemical shift perturbations at varying J7 concentrations 
 
[J7] Chemical shift (ppm) W44 W50 
0 δ -124.5034 -126.0800 
12 Δδ 0.0000  
25 Δδ 0.0030  
50 Δδ -0.0016 0.9900 
100 Δδ 0.0087 1.0537 
250 Δδ 0.0004 1.1231 
500 Δδ 0.0032 1.1237 
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Figure 5.32 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of J8.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of 5FW BrdT with increasing concentrations of J8. C) 
Chemical shift perturbations for all 5FW BrdT resonances at 500 μM J8. D) Binding 
isotherm of W50 perturbations for the titration of J8 
 
Table 5.30 5FW BrdT 
19
F chemical shift perturbations at varying J8 concentrations 
 
[J8] Chemical shift (ppm) W44 W50 
0 δ -124.5157 -126.0800 
25 Δδ -0.0199 -0.0956 
50 Δδ -0.0138 -0.1361 
100 Δδ -0.0248 -0.2140 
250 Δδ -0.0151 -0.3153 
500 Δδ -0.0081 -0.3017 
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5.4.4 Future Directions 
Additional small molecule synthesis is underway to further explore these J analogs. 
Given the success of the phenyl sulfonamide class of compounds, it could be interesting 
to explore additional extended substitutions on the phenyl ring, where most of the current 
analogs are monosubstituted phenyl groups. It would also be interesting to explore other 
sulfonamide attachments to the indanone. Other heterocycles in place of the phenyl 
substitution could provide additional handles for either hydrogen bonding or reactivity. It 
would also be ideal to obtain crystal structure data for all of these compounds with BrdT 
to have a better understanding of how these compounds are oriented within the protein.  
Another area that would be interesting to further study would be the different 
binding modes of these fragments and their impact on the chemical shifts in PrOF NMR. 
While most fragments only perturbed W50, some perturbed both W50 and W44 and 
caused them to both move downfield. Still other fragments had an effect similar to more 
elaborated compounds in which W44 moves downfield while W50 moves upfield. One 
fragment also perturbed only W44, potentially indicating a binding event that is actually 
taking place outside of the acetylated lysine binding pocket. It would be interesting to 
investigate what kinds of changes in chemical environment lead to an upfield or a 
downfield shift in resonances as well as how these fragments are able to induce these 
different effects. Our collaborators in the Schönbrunn lab may have some insight as they 
have crystallized a small subset of the synthesized ligands with Brd4 and BrdT.  
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5.5 BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual 
Screen 
 
Figure 5.33 
19
F NMR spectral analysis of 5FW BrdT in the presence of increasing 
concentrations of G4.  
A) Ribbon diagram of BrdT (PDB ID: 4FLP) with tryptophan side chains indicated as 
sticks. B) Stacked spectra of BrdT with increasing concentrations of V1. 
 
To further support ligand discovery efforts, I confirmed binding of compound V1 
to BrdT via PrOF NMR (Figure 5.33). This ligand, initially discovered through the use of 
a virtual screen was first analyzed by FP and was reported to have an IC50 of 5.2 μM and 
a Ki of 0.69 μM for BrdT.
166
 It was further characterized by DSF which reported a 4.8 °C 
increase in Tm for BrdT. Additionally an alpha-screen assay for V1 against Brd4 reported 
an IC50 of 0.90 μM. PrOF NMR corroborated the results from the fluorescence 
polarization assay with V1 exhibiting behavior consistent with slow to intermediate 
exchange (Figure 5.33B). Chemical exchange phenomenon in the slow to intermediate 
exchange regime, which is based on the residence time of the ligand bound to the protein 
and the relative frequency difference between the resonances for the bound and unbound 
states is consisted with a low micromolar to submicromolar binding ligand.
195, 207
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5.6 Conclusions 
The search for a selective BrdT ligand is still ongoing. Our recent efforts have 
made some progress, but more work will need to be done. Currently compounds either 
lack the necessary potency to function as drug candidates or they are not selective enough 
to be used without simultaneously inhibiting the other bromodomains. Ligand 
deconstruction efforts on BI-2536 identified what we thought to be a reasonable 
selectivity hypothesis which did not hold up with the fully elaborated compound. Though 
unsuccessful, we learned that there must be either a different binding mode of the 
compound or a different protein conformational change taking place when comparing the 
smaller truncated analogs to the fully elaborated compound. On the fragment side, there 
were several core scaffolds identified that could be further optimized, including 
pyridones (A and C), pyridazinone (B), imidazoles (D and E), benzodiazepinones (F and 
G), and an indanone (J). J was selected due to its optimal properties (Kd, LE, and LLE) 
and because the indanone scaffoled has not previously been reported in other 
bromodomain inhibitors, making it potentially a unique area of chemical space to 
explore.  
5.7 Materials, Methods, and Characterization 
5.7.1 Fluorinated Protein Expression 
Fluorinated proteins were expressed as previously described.
98, 195
 Briefly, BL21 
E. coli were transformed with the plasmid of interest. Cultures were grown in nutrient 
rich media until they reach a high concentration at which point the nutrient rich media is 
exchanged for a defined media containing 5-fluoroindole (60 mg/L) for tryptophan 
labeling. Proteins are purified by nickel affinity chromatography, and label incorporation 
is verified via liquid chromatography mass spectrometry.  
5.7.2 Protein Observed Fluorine NMR 
Fluorine NMR data was acquired at 470 MHz on a Bruker Avance III instrument 
equipped with a TCI Prodigy cryoprobe. NMR samples contained 30-50 μM 5FW BrdT 
or 5FW Brd4 and were prepared in a Tris buffer (50 mM Tris, 100 mM NaCl, pH 7.4) 
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with 5% D2O and 50 μM trifluoroacetic acid (-76.5 ppm) as a reference. Optimized 
parameters for PrOF NMR experiments included a 0.6 s delay time and a 0.1 s 
acquisition time. Spectral width and offset were 10 ppm and -125 ppm respectively. Line 
broadening of 15-20 Hz was applied to all protein spectra upon data processing. Spectra 
were acquired at 294 K, and experiments ranged between 400 and 800 scans.  
5.7.3 Small Molecule Synthesis from BI-2536 ligand deconstruction project 
General reaction schemes were shown in the main text. Below is the specific 
procedure for each compound synthesized as well as their corresponding spectral data.  
 
(1) (R)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)benzoic acid 
 
 
G2 (100 mg, 0.338 mmol) and 4-aminobenzoic acid (72.0 mg, 
0.525 mmol) were suspended in 0.3 mL of ethanol, 1.2 mL of 
water, and 65 μL of concentrated hydrochloric acid and refluxed for 
24 h. Residual volatile compounds were evaporated under reduced 
pressure, and the residue was dissolved in methanol. The product 
precipitated out of solution upon the addition of diethyl ether. The 
precipitate was filtered, yielding compound 1 (31.7 mg, 23.9%) 
 
1
H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 8.9 Hz, 2H), 7.82 (s, 1H), 7.67 (d, 8.8 Hz, 2H), 4.44 (dd, 
6.5, 3.0 Hz, 1H), 4.31 (quint, J = 8.9 Hz, 1H), 3.22 (s, 3H), 1.46-2.05 (m, 10H), 0.76 (t, J = 7.4, 3H) 
13
C NMR (100 MHz, DMSO-d6) δ 166.84, 162.51, 152.16, 130.26, 119.70, 116.06, 60.46, 60.12, 28.13, 
28.06, 27.86, 26.82, 22.76, 22.68, 8.26. Due to low S/N, some 
13
C signals may be obscured in the baseline. 
m/z calc’d [395.2], found [M-H] 394.2 
 
(2) (R)-8-Cyclopentyl-7-ethyl-2-((2-methoxyphenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one 
 
 
G2 (100 mg, 0.338 mmol) and o-anisidine (62 mg, 0.509 mmol) 
were suspended in 0.6 mL of ethanol, 2.4 mL of water, and 65 μL 
of concentrated hydrochloric acid and refluxed for 24 h. Volatile 
compounds were evaporated under reduced pressure and 
redissolved in ethyl acetate. Crude compound was extracted with 
ethyl acetate/water three times and once with brine. The organic 
layer was dried over anhydrous sodium sulfite and filtered. 
Volatiles were evaporated under reduced pressure. The product 
was then purified via column chromatography and eluted near 70% 
EtOAc/30% Hex. Remaining solvent was evaporated under 
reduced pressure, yielding 2 (127.6 mg, 98.8%)  
 
1
H NMR (500 MHz, CDCl3) δ 8.45 (dd, J = 7.7, 1.8 Hz, 1H), 7.67 (s, 1H), 7.45 (s, 1H), 6.94 (m, 2H), 6.88 
(dd, J = 7.7, 1.7 Hz, 1H), 4.50 (quint, J = 8Hz, 1H), 4.21 (dd, J = 7.9, 3.7 Hz, 1H), 3.91 (s, 3H), 3.32 (s, 
3H), 2.14 (m, 1H), 2.00 (m, 1H), 1.83 (m, 4H), 1.68 (m, 4H), 0.88 (t, J = 7.5 Hz, 3H) 
13
C NMR (125 MHz, CDCl3) δ 163.75, 155.66, 152.30, 147.62, 138.14, 129.97, 120.85, 120.66, 117.82, 
115.74, 109.85, 60.00, 58.40, 55.67, 29.69, 29.19, 28.14, 27.11, 23.44, 23.06, 9.20 
m/z calc’d [381.2], found [M+H] 382.2  
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Methyl 4-Amino-3-methoxybenzoate 
 
 
3-methoxy-4-aminobenzoic acid (1.05 g, 5.98 mmol) was 
dissolved in 100 mL of methanol. 2 mL of sulfuric acid was then 
added, and the solution was refluxed for 24 h. The reaction was 
quenched on ice with a saturated solution of sodium bicarbonate. 
Volatiles were evaporated under reduced pressure. The remaining 
residue was rinsed with ethyl acetate and water three times. The 
organic layer was dried over anhydrous sodium sulfite and filtered. 
All organic layers were combined, and volatiles were evaporated 
under reduced pressure to yield an orange-brown solid (1.10 g, 
97%). The product was used without further purification. 
 
1
H NMR (500 MHz, CDCl3) δ 7.58 (dd, J = 8.1, 1.7 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 6.75 (d, J = 8.1 Hz), 
3.92 (s, 3H), 3.89 (s, 3H) 
13
C NMR (125 MHz, CDCl3) δ 167.24, 146.52, 140.12, 123.98, 120.29, 113.82, 111.27, 55.66, 51.86  
 
(3) Methyl (R)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-
methoxybenzoate 
 
G2 (100 mg, 0.338 mmol) and methyl 4-amino-3-
methoxybenzoate (95 mg, 0.509 mmol) were suspended in 0.6 ml 
of ethanol, 2.4 mL of water, and 0.65 μL of concentrated 
hydrochloric acid and refluxed for 24 h. The reaction was 
quenched with a saturated sodium bicarbonate solution. Volatiles 
were evaporated under reduced pressure. The residue was washed 
three times with ethyl acetate and water, and once with brine. 
Organic layers were combined and dried over anhydrous sodium 
sulfite. The crude product was then purified via column 
chromatography and eluted between ~60%-80% EtOAc in 
hexanes. Volatiles were evaporated under reduced pressure, 
yielding 3 (41.5 mg, 27.9%)  
 
1
H NMR (500 MHz, CDCl3) δ 8.59 (d, J = 8.6 Hz, 2H), 7.70 (dd, J = 8.5, 1.8 Hz, 1H), 7.54 (d, J = 1.7 Hz, 
1H), 4.52 (quint, J = 8.5 Hz, 1H), 4.24 (dd, J = 7.9, 3.6 Hz, 1H), 3.99 (s, 3H), 3.92 (s, 3H), 3.34 (s, 3H), 
2.17 (m, 1H), 2.01 (m, 1H), 1.85 (m, 4H), 1.72 (m, 4H), 0.89 (t, J = 7.5 Hz, 3H) 
13
C NMR (125 MHz, CDCl3) δ 167.17, 163.76, 154.97, 152.27, 146.64, 123.44, 121.67, 115.76, 110.39, 
59.92, 58.47, 55.92, 51.90, 29.73, 29.21, 28.18, 27.19, 23.50, 23.10, 9.18 
m/z calc’d [439.2], found [M+H} 440.3 
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(4) (R)-2-Chloro-8-cyclopentyl-7-ethyl-5-isobutyl-7,8-dihydropteridin-6(5H)-one 
 
 
Sodium hydride in a 60% dispersion in mineral oil (36 mg, 0.95 mmol) 
was dissolved in 2 mL of dimethylacetamide (DMA) and stirred under an 
N2 atmosphere. G1 (204 mg, 0.727 mmol) was dissolved in minimal 
DMA and added dropwise to stirred NaH solution on ice. The reaction 
was stirred at 0 °C for 90 min. Isobutyl iodide (108 μL, 0.95 mmol) was 
added, and the reaction continued to stir for 21 hours while gradually 
warming to room temperature. The reaction was quenched by the 
addition of crushed ice and 4 mL of sat. ammonium chloride. The 
solution was then extracted three times with ethyl acetate/water. The 
organic layer was dried over anhydrous sodium sulfite, and volatiles were 
evaporated under reduced pressure to yield a viscous yellow oil. The 
crude product was then purified via column chromatography to yield 
product 4 (119 mg, 48 %) which eluted at approximately 
~20%EtOAc/80%Hex. 
 
  
1
H NMR (500 MHz, CDCl3) δ 7.69 (s, 1H), 4.40 (quint, J = 8.7 Hz, 1H), 4.20 (dd, J = 8.3, 3.6 Hz, 1H), 
3.84 (dd, J = 14.0, 7.0 Hz, 1H), 3.57 (dd, J = 14.1, 7.8 Hz, 1H), 1.58-2.14 (m, 11H), 0.96 (d, J = 6.7 Hz, 
3H), 0.94 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.7 Hz)  
13
C NMR (125 MHz, CDCl3) δ 163.73, 153.48, 152.50, 138.18, 120.67, 60.62, 59.59, 48.65, 29.47, 29.40, 
27.14, 26.48, 23.93, 23.66, 20.15, 19.99, 9.21 
m/z calc’d [336.2], found, [M+H] 337.1 
 
(G3) (R)-2-Chloro-8-cyclopentyl-5,7-diethyl-7,8-dihydropteridin-6(5H)-one 
 
 
Sodium hydride in a 60% dispersion in mineral oil (55 mg, 1.3 mmol) 
was dissolved in 2 mL of dimethylacetamide (DMA) and stirred under 
an N2 atmosphere. G1 (308 mg, 1.1 mmol) was dissolved in minimal 
DMA and added dropwise to stirred NaH solution on ice. The reaction 
was stirred at 0 °C for 1H. Iodoethane (222 mg, 1.4 mmol) was added, 
and the reaction continued to stir for 18 hours while gradually warming 
to room temperature. The reaction was quenched by the addition of 
crushed ice and 5 mL of sat. ammonium chloride. The solution was then 
extracted three times with ethyl acetate/water. The organic layer was 
dried over sodium sulfite, and volatiles were evaporated under reduced 
pressure to yield G3 as a viscous oil (208 mg, 61.6 %). The material was 
carried on without further purification.  
 
1
H NMR (500 MHz, CDCl3) δ 7.70 (s, 1H), 4.34 (quint, J = 8.4 Hz, 1H), 4.23 (dd, J = 7.4, 3.5 Hz, 1H), 
4.09 (dq, J = 14.6, 7.5 Hz, 1H), 3.76 (dq, J = 14.5, 7.3 Hz, 1H), 1.55-2.22 (m, 10H), 1.26 (t, J = 7.4 Hz, 
3H), 0.86 (t, J = 7.5 Hz, 3H) 
13
C NMR (125 MHz, CDCl3) δ 163.27, 153.56, 152.59, 137.41, 119.83, 60.57, 59.48, 36.61, 29.42, 29.22, 
27.26, 23.96, 23.78, 12.07, 8.8. 
m/z calc’d [308.1], found [M+H] 309.1 
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(5) (R)-4-((8-Cyclopentyl-5,7-diethyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid 
 
 
G3 (92.2 mg, 0.209 mmol) and 3-methoxy-4-aminobenzoic acid (55 
mg, 0.315 mmol) were suspended in 0.6 mL of ethanol, 2.4 mL of 
water, and 65 μL of concentrated hydrochloric acid and refluxed for 
48 h. Residual volatile compounds were evaporated under reduced 
pressure, and the residue was dissolved in methanol. The crude 
product was purified via column chromatography and eluted 
between 80% and 100% EtOAc in hexanes. Volatiles were 
evaporated under reduced pressure to yield 5 as a viscous oil.  (10.8 
mg, 11.7%) 
 
1
H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 8.5 Hz, 1H), 7.85 (s, 1H), 7.80 (d, J = 8.6 Hz, 1H), 7.75 (s, 1H), 
7.61 (s, 1H), 4.55 (quint, J = 7.7 Hz, 1H), 4.25 (dd, J = 7.7, 3.5 Hz, 1H), 4.11 (m, 1H), 4.01 (s, 1H), 3.80 
(m, 1H), 2.19 (m, 1H), 2.03 (m, 1H), 1.86 (m, 4H), 1.73 (m, 4H), 1.30 (dd, J = 13, 5 Hz, 3H), 0.90 (t, J = 
7.3 Hz, 3H) 
13
C NMR (125 MHz, CDCl3) δ 163.25, 154.70, 152.61, 146.77, 137.35, 135.23, 124.28, 121.00, 115.91, 
115.07, 110.83, 59.72, 58.53, 55.95, 36.45, 29.78, 29.70, 29.20, 27.10, 23.50, 23.11, 12.38,  
m/z calc’d [439.2], found [M+H] 440.3 
 
(G4) (R)-2-Chloro-8-cyclopentyl-7-ethyl-5-isopropyl-7,8-dihydropteridin-6(5H)-one 
 
 
Sodium hydride in a 60% dispersion in mineral oil (47 mg, 1.18 
mmol) was dissolved in 2 mL of DMA and stirred under an N2 
atmosphere. G1 (255 mg, 0.9 mmol) was dissolved in minimal 
DMA and added dropwise to stirred NaH solution on ice. Reaction 
was stirred at 0 °C for 1H. Isopropyl iodide (108 μL, 1.18 mmol) 
was added, and the reaction continued to stir for 22 hours while 
gradually warming to room temperature. Reaction was quenched 
by the addition of crushed ice and 5 mL of sat. ammonium 
chloride. Solution was then extracted three times with ethyl 
acetate/water. Organic layer was dried over sodium sulfite, and 
volatiles were evaporated under reduced pressure. The crude 
product was then purified via column chromatography and eluted 
at approximately ~15%EtOAc/80%Hex. Volatiles were again 
evaporated under reduced pressure to afford G4 (79.2 mg, 27.2%)  
 
1
H NMR (500 MHz, CDCl3) δ 7.89 (s, 1H), 4.88 (m, 1H), 4.35 (quint, J = 8.3 Hz, 1H), 4.12 (m, 1H, 
obstructed by impurity),  1.57-2.10 (m, 10H), 1.50 (d, J = 7.1 Hz, 3H), 1.43 (d, J = 7.1 Hz, 3H), 0.85 (t, J = 
7.5 Hz, 3H) 
13
C NMR (125 MHz, CDCl3) δ 164.60, 153.46, 153.38, 139.16, 119.63, 60.78, 59.04, 46.67, 29.61, 29.43, 
26.52, 23.91, 23.66, 20.48, 18.53, 9.10 
m/z calc’d [322.15], found, [M+Na] 345.1 
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(6) (R)-4-((8-Cyclopentyl-7-ethyl-5-isopropyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-
methoxybenzoic acid 
 
 
G4 (35.7 mg, 0.11 mmol) and 3-methoxy-4-aminobenzoic acid 
(27.6 mg, 0.165 mmol) were suspended in 0.6 mL of ethanol, 2.4 
mL of water, and 25 μL of concentrated hydrochloric acid and 
refluxed for 72 h. Residual volatile compounds were evaporated 
under reduced pressure, and the residue was dissolved in 
methanol. The crude product was purified via column 
chromatography and eluted near 10% MeOH/90% 
dichloromethane. Volatiles were evaporated under reduced 
pressure to yield 6 as a white solid.  (14.35 mg, 28.7%) 
 
1
H NMR (500 MHz, MeOD) δ 8.65 (d, J = 8.7 Hz, 1H), 7.93 (s, 1H), 7.84 (s, 1H), 7.76 (dd, J = 8.6, 1.8 
Hz, 1H), 7.59 (d, J = 1.7 Hz, 1H), 4.85 (m, 1H), 4.51 (m, 1H), 4.09 (m, 1H), 4.00 (s, 3H), 1.58-2.22 (m, 
10H), 1.51 (d, J = 7.1 Hz, 3H), 1.44 (d, J = 7.1 Hz, 3H), 0.86 (t, J = 7.5 Hz, 3H) 
13
C NMR (125 MHz, MeOD) δ 170.50, 164.56, 154.39, 153.49, 146.89, 138.93, 135.52, 124.14, 120.75, 
115.87, 115.32, 110.78, 60.36, 58.40, 56.04, 46.56, 29.90, 29.55, 26.16, 23.63, 23.20, 20.49, 18.56, 9.24 
m/z calc’d [453.2], found [M-H] 452.2 
 
4-Amino-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide 
 
 
300 mg, 1.80 mmol of 3-methoxy-4-amino benzoic acid dissolved 
in 3 mL DMF. EDCI (335 mg, 2.16 mmol) was added along with 
22 mg of DMAP. Once the material dissolved, 0.225 mL, 1.80 
mmol of methyl amino piperidine was added. The reaction was 
left for 4 days. 1 eq. of triethylamine was added, and the reaction 
was left to stir for an additional day. Solid material was filtered, 
rinsed with DCM and acetonitrile. Volatiles were evaporated 
under reduced pressure to form a viscous oil. The sample was left 
at room temperature, and the product recrystallized from the 
solution. (87.7 mg, 18.5% yield). This material was used without 
further purification. 
 
1
H NMR (500 MHz, MeOD) δ 7.36 (d, 1.9 Hz, 1H), 7.32 (dd, J = 8.1, 2.0 Hz, 1H), 6.72 (d, J = 8.2 Hz, 
1H), 3.92 (m, 4H), 2.95 (d, J = 12.2 Hz, 2H), 2.33 (s, 3H), 2.21 (td, J = 12.3, 2.1 Hz, 2H), 1.96 (dd, J = 
12.5, 2.2 Hz, 2H), 1.70 (qd, J = 12.5, 4.0 Hz, 2H)  
13
C NMR (125 MHz, MeOD) δ 168.57, 146.42, 141.03, 122.50, 120.90, 112.85, 109.13, 54.65, 54.37, 
46.62, 44.73, 30.97 
m/z calc’d [263.2], found [M+H] 264.2 
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BI-2536-Et (R)-4-((8-Cyclopentyl-5,7-diethyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxy-N-
(1-methylpiperidin-4-yl)benzamide 
 
G3 (23.8 mg, 0.077 mmol) and 4-amino-3-methoxy-N-
(1-methylpiperidin-4-yl)benzamide  (30 mg, 0.165 mmol) 
were suspended in 0.3 mL of ethanol, 1.2 mL of water, 
and 65 μL of concentrated hydrochloric acid and refluxed 
for 72 h. Residual volatile compounds were evaporated 
under reduced pressure, and the residue was dissolved in 
methanol. The crude product was purified via column 
chromatography (DCM/MeOH). Volatiles were 
evaporated under reduced pressure to yield an oil.  (14.28 
mg, 34%) 
 
1
H NMR (500 MHz, MeOD) δ 8.51 (d, J = 9.0 Hz, 1H), 7.83 (s, 1H), 7.50-7.55 (m, 2H), 4.54 (quint, J = 
8.4 Hz, 1H), 4.26 (dd, J = 7.8, 3.6 Hz,f 1H), 4.02-4.14 (m, 1H), 4.02 (s, 3H), 3.78-3.90 (m, 1H), 2.83 (t, J = 
12.4 Hz, 2H), 2.69 (s, 3H), 1.65-2.22 (m, 16H), 1.25 (t, J = 7.1 Hz, 3H), 0.88 (t, J = 7.6 Hz, 3H) 
13
C NMR (125 MHz, MeOD) δ 168.04. 163.67. 154.87*, 152.66. 147.20. 137.75. 133.22, 126.00, 120.06, 
116.10, 114.49*, 108.75, 59.78, 58.83, 55.22, 53.63, 45.36, 43.19, 36.14, 29.52, 29.10, 28.59, 26.48, 22.98, 
22.66, 11.17, 7.88.   *Chemical shifts are approximated due to low intensity 
m/z calc’d [535.3], found [M+D] 537.3 
 
BI-2536-iPr (R)-4-((8-Cyclopentyl-7-ethyl-5-isopropyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-
methoxy-N-(1-methylpiperidin-4-yl)benzamide 
 
G4 (32.6 mg, 0.101 mmol) and 4-amino-3-methoxy-N-(1-
methylpiperidin-4-yl)benzamide (30 mg, 0.165 mmol) 
were suspended in 0.6 mL of ethanol, 2.4 mL of water, and 
25 μL of concentrated hydrochloric acid and refluxed for 
72 h. Residual volatile compounds were evaporated under 
reduced pressure, and the residue was dissolved in 
methanol. The crude product was purified via column 
chromatography (DCM/MeOH). Volatiles were evaporated 
under reduced pressure to yield a white solid.  (28.53 mg, 
51.5%) 
 
1
H NMR (500 MHz, MeOD) δ 8.52 (d, J = 8.9 Hz, 1H), 8.00 (s, 1H), 7.50-7.55 (m, 2H), 4.70-4.82 (m, 
1H), 4.53 (quint, J = 8.1 Hz, 1H), 4.13 (dd, J = 8.4, 4.1 Hz, 1H), 4.02 (s, 3H), 3.15 (d, J = 12.2 Hz, 2H), 
2.47-2.58 (m, 5H), 1.60-2.20 (m, 16H), 1.53 (d, J = 7.1 Hz, 3H), 1.48 (d, J = 7.1 Hz, 3H), 0.88 (t, J = 7.5 
Hz, 3H)  
13
C NMR (125 MHz, MeOD) δ 167.85, 165.08, 154.69, 153.45, 147.20139.24, 132.889, 126.19, 120.03, 
116.13, 114.74, 108.76, 60.27, 58.48, 55.21, 53.99, 46.06, 43.04, 30.20, 29.29, 29.02, 25.52, 23.04, 22.63, 
19.19, 17.66, 8.28 
m/z calc’d [549.3], found [M+H] 550.3 
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1
H NMR of 1 (400 MHz, DMSO-d6) 
 
13
C NMR of 1 (100 MHz, DMSO-d6) 
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1
H NMR of 2 (500 MHz, CDCl3) 
 
13
C NMR of 2 (125 MHz, CDCl3) 
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1
H NMR of methyl 4-amino-3-methoxybenzoate (500 MHz, CDCl3) 
 
13
C NMR of methyl 4-amino-3-methoxybenzoate (125 MHz, CDCl3) 
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1
H NMR of 3 (500 MHz, CDCl3) 
 
13
C NMR of 3 (125 MHz, CDCl3) 
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1
H NMR of 4 (500 MHz, CDCl3) 
 
13
C NMR of 4 (125 MHz, CDCl3) 
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1
H NMR of G3 (500 MHz, CDCl3) 
 
13
C NMR of G3 (125 MHz, CDCl3) 
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1
H NMR of 5 (500 MHz, CDCl3) 
 
13
C NMR of 5 (125 MHz, CDCl3) 
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1
H NMR of G4 (500 MHz, CDCl3) 
 
13
C NMR of G4 (125 MHz, CDCl3) 
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1
H NMR of 6 (500 MHz, MeOD) 
 
13
C NMR of 6 (125 MHz, MeOD) 
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1
H NMR of 4-Amino-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (500 MHz, MeOD) 
 
13
C NMR of 4-Amino-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (125 MHz, MeOD) 
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1
H NMR of BI-2536-Et (500 MHz, MeOD) 
 
13
C NMR of BI-2536-Et (125 MHz, MeOD) 
 
  234 
 
1
H NMR of BI-2536-iPr (500 MHz, MeOD) 
 
13
C NMR of BI-2536-iPr (125 MHz, MeOD) 
 
  235 
Chapter 6. Oxygen Sensing with Perfluorocarbon-Loaded Ultraporous 
Mesostructured Silica Nanoparticles 
 
Partially reproduced with permission from “Oxygen Sensing with Perfluorcarbon-Loaded 
Ultraporous Mesostructured Silica Nanoparticles,” A. L. Lee*, C. T. Gee*, B. P. 
Weegman, A. A. Einstein, A. R. Juelfs, H. L. Ring, K. R. Hurley, E. M. Egger, G. 
Swindlehurst, M. Garwood, W. C. K. Pomerantz, C. L. Haynes,  ACS Nano, 2017, 11, 
5623-5632. Copyright 2017 The American Chemical Society 
 
Note: This work will also be published in full in the dissertation of Amani Lee. 
 
Motivation: This project was a three-way collaborative project between the Pomerantz, 
Haynes, and Garwood labs that began as a passing conversation in the NMR lab. It 
quickly became an opportunity to explore new uses for fluorine magnetic resonance in 
addressing biological questions. Building on my expertise in fluorine NMR, rather than 
ligand binding, our goal was to use fluorine NMR and MRI to both quantify the amount 
of perfluorinated material that was loaded into mesoporous silica nanoparticles and to use 
these loaded particles for oximetry experiments. My primary contributions to this project 
were in the quantification of perfluorocarbons in the PERFUMNS and NMR relaxation 
measurements. As such, portions of the original manuscript pertaining to the synthesis 
and characterization of the nanoparticles will be described in Appendix 1 so that this 
chapter focuses on areas of the project to which I directly contributed.  
6.1 Introduction 
Oxygen homeostasis is vital for regulating biological function, including 
metabolism and disease progression.
268-272
 In most cases, hypoxic tumors are resistant to 
both radiation and many traditional chemotherapy treatments; researchers are developing 
combinatorial therapies as well as agents activated by tumor hypoxia to treat cancer.
273-275
 
Additionally, pathogenic infections are highly sensitive to the oxygen level.
271-272
 Better 
measurements of oxygen levels in these tissue microenvironments are needed to optimize 
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oxygen dependent therapies. Given the significance of tissue oxygenation, many 
researchers have sought to develop efficient and sensitive technologies for oximetry 
measurements.
276
 However, current oximeters tend to be invasive, consume oxygen, or 
are limited to superficial measurements.
271, 277
 The combination of fluorine-19 magnetic 
resonance imaging (
19
F MRI) and biocompatible nanomaterials reported herein has the 
potential to be an effective platform for in situ oxygen detection.  
Noninvasive oximetry methods that measure oxygen levels are currently being 
explored for clinical applications. Magnetic resonance is a method that uses 
electromagnetic radiation to probe systems without a limitation in tissue penetration. 
Techniques such as electron paramagnetic resonance (EPR) spectroscopy, nuclear 
magnetic resonance (NMR) spectroscopy, magnetic resonance imaging (MRI), and 
magnetic resonance spectroscopy (MRS) are able to detect the levels of oxygen under 
strong magnetic fields.
278-279
 EPR is a spectroscopic technique that can detect species 
with unpaired electrons.
280
 Clinically approved EPR spectrometers are being developed 
and optimized with careful considerations of the microwave radiation needed for 
excitation.
281-284
 Alternatively, MRI and NMR detect signals from NMR-active nuclei. 
For in vivo oximetry, 
19
F MRI and fluorine-19 MRS (
19
F MRS), using highly fluorinated 
materials, are particularly attractive approaches and have already been used for enhanced 
imaging,
285-286
 cell tracking,
287
 and probing the microenvironments of tissue.
288
  
The 
19
F nucleus is 100% naturally abundant, has a high gyromagnetic ratio (γ = 
40.05 MHz/T), and is highly responsive to changes in its chemical environment. The use 
of 
19
F nuclei is also advantageous due to the lack of endogenous fluorine and thus 
background noise.
289-290
 In 
19
F MRI, partially or perfluorinated compounds (i.e., 
perfluorocarbons, PFCs), commonly used as contrast agents, have the capacity to dissolve 
high amounts of gases (e.g., O2, N2, and CO2).
291-293
  Upon dissolution into the PFC, the 
presence of O2 changes the spin−lattice relaxation time constant (T1) of the 
19
F nuclei, 
based on dipole−dipole interactions between the 19F nucleus and the O2 unpaired 
electrons, which is detected by NMR in a concentration-dependent manner. PFCs used 
for oxygen sensing or delivery have been established in the literature, including 
perfluoro-15-crown-5-ether (PFCE), hexafluorobenzene (HFB), perfluorodecalin (PFD), 
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perfluorooctyl bromide (PFOB), perfluoro(tert-butylcyclohexane) (PFTBCH), and 
perfluorotributylamine (PFTBA).
294-299
  
The current state-of-the-art method for dispersing PFCs in aqueous media, as must 
be done for in vivo imaging, is the emulsification of PFCs with surfactants.
298, 300-301
 
However, these emulsions can become unstable and lead to coalescence and Ostwald 
ripening, effectively restricting homogeneous dispersion of the probe.
302-303
 To increase 
the colloidal stability and homogeneous distribution, recent studies have encapsulated 
PFCs into biocompatible mesoporous silica nanoparticles (MSNs). The advantages of 
MSNs are their controllable pore size and surface chemistry; their internal space is 
suitable for loading cargo of interest, and their surfaces can be modified with biological 
targeting moieties. Chin et al. report a silica nanocapsule filled with PFD for ultrasound 
measurements.
304
 Thermogravimetric analysis and 
19
F NMR showed that 78 wt % of 
particles consisted of PFD, whereas the remaining mass consisted of the silica shell. 
While the silica nanocapsule stabilized the PFD, in comparison to the emulsion, the 
colloids destabilized completely after 24 h. Nakamura et al. reported a PFC core−shell 
MSN called mFLAME filled with PFCE for drug delivery.
305
 The mFLAME particles 
were modified with different surface ligands which allowed for dual-mode detection 
using 
19
F MRI and fluorescence microscopy. The authors were able to obtain in vitro 
19
F 
MR images from 2 mM PFCE concentration at 11.7 T with an acquisition time of 
approximately 30 min (1820 s). They also obtained in vivo measurements in a mouse 
model with an acquisition time as fast as 250 s. However, the core−shell structure limits 
both the amount and versatility of loadable PFC per nanoparticle.  
Here, we are evaluating the loading capacity of ultraporous mesostructured silica 
nanoparticles (UMNs) as an alternative material for 
19
F MRI. The insensitivity of MRI 
requires high concentrations of fluorine to overcome the detection limit. It is estimated 
that 30 mM of 
19
F may be needed for clinical application (≤3 T).286 Thus, the loading 
capacity of MSNs and the PFC fluorine density need careful consideration. The current 
MSNs have pore volumes much lower than 2 cm
3
 g
−1
, limiting the volume of PFCs that 
can be loaded. We recently reported on the synthesis of UMNs, spherical MSNs that 
feature pore volumes up to 4.5 cm
3
 g
−1
.
306
 The surfaces of UMNs are readily modified 
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with polyethylene glycol (PEG) and chlorotrimethylsilane (TMSCl) to improve their 
colloidal stability and biocompatibility as biologically inert vehicles. Given their 
comparatively high pore volume, stability under a variety of conditions, and prior 
precedent with silica nanoparticles, these particles were selected as an ideal candidate for 
loading with perfluorocarbons.  
 
Figure 6.1 Developing a perfluorocarbon (PFC)-loaded ultraporous mesostructured 
silica nanoparticles. 
 (Left) as an oximetry tool by monitoring relaxation with sample perflurocarbon 
perfluoro-15-crown-5-ether (right) 
 
In this study, we developed perfluorocarbon-loaded ultraporous mesostructured 
silica nanoparticles (PERFUMNs) as 
19
F-MRI-detectable oxygen-sensing probes. We 
assessed the loading efficiency of PERFUMNs loaded with three different PFCs, with 
19
F 
NMR spectroscopy, and compared the performance to existing MSNs. As our initial 
attempt to study our fluorinated contrast agents in a biologically relevant context, we 
evaluated the PERFUMNs’ stability in whole blood over several days. Finally, we 
demonstrated the sensitivity of PERFUMNs to oxygen with 
19
F NMR relaxometry.  
6.2 Results and Discussion 
Dual-modified UMNs were synthesized and characterized based partially on 
previously reported procedures.
306
 Further details on the synthesis, characterization, and 
loading of perfluorocarbons can be found in Appendix 1 
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Figure 6.2 Cryo-TEM images of UMNS (A) before and (B) after loading with 
perfluorocarbons.  
 
 
Figure 6.3 Stacked 
19
F NMR full spectra of three different PERFUMNs showing all 
resonances for each perfluorocarbon.  
All spectra are referenced to TFA at -76.5 ppm. All spectra were obtained at 470 MHz on 
a Bruker Avance III 500 MHz instrument equipped with a 5 mm Prodigy TCI Cryoprobe. 
Arrows indicate resonances corresponding to T1 values in Table 6.1. 
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6.2.1 19F NMR Quantification of PERFUMN Loading.  
The loading capacity of the PERFUMNs was calculated through quantitative 
NMR. For maximizing 
19
F MRI signal sensitivity, it is necessary to take into account not 
only the amount of perfluorocarbon loaded into the nanoparticles but also how much 
signal each sample provides per magnetically equivalent fluorine atom. For the materials 
under study here, PFCE contains 20 magnetically equivalent fluorine; PFTBCH contains 
9 equivalent fluorine, whereas PFD contains 4 equivalent fluorines.
307-308
 PERFUMNs 
were loaded in triplicate, and spectra for each PERFUMN were obtained (Figure 6.3 and 
Figure 6.4). The three different PERFUMNs, loaded with the PFCs above, were 
compared by the amount of fluorine per mass of nanoparticles (Figure 6.4, inset). 
Importantly, confinement in our UMNs does not affect the line widths of the observed 
fluorine resonances compared with the neat PFC resonances, supporting a highly mobile 
liquid phase within the UMNs (Figure 6.5). The PFCE−PERFUMNs had significantly 
higher loading than PFD−PERFUMNs (p < 0.05) and loaded five times more than PFCE-
filled MSNs (p < 0.05). The variation of the fluorine loading values of PFTBCH− 
PERFUMNs made them indistinguishable from the other three samples. Of note, the 
groups had different sample sizes, 3:6:9:3, from left to right, respectively. However, the 
one-way ANOVA has some power to account for unequal variances.  
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Figure 6.4 Stacked 
19
F NMR spectra of three different PERFUMNs.  
Equivalent fluorines used for quantification are highlighted in the structure and 
designated with an arrow in each spectrum. All spectra are referenced to trifluoroacetic 
acid at −76.5 ppm. Inset: PFC loading comparison with MSN particles (circle) and the 
three type of PERFUMNs (PFD = diamond, PFCE = square, PFTBCH = triangle). The 
strip chart reveals the spread of the data around the mean (solid line). The total numbers 
are 3:6:9:3 going from left to right. The perfluorochemical loading for 
PFCE−PERFUMNs is significantly higher than that for PFD−PERFUMNs and PFCE-
loaded MSNs (*p < 0.05). Loading of PFTBCH−PERFUMNs is indistinguishable from 
the other samples. 
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Figure 6.5 Evaluation of PFCs with and without nanoparticles.  
(A-C) Corresponding representative 19F NMR spectra in a neat solution (bottom), suspended in 
water (middle), and loaded in nanoparticles (top). (D) Chemical shift differences of select 
resonances for each perfluorocarbon relative to trifluoroacetic acid (-76.55 ppm) showing modest 
changes between neat PFCs and PFCs in water or nanoparticles. (E) Linewidths of select 
resonances for each perfluorocarbon showing modest differences between neat PFCs and PFCs in 
water or nanoparticles. It should also be noted that because PFCs are not soluble in water, 
lineshapes and consequently linewidths can be affected due to poor shimming quality. 
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PFC-loaded nanoparticles can address the stability challenge of emulsions of 
PFCs; however, the concentrations of PFCs are lower and particle-size-dependent. In the 
context of a PFCE emulsion, Ruiz-Cabello et al. reported cationic and anionic emulsion 
particles with DLS diameters of 158 nm (0.119 PDI) and 207 nm (0.09 PDI), 
respectively.
286
 In 8 μL volumes, the emulsion contained 4.8 mM PFCE. This 
concentration corresponds to 38 nmol PFCE (760 nmol of 
19
F). In comparison, in 8 μL, 
our PFCE−PERFUMNs, with a nanoparticle concentration of 1 mg mL−1, would have 19 
nmol PFCE (380 nmol 
19
F). Although not stated in the article, assuming the 4.8 mM 
corresponds to the anionic particles, then the 65 nm difference between their larger 
emulsion and our PERFUMNs led to a 2-fold increase in molar concentration of PFCE. 
Matsushita et al. have core−shell PFC-filled MSNs synthesized around 80 nm emulsions 
of PFCE.
309
 In 0.5 mL, they reported 1.3 mM PFCE; this concentration corresponds to 
0.65 μmol PFCE. In the same volume, Ruiz-Cabello et al. would have 30 μmol PFCE, 
and our PERFUMNs would have 1.21 μmol PFCE. While increasing the size of the 
nanoparticles may seem desirable to obtain more fluorine per nanoparticle, the change in 
size may affect the colloidal stability or biodistribution of the UMNs.
310
 As stated before, 
emulsions have to battle against coalescence and Ostwald ripening; the trade-off for PFC 
concentration is the added stability of the UMNs.  
 
Figure 6.6 Oxygen dependence of R1 values for different PERFUMNs, demonstrating the 
linear relationship between R1 and partial pressure of O2 in all three cases.  
PERFUMNs were measured at 656.8 MHz (16.4 T) at room temperature. Error bars from 
triplicate measurements are too small to be visible on this graph. 
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6.2.2 Oxygen Sensitivity of PERFUMNs.  
The presence of pores on the surface of PERFUMNs makes the internal liquid 
PFCs accessible to molecular oxygen outside the nanostructures. As the oxygen dissolves 
into the liquid PFC, the dipole−dipole interactions between the fluorine nuclei and 
unpaired electrons of the oxygen reduce the T1 relaxation times of the nuclei. 
Traditionally, T1 values are determined using an inversion− recovery sequence. By 
measuring the T1 at different partial pressures of oxygen (pO2), the relaxation rate 
constant (R1), or the inverse of the T1, can be plotted as a function of pO2 to give an 
oxygen calibration curve.
311
 Figure 6.6 shows the R1 as a function of pO2 at 22 °C, 16.4 T 
(tuned to 656.8 MHz). As expected, R1 relaxation rates increase as the concentration of 
oxygen increases. The slopes and their error were determined with a linear regression fit. 
PFCE−PERFUMNs had a sensitivity to oxygen with a slope of 322 ± 4 (10−5 mmHg−1 
s
−1). PFTBCH−PERFUMNs had a sensitivity of 334 ± 3 (10−5 mmHg−1 s−1), and 
PFD−PERFUMNs had the lowest sensitivity of the three PERFUMNs described herein at 
273 ± 3 (10
−5
 mmHg
−1
 s
−1
). To analyze the difference in sensitivities, an analysis of 
covariance was used to compare the slopes. There was a significant difference between 
the slopes (p < 0.05). A Newman-Keuls multiple comparison test, at a significance level 
of 0.01, revealed that PFD−PERFUMN sensitivity is significantly different from that of 
PFTBCH (p < 0.0001) and PFCE (p < 0.0001), whereas there is no significant difference 
between the most sensitive PERFUMNs loaded with PFTBCH and PFCE.  
In our previous study, we report neat PFCE and PFD have a sensitivity of 223.4 ± 
15 (10
−5
 mmHg
−1
 s
−1
) and 188.0 ± 38 (10
−5
 mmHg
−1
 s
−1
), respectively, at 16.4 T (37 
°C).57 During that study, we also found neat PFCE and PFD have a sensitivity of 280.4 ± 
13 (10
−5
 mmHg
−1
 s
−1
 ) and 197.3 ± 31 (10
−5
 mmHg
−1
 s
−1
), respectively, at 16.4 T, 22 °C 
(not reported). The trend in the intercepts of the PERFUMNs is consistent with the 
relationship of the inherent T1 relaxation times between PFCE, PFD, and PFTBCH, 
where PFD has the longest T1 relaxation time (Table 6.1). The PERFUMNs have a higher 
anoxic R1 compared to that of neat PFC, indicating shorter T1 relaxation times. The T1 
relaxation times are sensitive to the magnetic field, temperature, and the PFC 
microenvironment. In this case, the nanoparticles themselves could be affecting the 
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relaxation of PFCs, likely due to both a decrease in molecular mobility of PFC inside of 
UMNs and the molecular interactions between the SiO2 cage and PFC.
312-313
 Degradation 
of the silica nanoparticles may change the response curve of PFC to oxygen. As an initial 
evaluation of the PERFUMN stability, a preliminary analysis in whole blood is described 
in the section PERFUMN Oxygen Measurements in Whole Blood.  
Table 6.1 
19
F-NMR and 
19
F-MRS Longitudinal Relaxation Times (T1) of PERFUMNS 
System Temperature PFCE
 PFTBCH PFD
 
500 MHz (11.7 
T) 
300 K 0.775 ± 0.004 s 0.772 ± 0.001 s 1.302 ± 0.006 s 
700 MHz (16.4 
T) 
295 K 0.524 ± 0.001 s 0.541 ± 0.001 s 1.290 ± 0.002 s 
19F NMR and 19F MRS measurements were done with 500 MHz (11.7 T) and 700 MHz 
(16.4 T) systems respectively. Error was reported from instrument as standard deviations. 
The relaxation time of TFA was also recorded on the 500 MHz system; TFA had 
relaxation time of 2.659 ± 0.004 s. Refer to Figure S6 for the corresponding PFC 
resonance being measured. 
Our previous study shows oxygen concentration, as well as temperature, can 
influence the R1 relaxation rates of fluorine nuclei.
314
 We have also shown this 
phenomenon with PFCE− PERFUMNs (Figure 6.7). As the temperature increased (22 to 
45 °C), the O2 sensitivity of the PFCE−PERFUMNs dropped from 322 (10
−5
 mmHg
−1
 
s
−1
) to 161 (10
−5
 mmHg
−1
 s
−1
). The anoxic R1 (0 mmHg O2) shows PFCE−PERFUMNs 
have a sensitivity of −226 (10−4 °C s−1). If the error in temperature is ±1 °C, this could 
change the sensitivity to oxygen by 7 (10
−5
 mmHg
−1
 s
−1
). The variability in temperature, 
similar to in vivo conditions, adds to the uncertainty in oxygen quantification in a 
predictable fashion.
315-317
 One way to address this issue is to find the oxygen and 
temperature dependence of each PFC separately; this work is currently underway for 
future applications.  
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Figure 6.7 Temperature dependence of PFCE-PERFUMNs at 16.4 T.  
Oximetry measurements were taken at 22, 37, and 45 °C. Six replicate measurements 
were taken for each concentration of oxygen: 0 mmHg (+, solid line), 38 mmHg (X, long 
dash line), 76 mmHg (triangle, small dash line), 114 mmHg (diamond, dot-dash line), and 
152 mmHg (circle, dash-dot-dot line). Temperature is shown to have a negative 
relationship with the PFC relaxation rates (R1) as the temperature doubles the relaxation 
rates decrease by 25%. Of note, these PFCE-PERFUMNs are from a different batch than 
the batch used in Figure 6.6. 
 
In addition to the acquisition of 
19
F NMR spectra, PERFUMNs were imaged by 
1
H 
and 
19
F MRI at 16.4 T. Comparison of the 
1
H MRI and 
19
F MRI images of PFCE− 
PERFUMNs shows a decrease in the intensity of 
19
F signal consistent with the 2-fold 
dilution series (Figure 6.8). The 4 × 4 region of interest (ROI) analysis shows that the 
signal-to-noise ratio has a linear relationship with the fluorine concentration (Figure 6.9). 
The linear regression was a good fit (R
2
 = 0.95), and the SNR increased by a factor of 2.3 
± 0.3 with change in fluorine concentration. ROI analysis also reveals all clearly visible 
dilutions have an SNR greater than 10; this is a recommended threshold to overcome at 
any magnetic field strength.
318
 At this magnetic field strength, the lowest concentration 
(0.025 mg/mL, 1.6 mM equivalent 
19
F nuclei) of PFCE−PERFUMNs was barely visible, 
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indicative that concentrations of PERFUMNs ≥ 0.05 mg/mL with greater than 3.1 mM 
equivalent 
19
F nuclei are desirable for further oximetry measurements and imaging.  
 
 
Figure 6.8 MRI phantom images of a PFCE_PERFUMN 2 fold dilution series 
acquired at 16.4 T and room temperature.  
1
H and 
19
F images were acquired in 1.3 s and 27.3 min, respectively. (Left) 
1
H MRI 
image. (Right) 
19
F MRI image. Concentration of equivalent 
19
F nuclei in 0.8 mL: (1) 24.8 
mM (0.4 mg/mL); (2) 12.4 mM (0.2 mg/mL); (3) 6.2 mM (0.1 mg/mL); (4) 3.1 mM (0.05 
mg/mL); (5( 1.6 mM (0.025 mg/mL); (6) 0 mM (1 mg/mL UMN) 
 
 
Figure 6.9 Region of interest analysis of 2-fold serial PFCE-PERFUMN dilutions 
from 19F MR imaging at 16.4 T (656.8 MHz).  
The concentrations that were visible had a signal-to-noise ratio greater than or equal to 
10. Linear regression of the dilutions shows that the SNR increases by a factor of 2.3 ± 
0.3 (mean ± SD) when the concentration of fluorine increases. Error bars are the standard 
deviation. 
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Figure 6.10 Relaxation rates of PFCE-PERFUMNs in whole rabbit blood.  
Triplicate samples of rabbit blood were treated with PFCE-PERFUMNs, on day 0, and R1 
values were obtained by inversion recovery for 5 days at 470 MHz (11.7 T), 21% O2, 300 
K. The average R1 values are displayed above the bar graphs. The error bars are standard 
deviations between triplicate samples. Days 0-2 showed no significant change in 
relaxation; however, days 3 and 4 are significantly different from days 0-2 and each other. 
Significance was determined with one-way ANOVA and Tukey multiple comparison test 
(α = 0.05). 
6.2.3 PERFUMN Oxygen Measurements in Whole Blood.  
Mesoporous silica nanoparticles are known to be stable in biological environments, 
especially in the hour time frame of experiments previously described.
309, 319-320
 To test 
the feasibility of the PERFUMNs in biologically relevant conditions at long time scales, 
the oxygen sensitivity of PFCE−PERFUMNs was measured in whole blood. All 
PFCE−PERFUMN blood measurements were acquired at 470 MHz, 300 K. Triplicate 
measurements of PFCE−PERFUMNs reveals the R1 values were constant up to 2 days 
after incubation in whole blood but started to decrease after 3 days (Figure 6.10). In a 
second experiment, to measure the sensitivity of PFCE−PERFUMNs to varying oxygen 
levels, R1 relaxation rates were measured 2 days after nanoparticles were added to whole 
blood and compared to PFCE−PERFUMNs in water. Measurements of R1 at 0, 21, and 
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100% O2 reveal a linear dependence but a 1.6- fold decrease in sensitivity to oxygen in 
whole blood relative to water (Figure 6.11).  
 
Figure 6.11 Oximetry dependence of R1 values for PFCE-PERFUMNS in water 
(top) and in whole rabbit blood (bottom). 
Oximetry measurements were taken at 300 K, 470 MHz (11.7 T) at 0%, 21% and 100% 
O2. The measurements in blood were taken two days after blood was treated with 
PERFUMNS   
 
Of note, the rabbit blood was not treated with anticoagulation or anti-inflammatory 
agents. Potential blood degradation was apparent based on severe discoloration after 
week long agitation or introduction of anoxic conditions (Figure 6.12). The potential 
degradation of the blood sample could have affected the relaxation of the PERFUMNs by 
decreasing the total blood oxygen content. However, for at least up to 2 days, it is clear 
that oxygen measurements are possible in biological samples. The stability of 
PERFUMNs and the effects on oxygen sensitivity in biological environments will be the 
focus of future experiments. 
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Figure 6.12 Visible change in the integrity of PFCE-PERFUMN blood samples. 
 (A) Difference between blood samples after a week of agitation and freshly drawn blood 
samples. (B) Discoloration between PFCE-PERFUMN blood samples aerated with 100% 
O2 and 0% O2 (or 100% N2) for 30 minutes. The discoloration observed is qualitatively 
similar to blood samples treated with 10% bleach for 30 minutes, indicating that the 
blood was degrading or becoming unstable. 
6.3 Conclusions 
In summary, we have reported the use of mesoporous silica nanoparticles loaded 
with perfluorocarbon small molecules for application to oximetry. These particles feature 
a comparatively high loading capacity, making it possible to encapsulate a large amount 
of perfluorocarbons (five times greater than MSNs). Additionally, the postsynthesis 
loading of PFCs allows for use of a broad range of PFC liquids with a single platform 
nanoparticle carrier. The ability to analytically measure the oxygenation level in 
biological environments, which was shown feasible in whole blood, is important in the 
design or improvement of biomedical devices and clinical therapies (e.g., radiation 
therapy). PERFUMNs are ideal oximetry agents due to their noninvasive NMR-based 
detection, biologically inert and compatible material, and sensitivity to changes in oxygen 
levels in microscopic environments. Further exploration of this technology’s application 
in a wide range of settings is underway. 
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6.4 Materials and Methods 
6.4.1 Materials.  
Perfluoro-15-crown-5-ether was purchased from Exfluor Research Corporation 
(Round Rock, TX, USA). Perfluorodecalin was purchased from Fluoromed L.P. (Round 
Rock, TX, USA). Perfluoro(tert-butylcyclohexane) was purchased from Synquest 
Laboratories, Inc. (Alachua, FL, USA). All chemicals were used without further 
purification.  
6.4.2 Data Analysis.  
All statistical analyses were performed with Prism version 6.7 (GraphPad 
Software, San Diego, CA, USA). Quantitative TEM measurements were performed with 
ImageJ (NIH, USA). Measurements were made by drawing a line segment across the 
scale bar and setting the pixel/nm scale. The diameter of the particles was measured by 
using the oval draw tool to fit an ellipse diameter. Unless stated otherwise, all 
quantitative data are expressed as the mean ± standard deviation.  
6.4.3 TEM Images 
Electron micrographs of the UMNs and PERFUMNs were obtained via TEM 
(FEI Tecnai 12, Houston, TX, USA) and cryo-TEM (Tecnai G2 Spirit Biotwin, Houston, 
TX, USA), respectively. In TEM, 3 μL of UMNs was dried on Formvarcoated carbon 
grids overnight. For cryo-TEM, 3 μL of PERFUMNs was placed on lacey carbon grids, 
which were immediately dried with filter paper for 5 s at 100% humidity. The samples 
were vitrified by submerging grids into liquid ethane. Electron micrographs were 
obtained at 120 kV with an emission current of 4 mA.  
6.4.4 19F NMR Quantification. 
  All NMR spectra were obtained at 470 MHz on a Bruker Avance III 500 MHz 
instrument equipped with a 5 mm Prodigy TCI cryoprobe. Samples were prepared with 
5% D2O and 52 μM trifluoroacetic acid (−76.5 ppm) as a reference and calibration 
standard to calculate loading values. Loaded nanoparticle solutions were vortexed for 0.5 
to 1 min immediately prior to mixing with D2O and TFA. NMR tubes were vortexed for 
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30 s within 10 min prior to acquisition of NMR spectra. Parameters for 
19
F NMR 
experiments included an 8.5 s delay time and a 2 s acquisition time to allow for complete 
relaxation of magnetization following a full 90° pulse. PFD spectral width and offset 
were 80 ppm and −110 ppm, respectively. PFCE spectral width and offset were 30 ppm 
and −85 ppm respectively. PFTBCH, spectral width and offset were 25 ppm and −67 
ppm, respectively. Spectra were acquired at 296 K in 64 scans. PFC loading was 
calculated by comparing relative integrations of select resonances from the PFC to TFA. 
T1 relaxation times were measured using the inversion recovery method at 470 MHz and 
300 K for determining optimal delay times to allow for quantitative measurement of each 
fluorine resonance. These measurements were performed under standard atmospheric 
condition.  
6.4.5 19F MRS Oxygen Sensitivity.  
19
F spectra and images were acquired with a 16.4 T (tuned to 656.8 MHz). MR 
system (Agilent Technologies, Santa Clara, CA, USA) using a custom-built single-loop 
surface coil (2.5 cm diameter) tuned to 656.8 MHz. Oximetry and thermometry methods 
were previously described for neat compounds.
314
 Briefly, the selected PERFUMN was 
suspended in water and pipetted into a 2 mL vial. The vial was centered in the coil; the 
coil was tuned and inserted into the isocenter of the magnet. PFCs have been known to 
saturate with a gas after 15 min.
292-293
 The sample was then bubbled and equilibrated with 
a gas of known oxygen concentration for 30 min [as previously verified with a calibrated 
250 μm fluorescence-quenching fiber optic [FO] probe (Ocean Optics, Dunedin, FL, 
USA)] while the temperature was held constant. Temperature was monitored with an 
additional FO probe and was maintained using a forced-air heater and water circulator. 
The magnet was shimmed, and R1 (1/T1) was then measured with a standard 
inversion−recovery pulse sequence with customized delay times optimized to each 
sample’s R1.
321-322
 PFCE benefits from processing only a single resonance, but for PFD 
and PFTBCH (which have multiple resonances), the Ith
323
 and major (described above) 
resonances, respectively, were interrogated. R1 measurements were made for five 
different oxygen concentrations (0, 38, 76, 114, and 152 mmHg) at three different 
temperatures (22, 37, and 45 °C). Each condition was measured in replicate (N = 2−6) 
  253 
with a repetition time of at least 5/R1. R1 was assumed linear with both oxygen 
concentration and temperature as previously described.
297, 314, 316
  
6.4.6 MRI Phantom Images.  
Samples of UMN and PERFUMNs loaded with PFCE were transferred to 6 mm 
culture tubes. These tubes vertically centered within a 2.5 cm diameter surface coil for 
imaging. The central tube was the unloaded UMN at 1 mg/mL. A completely empty tube 
was included in the outer ring of samples between the highest and lowest PERFUMN 
concentration (0.03 mg UMN/mL and 0.08 mM PFCE). The 
19
F and 
1
H images were both 
acquired using a gradient echo pulse sequence with a resolution of 0.78 × 0.78 mm at 
16.4 T. The 
19
F image was acquired with the following settings: slice thickness = 10 mm; 
repetition time (TR) = 400 ms; echo time (TE) = 2.0 ms; flip angle = 90°; 64 averages, 
acquisition time (AQ) = 3.23 ms; receiver bandwidth (sw) = 19841 Hz; data matrix = 64 
× 64; and FOV = 50 × 50 mm. The measurement took 27.3 min. The 
1
H image was 
acquired with the following settings: slice thickness = 5 mm; TR = 40 ms; TE = 0.78 ms; 
flip angle = 2°; 1 average; AQ = 0.15 ms; sw = 208333 Hz; data matrix = 32 × 32; and 
FOV = 25 × 25 mm. The measurement took 1.3 s.  
6.4.7 Rabbit Blood Oximetry.  
Blood was drawn from New Zealand White rabbits purchased from Bakkom 
Rabbitry. In the first week, triplicate samples were made by placing 2.5 mL of rabbit 
blood in a round-bottom polystyrene culture tube with a snap cap. Three tubes with 8 mL 
of PFCE−PERFUMNs were centrifuged for 12 min at 22 °C and 66 000g. A soft pellet 
was formed, and 7 mL of supernatant was removed from the tubes. The remaining 1 mL 
of PFCE− PERFUMNs was vortexed for 20 s, until well mixed, and then added to the 
tube of rabbit blood. The treated rabbit blood was agitated on a benchtop rocking table at 
room temperature. Each day, 475 μL of blood was added to NMR tubes with 25 μL of 
D2O. All 
19
F NMR measurements were obtained at 470 MHz on a Bruker Avance III 500 
MHz instrument at 300 K. T1 relaxation times were measured using a standard inversion 
recovery method with time points ranging from 0.010 to 8 s, an acquisition time of 2 s, 
and delay time of 6 s. In the second week, 2.5 mL of fresh rabbit blood was placed in the 
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culture tubes. Without centrifugation, 1 mL of PFCE−PERFUMNs from stock was added 
to the rabbit blood. The blood was placed on the benchtop rocking table at room 
temperature. Two days after the PERFUMNs were added, 475 μL of treated blood was 
placed into three J-Young NMR tubes, with 25 μL of D2O each. One tube was aerated 
with 100% O2, and the other was aerated with 100% N2. Both tubes were aerated for 30 
min, and the headspace above the blood was subsequently filled with the corresponding 
gas to maintain an oxygen or nitrogen-rich environment. The third tube was left open to 
atmospheric air. The T1 relaxation times of these samples were measured as described 
above. 
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Chapter 7. Quantifying Protein Concentrations Using Smartphone 
Colorimetry: A New Method for an Established Test 
 
Reproduced with permission from “Quantifying Protein Concentrations using 
Smartphone Colorimetry: A New Method for an Established Test,” C. T. Gee, E. Kehoe, 
W. C. Pomerantz, and R. Lee Penn,  Journal of Chemical Education, 2017, 94 (7) 941-
945. Copyright 2017 The American Chemical Society and Division of Chemical 
Education, Inc.  
 
Motivation: As a side project and due to my interest in teaching and education, I 
undertook the project of developing a new lab experiment utilizing smartphone 
colorimetry, as established by the Penn lab, in the context of protein colorimetric assays, 
such as the Bradford and biuret assays. In making these experiments possible with the use 
of a few easily accessible reagents and smartphone cameras, more students would have 
access to and the opportunity to learn about proteins and their vital role in biology.  
7.1 Introduction 
Proteins are large biomacromolecules that play necessary roles in nearly all biological 
processes, including cell growth, metabolism, and differentiation. Consequently, 
significant research efforts are dedicated to studying the biological function of proteins 
and designing synthetic molecules to modulate the function of proteins in the context of 
disease. High school students encounter proteins in both the life sciences as well as in 
their chemistry courses (e.g., Next Generation Science Standards (NGSS)
324
).   
One example of an interesting protein is the bromodomain containing protein 4, 
(Brd4).  When functioning properly, Brd4 is a necessary protein for regulating gene 
transcription and cell growth, but when functioning improperly, Brd4 has been linked to 
cancer,
189
 a topic covered in life sciences classes and a reality that has impacted many 
people personally.  
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Accurate quantification of protein concentration is crucial to studying the roles 
proteins play in biological processes.  This is particularly important in biochemical 
experiments (e.g., circular dichroism and enzymatic assays) for quantitative 
characterization of protein structure and function. There are several different methods for 
protein quantification.  Some methods are colorimetric assays that involve the formation 
of a colored complex. Quantitation is accomplished by determining visible light 
absorption and using Beer’s Law to convert absorbance to concentration by comparison 
to a standard calibration curve.  Two such colorimetric assays are the Bradford and Biuret 
assays.
325
 Using known standards within concentration ranges that obey Beer’s law, one 
can generate a linear calibration curve that can be used to estimate a protein concentration 
of an unknown sample. These methods are particularly useful when the protein 
concentration in solution cannot be determined by other techniques., particularly in cases 
when the protein extinction coefficient is unknown or is too low for direct determination 
of the concentration based on the protein solution’s absorbance at 280 nm.326 
Colorimetric assays are typically performed using a UV-Vis Spectrophotometer.  In 
the presence of varying concentrations of protein, absorbance values at 595 nm and 540 
nm, are monitored in the Bradford and Biuret assays respectively. However, these 
specialized instruments are expensive and may not be available in laboratories such as 
teaching laboratories in high schools. To mitigate this challenge, recent reports have 
demonstrated the efficacy of handheld cameras for quantitative colorimetry, making 
colorimetric experiments accessible to a wider range of students and researchers.
327
 
Smartphone colorimetry has been used with kinetics experiments with crystal violet,
328
 
quantification of gold nanoparticles present in dietary supplements
329
 and a variety of 
other experiments.
330-334
 These examples involve a single color, with a colorless blank.  
The use of camera phone colorimetry with a color change has yet to be explored. Here, 
we extend quantitative colorimetry to protein assays that involve color changes and its 
application to quantify protein concentration (Figure 7.1). 
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Figure 7.1. Concept figure depicting smartphone colorimetry. 
 
Bradford assays are commonly employed in laboratory experiments for introductory 
biochemistry courses. The protein-responsive molecule in the Bradford solution, 
Coomassie Blue G-250, is an environmentally sensitive triphenylmethane dye compound 
that exists in varying charge states depending on the surrounding solution conditions. The 
hydrophobic interactions provided by the presence of a protein stabilizes the anionic form 
of the dye, resulting in color change from a brownish green, with a maximum absorption 
at 470 nm (cationic form), to a blue color, with a maximum absorption at 595 nm 
(anionic form) (Figure 7.2). 
While the Bradford assay is a dye-based assay, the Biuret assay involves the 
formation of a Cu(II) complex with the amide backbone present in peptides and proteins. 
This coordination complex results in a color change from blue (free Cu
2+
), with a 
maximum absorption at 650 nm, to violet (HN---Cu
2+
---NH), with a maximum 
absorption at 540 nm (Figure 7.2). The Bicinchoninic Acid (BCA) and Lowry assays are 
examples of other copper-based assays that are commercially available.  
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Figure 7.2. Chemical scheme and sample images for protein colorimetric assays.  
A) Chemical scheme for Coomassie Blue G-250 which becomes fully deprotonated in the 
presence of a protein, yielding a blue color. B) Sample image of Bradford reagent plus 
water (left) and Bradford reagent plus 0.04 mg/mL Bovine Serum Albumin (BSA) 
(right). C) Chemical scheme for complexation of cupric ions in the presence of peptides 
and proteins form a complex with the amide backbone, resulting in a color change from 
blue to violet. D) Sample image of Biuret reagent plus water (left) and Biuret reagent plus 
0.75 mg/mL BSA (right) 
 
Herein we report the first application of smartphone colorimetry for protein 
quantification using two well-known protein assays that involve changes in color as a 
function of protein concentration. The ubiquity of the Bradford assay as a standard 
laboratory experiment in biochemistry and the cheap and accessible nature of the Biuret 
assay combined with the clear color change that occurs upon complexing with protein 
made these two assays ideal for use with smartphone colorimetry.   
7.2 Materials and Methods 
7.2.1 Preparation of Chemicals 
The Bradford reagent was prepared with Coomassie Blue G-250 (Sigma), methanol 
(Sigma), phosphoric acid (Macron), and water according to the following protocol: 1) 
Dissolve 50 mg Coomassie Blue G-250 in 50 mL methanol. 2) Add 100 mL 85% (w/v) 
phosphoric acid. 3) Add this mixture slowly to 850 mL of water. 4) Store away from light 
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at 4° C. Because Flinn is a common vendor for high school laboratories, the Biuret 
reagent was prepared using the Flinn Scientific specifications (0.2% (w/v) CuSO4, 30% 
(w/v) NaOH) for this reagent. This solution can be made by mixing 100 mg CuSO4·5H2O 
(dissolved in 10 mL of water) and 40 mL of 37.5% (w/v) NaOH in water. It is important 
to note that Biuret from Flinn contains 30% sodium hydroxide while many other vendors 
and recipes employ only 3% (w/v) sodium hydroxide with the addition of 0.6% (w/v) 
potassium sodium tartrate.
335
 Both solutions will provide adequate results, but the 
tartrate-containing solution performs significantly better than the solution without it at 
protein concentrations above 0.5 mg/mL because it prevents protein precipitation. If 
tartrate is not available, citrate may also be used as a substitute to prevent turbidity (See 
Supplemental Information). While the Bradford reagent is more common in biochemistry 
labs for its greater sensitivity to a wider protein concentration range, Biuret is roughly 
10% of the cost of Bradford, making it more accessible for a high school or a low-budget 
laboratory. Bovine serum albumin (BSA) for the calibration curve was purchased from 
RPI and used as is. Brd4 was expressed from recombinant DNA using standard protein 
expression protocols in BL21 (DE3) E. coli cells.
98
  
7.2.2 Preparation of Calibration and “Unknown” Solutions 
Standard Bradford or Biuret solutions for the calibration curve were prepared by 
diluting 0.10 mg/mL BSA (for Bradford assay) or 3 -10 mg/mL BSA (for Biuret assay) 
with 1.5 mL of Bradford or Biuret solution and water. To prepare the calibration 
standards, 1.5 mL of the Bradford or Biuret solutions; 0.1, 0.2, 0.3, 0.4, and 0.5 mL of 
appropriate protein stock solution, and enough water to yield a final volume of 2.0 mL 
were added to individual vials. The blank sample was prepared by mixing 1.5 mL of the 
Bradford or Biuret and 0.5 mL of water. Experiments can all be performed with regular 
tap water. As noted in the sample student guide (Supporting Information), these low 
volumes of protein solution can be delivered into the individual square plastic cuvettes (1 
cm pathlength) by counting drops of the solution and weighing the sample using an 
balance after each addition to account for the actual amounts added. This approach works 
well since the densities of each solution and water are all nearly identical. Further, if 
students do not have access to a balance, counting drops and converting volume to mass 
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can also provide adequate data, as noted in the results section. Absorbance measurements 
were performed 40 minutes after mixing for the Bradford and 20 minutes after mixing for 
the Biuret samples in order to ensure full development of the color change. The 
“unknown” protein concentration sample was prepared in a similar manner, with the 
estimated concentration falling within the linear range of the colorimetric agents. The 
“unknown” protein concentration in the sample Bradford assays was 0.014 mg/mL Brd4 
as determined by UV absorption (Ɛ280: 26930 M
-1
 cm
-1
) and 1.25 mg/mL BSA by mass in 
the sample Biuret assay. Because the change in color is a time-dependent process, the 
equilibration time is important for the color to fully develop. Insufficient equilibration 
time will often lead to poorer results.   
 
Figure 7.3. Bradford assay data (via UV-Vis) at selected time points demonstrating 
the time dependent effect on the results.  
The samples were measured after approximately A) 20 min, B) 40 min, C) 60 min, and 
D) 90 min with a gradual increase in R
2
 as the data became more linear. 
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7.2.3 Instrumentation and Setup 
Cuvettes containing the standard, blank, and “unknown” samples were analyzed using 
both a standard UV-Vis Spectrophotometer and smartphone colorimetry. For absorption 
measurements, samples were analyzed at 595 nm for Bradford and 540 nm for Biuret 
using a Beckman Coulter DU 720 UV-Vis Spectrophotometer.  
 
 
Figure 7.4. Photographs of calibration samples plus an unknown sample for 
smartphone colorimetry.  
A) Biuret standards for calibration and “unknown” sample in front of a white 
background. B) Biuret standards for calibration and “unknown” sample in front of a 
green (129, 255, 0) background. C) Biuret standards for calibration and “unknown” 
sample in front of a yellow-orange (255, 207, 0) background. 
 
7.2.4 Acquiring Images 
For smartphone colorimetry, cuvettes were lined up in front of a computer monitor, 
and images were acquired using the back facing lens of varying smartphones (Samsung 
Galaxy S5, iPhone 6). Cuvettes were lined up in front of a computer monitor with 
varying background colors matching the wavelengths measured for absorption in addition 
to a white background (Figure 7.4). For Bradford samples, an RGB code of (255, 207, 0) 
was used, while (129, 255, 0) was used for the Biuret. These values can be obtained using 
an online wavelength to RGB conversion tool (e.g. Academo’s Wavelength to Colour 
Relationship
336
).  
7.2.5 Data Analysis and Comparison 
Absorption data from the spectrophotometer were plotted using spreadsheet software 
and fitted to a linear trendline. The generated equation was used to estimate the protein 
concentration. Absorbance measurements from the smartphone images were obtained by 
analyzing RGB (red, green blue) values from images of each sample (intensity range of 
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0-255). A variety of software, freeware, and web applications (e.g., Adobe Photoshop, 
ImageJ, Color Code Picker)
327
 as well as smartphone applications (e.g., Colorometer for 
iPhone and ColorMeter Free for Android)
333
 is available for this type of analysis and 
provide similar results. Download links can be found in the supporting information. RGB 
values can be obtained by analyzing single points or averaging multiple points over a 
specified area. Single point and area measurements yield nearly identical results, as noted 
in a previous report.
327
  
Absorbance (A) is calculated from RGB values using the following formula: 
      𝐴 =  −log (
𝐼𝑛
𝐼𝑏𝑙𝑎𝑛𝑘
)                                                                                          (1) 
where In corresponds to the R, G, or B value of each sample and Iblank corresponds to the 
R, G, or B value for the blank. For the Bradford assay, the best results were obtained 
using the R values while for the Biuret assay, the best results were obtained using the G 
values. For alternative colorimetric experiments or assays, it would be best to follow 
whichever channel (R, G, or B) provides the greatest dynamic range. These “absorbance” 
values were plotted as a function of concentration and fit to a linear trendline to estimate 
protein concentration of the “unknown” sample.  
7.3 Hazards 
The Bradford solution is acidic while the Biuret solution is basic. Both are corrosive 
and should be handled with care. Both solutions should be neutralized appropriately prior 
to disposing down the drain with excess water. Alternatively, solutions can be disposed 
of in separate waste containers as appropriate. Protective gloves and eyewear (preferably 
splash proof goggles) in addition to standard lab-appropriate attire (long pants and 
closed-toed shoes) should be worn at all times while handling Bradford or Biuret 
reagents.  
7.4 Results 
Samples from both the Bradford and Biuret assays were evaluated by a UV-Vis 
spectrophotometer and by smartphone colorimetry to benchmark a newer technique 
against an established technique. Calibration curves generated R
2
 values greater than 0.9, 
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and using the equation generated from fitting a linear trendline, the concentration of 
protein in the “unknown” sample was calculated (Figure 7.5). 
 
Figure 7.5. Comparison of colorimetric assays by UV-Vis spectrophotometry and 
smartphone colorimetry.   
A) Photograph of Bradford assay cuvettes in front of 595 nm (RGB: 255, 207, 0) colored 
background. B) Graph of absorbance (via spectrophotometry) versus protein 
concentration. C) Graph of absorbance (via smartphone colorimetry following R values) 
versus protein concentration D) Photograph of Biuret assay cuvettes in front of 540 nm 
(RGB: 129,255,0) colored background. E) Graph of absorbance (via spectrophotometry) 
versus protein concentration F) Graph of absorbance (via smartphone colorimetry 
following G values) versus protein concentration In all plots, Blue diamonds refer to 
protein calibration and the red circle indicates the  “unknown” sample  at its expected 
concentration. 
7.5 Discussion 
The use of a smartphone camera is effective for quantitative colorimetry 
measurements.  It can be used for the appearance of color, as previously reported
327-332
 
and also for a color change, as described here. The obtained data were adequate for 
correctly estimating a given protein concentration using Beer’s Law and a standard 
calibration curve.  
Smartphone colorimetry data were comparable to data collected using the 
spectrophotometer (Figure 7.5). In the example of the Bradford assay above (Figure 7.5 
A-C), the “unknown” concentration was 0.014 mg/mL, and the UV-Vis absorption 
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measurements yielded an estimated concentration of 0.011 mg/mL while a concentration 
of 0.0090 mg/mL was estimated via camera phone colorimetry. In the example of the 
Biuret assay (using the tartrate-containing solution) (Figure 7.5. D-F), the “unknown” 
concentration was 1.25 mg/mL, and the UV-Vis absorption measurements yielded an 
estimated concentration of 1.32 mg/mL while a concentration of 1.28 mg/mL was 
estimated via camera phone colorimetry. Images acquired in front of backgrounds 
displaying the color matching the maximum absorption wavelength of the color agent 
yielded more accurate results as compared to images of the samples arranged in front of a 
white display. However, if a backlit background is not available, a plain white 
background is suitable for collecting quantitative measurements. Kuntzleman and 
Jacobson also reported good success using colored construction paper in lieu of a colored 
backlit screen for similar types of measurements.
333
  
The utility of this method lies not only in its efficacy for determining protein 
concentration via the measurement of a color change but also in its robustness to a range 
of factors, including lighting conditions and picture quality, which can vary dramatically 
from one classroom to another. Given the camera quality found in the average 
smartphone, this type of protein quantification colorimetry experiment is now more 
widely accessible to students who may have previously been unable to perform such an 
experiment.  
As a final assessment of the suitability of the experiment for a high school 
classroom as well as the clarity of the instructions for the experiment, the method was 
tested with a group of tenth grade high school chemistry students.  The lab was conducted 
with two different class sizes of 25 and 15 students respectively, and run over three 50 
minute class periods.  The first class period was used to introduce the background for the 
lab and demonstrate the experimental procedure which can be found in Appendix 2. The 
second period was used to prepare the solutions and capture the image using 
smartphones.  During the last day, the images were analyzed and the results discussed.  
In order to ensure the method is easily reproducible in any high school setting, a 
few changes were made from the original protocol.  For high school implementation we 
used the Biuret and Albumin as they are available from Flinn Scientific. Also, because 
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many labs may not have access to protein expression facilities, using an unknown 
concentration of Albumin, or other commercially available proteins (e.g., lysozyme, or 
cytochrome C are more practical alternatives than Brd4.)   For this study, six groups had 
access to electronic balances with centigram precision.  In order to balance time 
efficiency and reagents, the students worked in groups of five. The two groups without 
access to balances were provided with a conversion from drops of solution to mass for 
each of the solutions.   
 
Figure 7.6. Representative examples of poor quality and good quality student data.  
A, B) Sample images from students showing a poor quality, washed out image (A) and a 
clear, usable image (B). C, D) Sample data generated from A and B, respectively, 
demonstrating the quality of fit for each photo. E) Summary table of student results for 
measuring the “unknown” sample which was prepared at 1.1 mg/mL Albumin. Each 
group consisted of five students. A comparison of the student data generated from 
samples prepared using a balance versus counting drops is also included. 
 
Analysis of the students’ data pointed to several areas for further clarification in 
the protocol (Figure 7.6). At this point, all students had a strong grasp of Beer’s law; 
however, analysis of the results showed of the eight groups performing the experiment, 
four had unknown concentrations that agreed within ten percent of the unknown protein 
concentration. The remaining four groups had considerably larger errors.  Examples of 
both preparations of data collection are shown in the supporting information. It should be 
noted that positive results were independent of sample preparation method. In the four 
  266 
groups that yielded accurate results and in the four that yielded poor data, three groups 
prepared samples with a balance and one group counted drops. After reviewing the 
students' work, it became clear that some groups whose analysis fell outside of 10% of 
the accepted concentration, had not taken images of suitable quality for analysis. A 
common error was taking the picture from too far away, leaving the color intensity in the 
image washed out, as the area of interest was very bright relative to the background.  
Poor image focus also led to unreliable data.  To alleviate these problems for future 
implementation, providing students with examples of good and poor images have now 
been added to the instructional guide.  
 In general, the instructor felt the results were of similar quality to other 
quantitative methods carried out by high school students at this level. The use of 
photocolorimetry, Beer’s Law, and protein topics, align well with courses introducing 
content that use the next generation science standards,  HS-LS1-1, regarding content on 
protein function, as well as HS-PS4- 5 which describes how some technological devices 
use the principles of wave behavior and wave interactions with matter to transmit and 
capture information and energy. 
7.6 Conclusion 
Smartphones and other portable cameras were successfully used to determine the 
concentration of a protein sample using assays that yield a color change as a function of 
protein concentration. This new method for measuring protein concentrations allows for 
greater accessibility to such colorimetric assays for introductory labs and labs lacking 
expensive equipment like spectrophotometers. This type of experiment also fits in well 
with the Science and Engineering Practices from the HS-LS1 section of the NGSS.
324
 A 
detailed step-by-step procedure for the experiment suitable for use in high school or 
college settings is provided in Appendix 2. 
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Chapter 9. Appendices 
9.1 Appendix 1: Oxygen Sensing with Perfluorocarbon-Loaded Ultraporous 
Mesostructured Silica Nanoparticles 
Partially reproduced with permission from “Oxygen Sensing with Perfluorcarbon-Loaded 
Ultraporous Mesostructured Silica Nanoparticles,” A. L. Lee, C. T. Gee, B. P. Weegman, A. A. 
Einstein, A. R. Juelfs, H. L. Ring, K. R. Hurley, E. M. Egger, G. Swindlehurst, M. Garwood, W. 
C. K. Pomerantz, C. L. Haynes,  ACS Nano, 2017, 11, 5623-5632. Copyright 2017 The American 
Chemical Society 
9.1.1 Results and Discussion 
9.1.1.1 Synthesis and Characterization of Dual-Modified UMNs 
To achieve optimal colloidal and hydrolytic stability, we modified the surface 
functionality of our mesoporous nanoparticles. The dual-modified UMNs were 
successfully synthesized via the sol−gel method.337-339 The UMN surfaces were modified 
with PEG-silane, containing a heterogeneous mixture with 9−12 repeating units, and 
TMSCl to increase the nanoparticle colloidal stability. The PEG-silanes are hydrophilic 
moieties that aid in dispersion of particles in aqueous media and reduction of nonspecific 
protein adsorption.
340
 The hydrophobic trimethylsilyl group protects the particles from 
hydrolysis reactions in aqueous environments.
341
 A descriptive statistical analysis of the 
UMN physical properties was carried out between 15 different batches of dual-modified 
UMNs (Table 9.1). 
Table 9.1 Physical Characteristics of Dual-Modified UMNs 
Parameter 
Estimated 
Valuea 
SDb 
Confidence 
Interval (0.95)c 
Hydrodynamic Diameter (nm) 142 ± 33 ± 21 
Polydispersity 0.11 ± 0.06 ± 0.04 
BJH Surface Area ( m2/g) 532.4 ± 74.9 ± 41.5 
BJH Pore Volume (cm3/g) 1.8 ± 0.3 ± 0.7 
BJH Pore Size (nm) 13.2 ± 1.3 ± 12.9 
a
All estimate values are means of the sample distributions. 
b
Standard deviation. 
c
The 95% confidence 
interval, n=15. 
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Figure 9.1 Characterization data and images of nanoparticles.  
(A) N2 physisorption data from replicate unloaded nanoparticle batches showing type IV 
isotherms with a type 5 hysteresis (H5) loop. (B) TEM image of unloaded nanoparticles 
with hollow lacey cavities surrounded by a silica wall with an average thickness of 22 ± 1 
nm (mean ± SEM). (C) Triplicate, pairwise, DLS diameter comparison between UMNs 
and PFCE−PERFUMNs; error bars are the standard error; PERFUMNs are statistically 
(*p < 0.05) distinguishable from the unloaded nanoparticles. (D) Cryo-TEM image of 
PERFUMNs; the previously hollow cavities now show a change in mass−thickness 
contrast, indicating the nanoparticles are packed by atomically heavy PFCs. 
  
Dynamic light scattering (DLS) reported a polydispersity index (PDI) of 0.11 ± 
0.06. A PDI < 0.2 indicates that the size distribution of the particles is moderately 
uniform.
342
 The ζ- potential of the various batches of UMNs was measured with a range 
of −25 to −50 mV, indicating a suitable surface charge for colloidal stability. A 
significant difference between the dual-modified UMNs and the previously reported bare 
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UMN nanoparticles is the pore volume and surface area. The Barrett− Joyner−Halenda 
(BJH) pore volume and surface area for bare UMNs were greater than 4 cm3 g
−1
 and 
1100 m
2
 g
−1
, and the modified UMNs are 1.8 ± 0.3 cm
3
 g
−1
 and 532.4 ± 74.9 m
2
 g
−1
 
respectively. This reduction in pore size can be explained due to the pore volume and 
nanoparticle surface area occupied by the modifying ligands. 
 The pore volumes of UMNs, compared to traditional MSNs, are on the higher end 
of the pore volume limit. The 95% confidence interval indicates that UMNs are capable 
of overcoming pore volumes of 2 cm3 g
−1
. The average pore volume can be shifted based 
on the stoichiometry and type of surface modification moieties.
340
 Furthermore, many 
MSNs have lower pore volumes due to the limited space from internal pore tunnels.
343
 In 
comparison, UMNs have a large internal cavity allowing better packing in the open 
space. 
 Analysis of the N2 physisorption isotherm (Figure 9.1A) shows that UMNs have 
a type IV isotherm with a type 5 (H5) hysteresis loop. Type IV isotherms are indicative 
of mesoporous particles, and H5 loops indicate the presence of both open and blocked 
pores.
344
 The hysteresis is likely a feature due to the difference in desorption between 
different pores. The BJH pore size analysis shows a bimodal distribution for the UMN 
population (Figure 9.2), in support that the UMNs contain surface pores and a large 
internal cavity. 
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Figure 9.2 N2 physisorption pore distribution of replicate unloaded UMNs. 
The derivative of the BJH adsorption shows a bimodal distribution of pore diameters. 
Inset is a zoomed in area between 0 to 20 nm pore diameters. 
  
Transmission electron microscopy (TEM) analysis shows a difference in 
mass−thickness contrast between the center and edges of unloaded UMNs, indicating 
hollow or lacey silica network in the center (Figure 9.1 B and Figure 9.3A−C). Image 
analysis of the UMNs (n = 750) revealed average particle diameters of 122 ± 32 nm, with 
a silica shell thickness of 22 ± 21 nm. These values support the diameter found by DLS 
(142 nm). In our previous study with bare UMNs, scanning electron microscopy analysis 
revealed a spherical 3D structure with raspberry-like surface textures.
306
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Figure 9.3 TEM images. 
(A-C) TEM images of unloaded dual-modified UMNs with scale bars at 500, 200, and 
100 nm respectively; the nanoparticles are spatially dispersed with moderately uniform 
sizes. (D-F) Cryo-TEM images of PFTBCH, PFCE, and PFD-PERFUMNs respectively; 
there are nano-sized bubbles in the PFC cavities indicating that not all nanoparticles are 
fully filled with PFCs; scale bars are 200, 500, and 500 nm respectively. 
9.1.1.2 Loading and Characterization of PERFUMNs 
PERFUMNs were made by loading UMNs via sonication with different types of 
PFCs: PFCE, PFD, and PFTBCH. PERFUMNs were extracted into an ultrapure water 
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phase after vortexing the sample. The PEG-silanes on the surface of the PERFUMNs 
promote the particle extraction from the liquid PFC layer. During the extraction, the 
aqueous phase became turbid after complete phase separation, whereas the liquid PFC 
phase became clear (Figure 9.4). 
 
Figure 9.4 PERFUMN phase separation and extraction.  
Top panel shows the separation of water (top) and liquid perfluorocarbon (bottom). The 
bottom panel shows the turbidity of the extracted aqueous phase with PFCE-
PERFUMNs. 
 
A two-tailed paired t test shows all PERFUMNs demonstrated an increase of ≥30% 
in their effective diameter (p = 0.023) relative to their unloaded counterparts (Figure 9.1 
C). This measured increase is likely a result of the increased mass and change in 
refractive index from the addition of highly dense liquid PFC. The same test did not 
reveal significant difference in uniformity between PERFUMNs and unloaded UMNs 
(Figure 9.5). This would suggest that the extraction of PERFUMNs is not selective to a 
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narrow size range of nanoparticles. Cryo-TEM images show the internal space of the 
UMNs have been packed with an atomically heavy substance (Figure 9.1 D and Figure 
9.3 D−F). The mechanisms that control electron microscopy contrast are mass−thickness, 
diffraction, and phase contrast.
345-346
 Because fluorine atoms have the second highest 
atomic mass after silica atoms in these PERFUMNS, the contrast in the internal space of 
PERFUMNs, compared to unloaded UMNs, demonstrates the high concentration of 
fluorine atoms in the nanoparticles. 
 
Figure 9.5 Dynamic light scattering polydispersity between unloaded and loaded 
nanoparticles.  
The polydispersity in DLS is the square of the distribution width over the mean 
([width/mean]
2
); error bars are the reported standard error from multiple measurements 
within the instrument. Two-tailed paired t-test reveals there is no significant difference in 
the uniformity between UMNs and PERFUMNs (α = 0.05). 
 
Since electron microscopy is a complementary technique for particle 
characterization, it can help explain differences found in DLS. The DLS hydrodynamic 
diameters are sensitive to interparticle interactions (e.g., electrostatic repulsion, van der 
Waals forces, and adsorbed polymers) and the change in diffusion, leading to an 
overestimation of the particle diameter.
347
 Additionally, UMNs with PFCs will change 
the effective particle density, which will affect the particle diffusion. Slower diffusion 
leads to larger particle size in DLS. Thus, the physical diameters from DLS were 
compared to measurements from TEM and cryo-TEM. No significant difference was 
found between the DLS effective diameter and both electron microscopy diameter 
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measurements (Figure 9.6A). The lack of difference shows that the physical diameters of 
the particles remain the same but is supportive that DLS distinguishes UMNs from 
PERFUMNs based on particle behavior. 
 
Figure 9.6 Comparison of loaded and unloaded nanoparticles. 
(A) Comparison of effective diameter of UMNs (DLS, TEM) and PERFUMNs (cryo-
TEM, n = 450); a one-way ANOVA does not reveal a significant difference between 
different particle sizing techniques, indicating that the physical diameter of the 
nanoparticles is not changing. (B) Particle size distributions of UMNs and PERFUMNs 
showing the overlap in particle size with unimodal distributions. 
 
Analysis of the particle size distributions (PSDs) shows both TEM (UMNs) and 
cryo-TEM (PERFUMNs) have a unimodal distribution with a right skew (Figure 9.6B). 
The PDI is the squared quotient between the full width at half-maximum height and the 
mean of the PSDs ([width/mean]
2
).
342
 The PSDs of TEM and cryo-TEM have PDIs of 
0.263 and 0.335, respectively. The decrease in the uniformity can be expected for 
electron microscopy techniques due to their low sample size, relative to the nanoparticle 
population, static conditions, and high vacuum environment.
346, 348
 Together, these data 
demonstrate that dual-functionalized UMNs can be synthesized with a large pore volume 
that is easily filled with PFCs. This success inspired further studies for 
19
F NMR and 
MRI behavior 
 
 
 
  299 
Sources of variability could be reflected in both the pore volume distribution of 
our UMNs and variability of the loading procedure itself. Cryo-TEM shows nanosized 
bubbles (Figure S2E,F) in the PERFUMNS, indicating incomplete loading of the UMN 
cavities. To evaluate the experimental variability in loading, two batches of 
PFCE−PERFUMNs (batches X and Y) were loaded in triplicate to compare loading 
variability. Batch X had the highest loading variability with a coefficient of variation 
(CV) of 87.6%; batch Y had a CV of 31.2% (Figure 9.7). There was no significant 
difference between batch X and batch Y. This variability in experimental loading 
suggests that it may be difficult to determine more subtle changes in loading during a 
complete analysis of loading conditions. Further differences in loading may be a result of 
the molecular packing of each PFC, but these effects are difficult to evaluate based on the 
current variability in our data. A complete analysis of the PFC physicochemical variants 
that affect molecular packing inside the UMN will be the focus of future PERFUMN 
experiments.  
 
Figure 9.7 Variation in loading with PFCE-PERFUMNs.  
Two batches of UMNs (X, Y) were loaded in triplicate (I, II, III) to measure the 
variability in loading procedure. Batch X was more variable than batch Y however they 
are not significantly different. In order to compare variability coefficient of variation 
(standard deviation/mean), or CV, was calculated as a percentage. Batch X has a CV of 
87.6% and batch Y has a CV of 31.2%. Black line is the mean. 
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In addition to the fluorine content per nanoparticle, the PERFUMNs were also 
compared based on their loading yield and efficiency (Appendix X “Calculations for 
PERFUMN Loading Yield & Efficiency”). The efficiency analysis of 
PFCE−PERFUMNs (n = 6) shows a mean specific loading yield of 33 ± 21%, and mean 
efficiency is 15 ± 9% with typical nanoparticle concentrations of 0.4 mg UMNs/mL 
water. In comparison, PFCE-filled MSNs (n = 3) had an average yield of 14 ± 9% and 
efficiency of 1.3 ± 1%. These values indicate that improvements need to be investigated 
for the maximal filling of nanoparticle internal volume and the complete extraction of 
nanoparticles from the PFC layer. However, an important facet of these loading data is 
that clinical MRI field strengths, as previously discussed, require around 30 mM fluorine 
to be detected, which is already achievable with PFCE−PERFUMNs at a low 
nanoparticle concentration (∼0.5 mg/mL).  
9.1.2 Materials and Methods 
9.1.2.1 Materials.  
Hexadecyltrimethylammonium bromide (CTAB), chlorotrimethylsilane (TMSCl), 
trifluoroacetic acid (TFA), tetraethyl orthosilicate (TEOS), and N,N-
dimethylhexadecylamine (DMHA) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). The PEGsilane, 2-[methoxy(polyethyleneoxy)9-12propyl]trimethylsilane, was 
purchased from Gelest, Inc. (Morrisville, PA, USA). Decane was purchased from Tokyo 
Chemical Industry Co., Ltd. (Toshima, Kitaku, Tokyo, Japan). Perfluoro-15-crown-5-
ether was purchased from Exfluor Research Corporation (Round Rock, TX, USA). 
Perfluorodecalin was purchased from Fluoromed L.P. (Round Rock, TX, USA). 
Perfluoro(tert-butylcyclohexane) was purchased from Synquest Laboratories, Inc. 
(Alachua, FL, USA). All chemicals were used without further purification. Data 
Analysis. All statistical analyses were performed with Prism version 6.7 (GraphPad 
Software, San Diego, CA, USA). Quantitative TEM measurements were performed with 
ImageJ (NIH, USA). Measurements were made by drawing a line segment across the 
scale bar and setting the pixel/nm scale. The diameter of the particles was measured by 
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using the oval draw tool to fit an ellipse diameter. Unless stated otherwise, all 
quantitative data are expressed as the mean ± standard deviation.  
9.1.2.2 Synthesis of UMNs.  
UMNs were synthesized via the sol−gel approach as reported previously.306 
Batches of UMNs that were made in triplicate were used to analyze variation in 
synthesis. In a 20 mL scintillation vial, 0.145 g of CTAB was mixed with 10 mL of 
ultrapure water, 150 μL of DMHA, and 116 μL of decane. The solutions were stirred 
with magnetic stir bars at 50 °C for 1 h. The solutions were then sonicated for 1−3 h in a 
sonication bath (Branson 2510). The rest of the synthesis steps were performed at 50 °C. 
The sonicated solution was mixed in an Erlenmeyer flask containing 150 g of 0.256 M 
NH4OH. Next, 2.5 mL of 0.88 M TEOS was added dropwise and stirred for 1 h. The 
surfaces of the newly formed UMNs were modified by adding 450 μL of PEG, stirred for 
30 min, and then addition of 68 μL of TMSCl in a dropwise manner. The solutions were 
aged at 50 °C for 16−18 h until final volumes were below 50 mL. The particles were then 
hydrothermally treated by heating solutions within a glass media bottle in a 90 °C oven 
for 24 h.
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At 24 h, the solutions were removed from the oven and vacuum filtered. The 
solutions were centrifuged several times for 35 min at 4 °C and 66 000g (Beckman 
Coulter Optima L-100 K) with two intermediate ion-exchange steps in a reflux apparatus. 
The CTAB was removed in the ion-exchange steps by dispersing UMN pellets in 6 g/L 
NH4NO3 (dissolved in 190 proof ethanol) and stirring solutions in a 100 mL round-
bottom flask at 50 °C for 1 h. Ion-exchange washes were followed by washes with 190 
proof ethanol. UMNs were washed once in 200 proof ethanol and then redispersed in 200 
proof ethanol. Final solutions of UMNs were filtered through 5 μm Versapor membrane 
syringe filters (Pall Co., Radnor, PA) to remove hair and dust particles.  
9.1.2.3 Loading and Extraction of PERFUMNs.  
PERFUMNs were made by loading UMNs with different types of PFCs: PFCE, 
PFD, or PFTBCH. UMN synthesis replicates were loaded in triplicate to analyze the 
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variation in loading. UMNs were dried from 200 proof ethanol at 10 Torr, 21 °C, for 1 h. 
The mass-to-volume ratio of UMNs to PFC liquid was kept at a range of 3−4 (e.g., 10 mg 
UMN/3 mL PFC). UMNs were added to liquid PFCs at room temperature in Nalgene 
centrifuge tubes. The colloid solution was shaken by hand and then sonicated for 10 min 
in a sonication bath. After sonication, the PERFUMNs were extracted in ultrapure water 
(pH ≤7.4) by adding an equal volume of water to PFC and vortexing the phases for 10 s. 
The opacity of the aqueous phase became turbid after complete phase separation. The 
washing step was performed two or three more times as needed; ultrapure water was 
added to the solution to make the final volume equal to the mass of nanoparticles (i.e., 1 
mg/mL). The concentration of nanoparticles was determined by drying 3 mL aliquots in a 
20 mL scintillation vial at 10 Torr, 40 °C, for 1 h. The difference in mass of the vial 
before and after was used to calculate the mass of nanoparticles in solution.  
9.1.2.4 Materials Characterization.  
The hydrodynamic diameter and ζ- potential of the nanoparticles were measured 
by dynamic light scattering (DLS, Brookhaven BIC ZetaPals), with a 35 mW 660 nm 
laser at room temperature. The ζ-potential was measured in ultrapure water with a 
Brookhaven ZetaPALS ζ-potential analyzer (Holtsville, NY). Particle porosity and 
surface area were measured with N2 physisorption (Micromeritics ASAP 2020, GA, 
USA). Samples were then analyzed under the ASAP 2020 analysis port at cryogenic 
temperatures. The surface area and pore size of samples were determined by the BJH 
method. Electron micrographs of the UMNs and PERFUMNs were obtained via TEM 
(FEI Tecnai 12, Houston, TX, USA) and cryo-TEM (Tecnai G2 Spirit Biotwin, Houston, 
TX, USA), respectively. In TEM, 3 μL of UMNs was dried on Formvarcoated carbon 
grids overnight. For cryo-TEM, 3 μL of PERFUMNs was placed on lacey carbon grids, 
which were immediately dried with filter paper for 5 s at 100% humidity. The samples 
were vitrified by submerging grids into liquid ethane. Electron micrographs were 
obtained at 120 kV with an emission current of 4 mA.  
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9.1.2.5 Calculations for PERFUMN Loading Yield & Efficiency 
 
𝐶𝑃𝐹𝐶 = (𝑓𝑐 × 𝑓𝑑) (
𝐶1×𝑉𝑎𝑣𝑔
𝑆 ×𝜌𝑃𝐹𝐶
𝑀𝑀𝑃𝐹𝐶
)  (1) 
Υ =  
𝐶𝑒𝑥𝑝
𝐶𝑃𝐹𝐶
× 100  (2) 
Υ∗ =  
Cexp
CPFC
∗ × 100  (3) 
 
CPFC is the theoretical concentration of PFC, Cexp is the experimental concentration found 
with NMR, fc is a conversion factor (10
6
), fd is the dilution ratio (V1/V2) from stock 
volume to final NMR tube volume, C1 is the concentration (mg/mL) of the PERFUMNs,  
𝑉𝑎𝑣𝑔
𝑆  is the average loadable volume (cm
3
/mg), ρPFC is the density of the PFC, and MMPFC 
is the molar mass of PFC. In equations 2 and 3, ϒ and ϒ* are the specific sample yield 
and loading efficiency respectively. In loading efficiency, 𝐶𝑃𝐹𝐶
∗  is the same as CPFC, but 
C1 is set to 1 mg/mL, and 𝑉𝑎𝑣𝑔
𝑆  is set to the upper confidence band limit of the BJH pore 
volume described in Table 1.1 in Chapter 6. . 
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9.2 Appendix 2: Quantifying Protein Concentrations using Smartphone 
Colorimetry: A New Method for an Established Test 
 
Partially reproduced with permission from “Quantifying Protein Concentrations using 
Smartphone Colorimetry: A New Method for an Established Test,” C. T. Gee, E. Kehoe, 
W. C. Pomerantz, and R. Lee Penn,  Journal of Chemical Education, 2017, ASAP. 
Copyright 2017 The American Chemical Society and Division of Chemical Education, 
Inc.  
Motivation: This appendix features both a sample student worksheet for this lab 
experiment that provides a brief introduction and background to the technique and a step-
by-step procedure to perform the experiment. Also included is an instructor guide with 
tips and suggestions for how to use this material successfully, including troubleshooting 
tips, links for resources, and reagent preparation.  
9.2.1 Student Worksheet 
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Name ___________________________________ Date __________ 
 
Quantifying Protein Concentrations using Smartphone 
Colorimetry: A New Method for an Established Test 
 
Question: 
What is the concentration of a protein in solution? 
 
Introduction: What are proteins and why do we care? 
Proteins are large biomolecules made up of smaller connected units called amino 
acids. There are 20 common amino acids found in nature, and the sequence of those 
amino acids determines a protein’s structure and function. Interactions between different 
proteins are involved in nearly all biological functions. However, in the case of a disease, 
like cancer, these interactions between proteins are perturbed. One example is the 
bromodomain containing protein 4 (Brd4), which has been validated as a target for anti-
cancer drugs.  
 
Background: How do we measure protein concentrations? 
In order to effectively work with and study proteins, a researcher must often know 
the concentration of the protein in solution. There are a variety of techniques that exist to 
measure protein concentration, but they often require specialized instrumentation. One 
common method to quantify protein in solution is to use a colorimetric assay, which 
exhibits a color change in the presence of protein.  This color change can be monitored 
by quantifying the absorption of a particular wavelength of light. (Fig. 1) By using Beer’s 
law (Eq. 1), one can generate a calibration curve using solutions with known protein 
concentrations to predict the concentration of another sample.  
 
                                            A = ƐlC                                             (Eq. 1) 
 
where A is equal to the absorbance, Ɛ is the molar absorptivity, l is the pathlength of the 
sample, and C is the concentration. 
 
          Traditionally these colorimetric experiments are performed using a 
spectrophotometer. In this lab experiment, you will instead be taking pictures with a 
smartphone and analyzing the Red, Green, and Blue (RGB) values of the digital image to 
determine the absorption using the following equation.  
 
                                   𝐴 =  −log (
𝐼𝑛
𝐼𝑏𝑙𝑎𝑛𝑘
)                                             (Eq. 2) 
 
  306 
Where In corresponds to the R, G, or B value of each sample and Iblank corresponds to 
the R, G, or B value for the blank.  
 
 
Figure 9.8 Chemical scheme and sample images for protein colorimetric assays  
A) Chemical scheme for Coomassie Blue G-250 which becomes fully deprotonated in the presence of a 
protein, yielding a blue color. B) Sample image of Bradford reagent plus water (left) and Bradford reagent 
plus 0.04 mg/mL Bovine Serum Albumin (BSA) (right). C) Chemical scheme for complexation of cupric 
ions in the presence of peptides and proteins form a complex with the amide backbone, resulting in a color 
change from blue to violet. D) Sample image of Biuret reagent plus water (left) and Biuret reagent plus 
0.75 mg/mL BSA (right) 
 
 
 Hazards and Safety:  
Bradford and Biuret solutions are both corrosive and should be a handled with 
care. Both solutions should be neutralized appropriately prior to disposal. Protective 
gloves and eyewear (preferably splash proof goggles) in addition to standard lab 
appropriate attire (long pants and closed-toed shoes) should be worn at all times while 
working in the lab.  
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Procedure 
Materials needed per group: 
- 6 cuvettes 
- 1.5 mL H2O 
- 9 mL Bradford and/or Biuret Solution 
- 1.5 mL Bovine Serum Albumin (BSA) stock solution (Concentration: 0.10 mg/mL for 
Bradford and 10 mg/mL for Biuret)) 
- Sample protein of unknown concentration 
- Disposable glass Pasteur pipets 
 
Procedure for preparing samples with known protein concentrations: 
*To simplify experimental setup, the approximation is being made that all solutions in 
this experiment have the same density.* 
 
1.  Tare the balance with an empty cuvette 
 
2. Add 1.5 g of Bradford or Biuret solution. (~55-60 drops from Pasteur pipet) 
 
3. Record mass of Bradford or Biuret solution added 
 
4. Tare the cuvette containing the colored solution from step 3.  
 
5. Add X drops of water to the tared cuvette from step 4 (see table) 
 
6. Record the mass of water added (this number will be zero for the top protein 
concentration) 
 
7. Tare the cuvette.  
 
8. Add Y drops of BSA solution to the cuvette. (see table) 
 
9. Record the mass of the BSA solution added (this number will be zero for the blank) 
 
10. Repeat steps 1-9 with all 6 cuvettes.  
 
 There should be an increasing blue color that forms with higher concentrations of 
protein in the Bradford assay and a gradual transition from blue to purple with higher 
concentrations of protein in the Biuret assay.  
 
 
 
 
 
 
  308 
 
 
Target 
Bradford 
BSA 
Concentration 
(mg/mL)  
0 
(Blank) 
0.005 0.010 0.015 0.020 0.025 
Target Biuret 
BSA 
Concentration 
(mg/mL) 
0 
(Blank) 
0.5 1.0 1.5 2.0 2.5 
Color Agent 1.5 g 1.5 g 1.5 g 1.5 g 1.5 g 1.5 g 
H2O (X) 15 drops 12 drops 9 drops 6 drops 3 drops 0 drops 
BSA (Y) 0 drops 3 drops 6 drops 9 drops 12 drops 15 drops 
Record Your Masses Below 
Color Agent 
 
 
      
H2O 
 
 
      
BSA 
 
 
      
 
11. Mix the Bradford/Biuret solutions and 
protein in each cuvette well by pipetting the 
solution up and down a few times with a fresh 
Pasteur pipet.  
 
12. Once the solution appears to be a uniform 
color, let the cuvettes incubate on the bench 
for at least 10 minutes for the Bradford and 
20 minutes for the Biuret for the color to 
develop.  
  
13. Obtain a picture of your cuvettes along 
with the provided cuvette containing the 
unknown concentration of the sample protein. 
(See Figure 1). (Note: The accuracy of the 
measurements can be improved by taking the picture in front of a complementary colored 
background [Bradford: RGB code (255, 207, 0), Biuret: (129, 255, 0).] 
 
Analysis of obtained images: 
14. Using an online color picker application or some other graphics processing software 
(e.g., ImageJ, Adobe Photoshop, etc…), identify the R, G, and B values for each of the 
cuvettes and record these in a spreadsheet.  
 
 
Figure 9.9  Sample smartphone image of 
Bradford solutions with BSA calibration 
curve and unknown sample.  
From left to right: blank, 0.008 mg/ mL, 0.016 
mg/mL, 0.024 mg/mL, 0.032 mg/mL, 0.040 
mg/mL, Brd4 sample of unknown 
concentration. 
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15. Calculate the protein concentrations for your calibration samples using the mass of 
protein solution added and the total volume.  
 
 
 Blank 1 2 3 4 5 Unknown 
Protein 
Concentration 
0      ----- 
R Value 
 
 
      
G Value 
 
 
      
B Value 
 
 
      
AR [-log(R/R0)] 
 
 
      
AG [-log(G/G0)] 
 
 
      
AB [-log(B/B0)] 
 
 
      
 
 
16. Plot the AR, AG, and AB, values as a function of protein concentration to generate 
your calibration data. The results should be linear, with the best results for the Bradford 
from following the R values while the best results for the Biuret will come from 
following the G values.  
 
17. Calculate the concentration of the unknown protein sample that was provided for you 
using your calibration data. Report the value below.  
 
Unknown protein sample concentration __________________ 
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9.2.2 Instructor Notes 
 
Biuret Solution Turbidity 
Because proteins are sensitive to their environment, solution conditions can sometimes 
cause proteins to precipitate out of solution, causing significant turbidity. The color 
change still takes place, so it is usually still possible to get adequate results (with lower 
R
2
 values). This occurrence often takes places in the Biuret solutions without tartrate or 
citrate at protein concentrations above 0.5 mg/mL. If it is not possible to prepare a Biuret 
solution with tartrate or citrate, lower protein concentrations can be used. With the 
provided procedure, the stock protein concentration can be reduced from 10 mg/mL to ≤ 
3 mg/mL.  
 
Image Quality 
There are a variety of factors that affect image quality. We have found that better images 
can be acquired in front of a monitor in lower light settings so that there is less light 
interference, which can be done by closing blinds or turning off lights. If a 
monitor/screen is not available, images can be acquired in front of a piece of white or 
colored paper. With the auto-focusing, color balance, and lighting settings on most 
cameras, one must be careful that the cuvettes are the main focus and that the color is not 
being distorted by something else that is also being captured in the image.  
 
It will be helpful to show students examples of good and poor images so that they know 
how they should be taking their pictures. Images must be taken from far enough back to 
minimize path length distortions in the cuvettes but close enough such that the 
background lighting/color is occupying most of the image for the camera to be able to 
adjust its lighting. Having the cuvettes as centered in the image as possible will also help 
with the correct equivalent path lengths.  
 
 
Figure 9.10 Poor Quality Image:  
Color is washed out and results in data with a low R
2
 
value 
 
Figure 9.11 Good Quality Image:  
Color is clearly distinguishable in each cuvette and 
results in data with a high R
2
 value 
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RGB Analysis 
Ensure that students know which color value to analyze for their samples. The R values 
generally work best for the Bradford samples while the G values generally work best for 
the Biuret. Students should also know that the blank should have the highest RGB value 
as these values are inversely proportional to the calculated absorbance. Knowing that the 
blank should provide the highest value can serve as a check that the image is being used 
correctly. If the blank is visibly brighter in the picture but is reporting a lower RGB 
value, students should try selecting a slightly different area to analyze. Analyzing the 
incorrect color channel may also lead to erroneous measurements.  
 
Some online RGB analysis tools do not allow one to zoom in to the area of interest, 
making it difficult to accurately select the desired portion of the cuvette in the picture. If 
this challenge negatively impacts the data analysis, the image can be cropped first which 
should functionally enlarge the area of interest.  
 
If your students are not familiar with using spreadsheets, it is helpful to walk through 
how to set one up ahead of time for calculating the unknowns. An example spreadsheet 
can be found here <https://goo.gl/vAh5rp> 
 
Online Tools 
Conversion of wavelength to RGB values  
(https://academo.org/demos/wavelength-to-colour-relationship/) 
RGB color picker 
(http://www.colorcodepicker.com/colorpicker/index.php#) 
ImageJ Freeware 
(https://imagej.nih.gov/ij/) 
Colorometer 
(https://itunes.apple.com/us/app/colorometer/id509865412?mt=8) 
ColorMeter Free 
(https://play.google.com/store/apps/details?id=com.vistechprojects.colormeterfree&hl=en) 
 
 
 
Solution Preparation 
Talk with the students about what to do if they forget to tare the balance in between the 
addition of solutions. They can subtract off what has previously been added to determine 
how much has just been added.  
 
To record an accurate mass, students should also be instructed and reminded that the 
pipette cannot be touching the cuvette during the addition of solutions.  
 
If students are going to use the same pipette to mix all of the solutions, ensure they are 
going from the least to the most concentrated samples and emptying the pipette as well as 
possible in between solutions.  
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Reagent Preparation 
 
Biuret Reagent (Flinn Scientific) 
30 % (w/v) NaOH 
0.2 % CuSO4·5H2O 
- Dissolve 100 mg CuSO4·5H2O in 10 mL H2O 
- Prepare a 37.5% (w/v) NaOH solution 
- Mix 40 mL of the NaOH solution with the 10 mL copper solution. The solution will 
turn from a light blue to a slightly darker blue. Discard if black precipitate forms.  
- Store at 4° C away from light 
 
Biuret Reagent (Traditional) 
3% (w/v) NaOH 
0.15% (w/v) CuSO4·5H2O 
0.6% Potassium Sodium Tartrate (KNaC4H4O6·4H2O) 
- Dissolve 75 mg CuSO4·5H2O and 600 mg KNaC4H4O6·4H2O in 25 mL H2O 
- Prepare a 10% (w/v) NaOH solution 
- Add15 mL of 10% NaOH to the 25 mL copper/tartrate solution. Solution will turn from 
a light blue to a slightly darker blue.  
- Dilute to 50 mL.  
- Store at 4° C away from light 
 
Biuret Reagent (Alternative) 
3% (w/v) NaOH 
0.15% (w/v) CuSO4·5H2O 
0.1% Sodium Citrate 
- Dissolve 75 mg CuSO4·5H2O and 100 mg sodium citrate in 25 mL H2O 
- Prepare a 10% (w/v) NaOH solution 
- Add15 mL of 10% NaOH to the 25 mL copper/citrate solution. Solution will turn from 
a light blue to a slightly darker blue.  
- Dilute to 50 mL.  
- This solution is stable for about 1 hour before material begins precipitating out of 
solution. For best results, prepare immediately prior to the start of the lab.  
 
Bradford Solution 
0.005% (w/v) Coomassie Blue G-250 
5% (v/v) Methanol 
8.5 % (w/v) Phosphoric Acid 
- Dissolve 50 mg Coomassie Blue G-250 in 50 mL methanol 
- Add 100 mL 85% (w/v) phosphoric acid 
- Add this mixture slowly to 850 mL of H2O 
- Store at 4° C away from light 
 
 
 
